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  Chapter 1| Introduction 
 
In most women, cyclical ovulation at 25- to 35-day intervals continues during almost 40 
years between menarche and menopause, which represents approximately 400 
opportunities for pregnancy, if no contraception is used (Cunningham und Williams 
2010). Nevertheless, the total fertility rate (TFR), understood as the average number of 
children that would be born to a woman over her lifetime, arises only 2.56 in the world 
and is even less than 2.0 in developed countries (Agency 2010). Besides the cultural and 
social implications, this low birth rate may also be attributed to poor pregnancy outcome.  
 
Despite belonging to mammals, human beings do not exhibit the characteristic high 
fertility of this genealogical class. Whereas fertility rates of baboons and rabbits can 
reach 80%, in humans it only arises ca. 20% (Evers 2002). This difference is caused, 
among others, by the high embryo wastage and pregnancy loss in humans, estimated to 
be 30% prior to implantation (preimplantation loss), 30% before 6 weeks gestation and 
10% miscarries, mostly prior to 12 weeks gestation (Teklenburg et al. 2010, Macklon et 
al. 2002). Therefore, the study of the embryo implantation and the molecular 
mechanisms underlying this process is essential in the understanding of the natural 
limits of human fertility and their implications in the success of in vitro fertilization 
(IVF) techniques. 
1.1. Where do babies come from? The first stages: From fertilization to 
implantation 
 
Union of egg and sperm at fertilization represents one of the most important and 
fascinating processes in biology. Two haploid nuclei fusion to form the genome of a 
diploid organism by a very complex process which includes binding of the head of the 
sperm with the surrounding glycoprotein layer of the unfertilized egg, following by 
digestion of this zona pellucida finally allowing sperm and egg to fuse (Cunningham und 
Williams 2010, Alberts 2002). Several regulatory mechanisms like depolarization of the 
egg plasma membrane and egg cortical reaction occur to ensure that only one sperm 
fertilizes the egg (Alberts 2002). Fertilization, however, does not seem to be the main 
problem for pregnancy establishment. As described before, fertilized eggs are often lost 
during implantation, a process in which the blastocyst embeds itself into the lining of the 
uterus and which requires a receptive endometrium, a normal and functional embryo at 
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the blastocyst stage and coordinated embryo-maternal dialogue (Achache und Revel 
2006). 
1.1.1. Menstrual cycle and functional windows 
 
The endometrium is the inner layer of the uterus and changes with the menstrual cycle 
to provide the optimal environment for the blastocyst implantation.  A sequence of 
hormonal events defines the follicular, ovulation and lutheal phases within the 
menstrual cycle. During the follicular phase (1-14 days), gradual increasing amounts of 
estrogen stop the menses and stimulate thickening of the endometrium. Simultaneously 
within the ovary, selection of the dominant “ovulatory” follicle occurs. When the egg is 
almost mature, levels of estradiol reach a threshold above which the Luteinizing 
Hormone (LH) can be expressed, thus the dominant follicle releases an egg, an event 
called ovulation (Nussey und Whitehead 2001, Gilbert 2000). After ovulation, the 
follicular phase starts, and the vestige of the dominant follicle remains in the ovary and 
becomes a corpus luteum (CL). This temporary structure has the function of producing 
estrogen and progesterone which prepare the endometrium for implantation. If 
implantation occurs, the blastocyst produces human chorion gonadotropine (hGC) and 
rescues the CL, thus maintaining progesterone production. On the other hand, if 
implantation does not occur, the corpus luteum decreases in size causing reduction in 
progesterone and estrogen levels which leads back to menses (Nussey und Whitehead 
2001, Cunningham und Williams 2010). 
 
Two main periods of time within the menstrual cycle are recognized for their relevance 
in conception and pregnancy, and are known as “fertile window” and “implantation 
window”, respectively (Figure 1) (Teklenburg et al. 2010, Wilcox et al. 2000). Since most 
of the human pregnancies result from intercourse during a 6-day interval ending on the 
day of the ovulation, this period has been termed “fertile window” and is characterized 
by increasing pre-ovulatory estradiol levels on vaginal mucus, cervical opening and 
subendometrial contraction waves that allow sperm transport trough the female 
reproductive tract (reviewed by (Teklenburg et al. 2010)). Between days 5 and 10 
following the luteinizing hormone (LH) surge, a second interval of time occurs, in which 
the blastocyst is allowed to implant in the lining of the uterus, this interval is called 
“implantation window”. During this time, decidualization starts around the spiral 
arteries and expands to the endometrium.  As the endometrial extracellular matrix 
Introduction 
 
 3 
(ECM) attracts water, it becomes distended allowing the blastocyst to implant (Bischof 
und Campana 1996).  
 
1.1.2. Blastocyst implantation  
 
As early as 4 to 5 days after fertilization, the blastula differentiates into the embryo-
producing cells (inner cell mass) and the outer cells destined to form trophoblasts. Once 
the blastocyst arrives in the uterus, the embryonic pole is oriented to the potential 
implantation sites (Fitzgerald et al. 2008). As soon as the zona pellucida dissolves, the 
blastocyst can interact with the endometrium and adhere it in a process called 
apposition, but the connections between blastocyst and endometrium are not strong 
enough at this point and can be disrupted by washing. An increase in the physical 
contact between blastocyst and the uterine epithelium occurs during the second big 
process termed adhesion, after which the embryo cannot be dislodged. Finally, the 
embryo embeds itself in the uterus by a process called invasion, by which trophoblast 
cells coming from the embryo intrude between the endometrium, inner third of the 
myometrium, and uterine vasculature (Figure 2) (Dimitriadis et al. 2010b, Bischof und 
Campana 2000, Bischof und Campana 1996).  
 
Invasion of trophoblasts into maternal tissues is an outstanding process that aims to 
connect maternal bloodstream with the embryonal tissue. Maternal spiral arteries 
should be transformed into large vessels of low resistance to ensure an effective 
Figure 1. Menstruation cycle including alterations of the endometrium. The 
"implantation window” that corresponds to the period of maximum uterine 
receptivity is depicted in yellow, “fertile window” that constitutes the maximum 
period of conception, in purple. (Modified after (Cunningham und Williams 2010)). 
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uteroplacental circulation, which constitutes a prerequisite for normal fetal growth. An 
inappropriate blood supply to the fetus results in pregnancies complicated by pre-
eclampsia or intrauterine growth retardation (IUGR) (Moffett-King 2002, Ashton et al. 
2005, Parham 2004). Conversely, hyperactive trophoblast invasion can lead to placenta 
accreta or percreta (Dimitriadis et al. 2010a), or results also in malignancies mostly 
related to gestational trophoblastic disease (GTD). Among other pathologies of the GTD, 
molar pregnancies are distinguished by hyperplasia of trophoblast cells and grapelike 
vesicles; as a result, pregnancy ends almost always as a spontaneous abortion. In some 
cases, molar pregnancies may lead to choriocarcinoma, a very aggressive cancer which 
may be fatal if metastasis to brain or lungs occurs (Fu et al. 2009, Seckl et al. 2010). 
 
Interestingly, during blastocyst implantation trophoblasts cells resemble cancer cells as 
both cell types exhibit high proliferation, lack of cell-contact inhibition and the ability to 
protect themselves from the maternal immune system (“host” in the case of tumor cells) 
(Fitzgerald et al. 2008). In contrast, trophoblast cells are distinct from tumor cells in a 
very important feature uniquely happening in pregnancy, which is the tightly regulated 
proliferation and invasion depending on surrounding tissues and progress of gestation 
(Chakraborty et al. 2002, Fitzgerald et al. 2005a, Knofler 2010).  The molecular 
mechanisms that control trophoblast invasiveness are therefore of great interest because 
they may be useful in the development of treatments for pregnancy diseases and cancer 
(Cheng et al. 2009). 
 
Figure 2. Blastocyst implantation to endometrium. Novel biomarkers:  
integrins (red), pinopodes (violet) and LIF (orange) and trophectodermal 
integrins (green) are illustrated. (1) Blastocyst is floating in uterus and 
then oriented to the implantation site. (2) Blastocyst hatching occurs when 
LIF is secreted by the endometrium and the blastocyst exhibit LIF 
receptors. (3) Trophoblast differentiate into cytotrophoblast and 
syncytiotrophoblast, the last ones invade the luminal epithelium (4) 
Blastocyst ist completely embedded in the myometrim and the 
implantation is complete (Taken from (Fitzgerald et al. 2007)) 
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1.2. Regulating implantation: A plethora of small molecules 
 
Several substances are recognized to play a role in the establishment of a receptive 
endometrium and in the regulation of trophoblast invasion, either in an autocrine way 
(trophoblastic factors) or in a paracrine way (uterine factors) (Bischof et al. 2000). The 
group of regulatory molecules includes hormones (e.g. Progesterone)(Szekeres-Bartho et 
al. 2009), cell adhesion molecules (CAMs) (Achache und Revel 2006), growth factors (e.g. 
EGF, PlGF)(Guzeloglu-Kayisli et al. 2009), enzymes (e.g. MMPs) (Cohen und Bischof 
2007) and cytokines.  
 
Of the hormones involved in the female menstrual cycle, progesterone is well-known for 
playing a critical role in the establishment and maintenance of pregnancy. This steroid 
hormone mediates interaction between the endocrine and immune systems creating a 
favorable immunological environment for the fetus. Besides, progesterone triggers genes 
that contribute to the regulation of blastocyst implantation including cell cycle 
regulatory genes like p53 and p27, both recognized for their role in the establishment of 
a receptive endometrium and in the control of trophoblast invasion (Szekeres-Bartho et 
al. 2009, Chen et al. 2011). 
 
The family of cell adhesion molecules (CAM) is composed by integrins, cadherins, 
selectins and immunoglobulins. Mostly, these proteins mediate cell-to-matrix and cell-to-
cell adhesion in many physiologically processes including embryological development, 
haemostasis, thrombosis, wound healing, immune and non-immune defense 
mechanisms, and oncogenic transformation. Some members of the CAM family like L-
selectine, ICAM-1 and some integrins are expressed by trophoblasts cell and/or 
endometrium during the time of implantation and their deregulation is associated with 
unexplained infertility and endometriosis, which suggests a regulatory role in the 
implantation process. Cadherins like E-cadherin are expressed at the cell surface during 
the preliminary phases, but should be down-regulated to enable epithelial cells 
dissociation and blastocyst invasion. Lastly, some mucins like MUC-1, which is found in 
the human endometrium, serve as negative factors for embryo implantation and are 
vanished in the area where implantation takes place (Reviewed in (Achache und Revel 
2006)).  
 
Finally, several cytokines and growth factors are found in the site of implantation or 
expressed by trophoblasts. For several years, research in Placenta-lab group has been 
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focused mostly on the interleukin-6 family of proinflammatory cytokines, which is known 
to be critical in the establishment and maintenance of a pregnancy and whose 
deregulation results in endometriosis, infertility or recurrent miscarriage (Paiva et al. 
2009, Fitzgerald et al. 2005b). Six cytokines belong to the IL-6 family: Interleukin- 6 (IL-
6) and 11 (IL-11), oncostatin M (OSM), the ciliary neurotrophic factor (CNTF), the 
leukemia inhibitory factor (LIF) and the recently identified cardiotrophin-1 (Cullinan et 
al. 1996).  
 
The study of cytokines and growth factors with biological relevance in the control of 
trophoblast behavior is, however, more extensive. In order to summarize the vast 
amount of information about these mediators and their signal transduction pathways, 
we decided to write a review in cooperation with scientists from different continents. The 
central goal was to describe the main characteristics of these mediators, including their 
distribution within the reproductive tract, cellular origin, signaling transduction 
pathways and their implication with human pregnancy pathologies. Likewise, in a 
second paper, we reviewed the information of IL-6, IL-11 and LIF covering the current 
knowledge and the possible future applications of these cytokines in the field of human 
reproduction.  
 
1.2.1. Classical signaling pathways 
 
Depending on the cellular context, cytokines and growth factors mediate their effects 
trough activation of different intracellular cascades. Mechanistically, transmembrane 
cell receptors recognize these cytokines and activate signaling pathways that translate 
extracellular stimuli into cellular responses like increase of proliferation or invasiveness. 
Two main signaling pathways are essential in the response of trophoblast to stimulus 
and thus, relevant in the control of their proliferative and invasiveness properties: The 
Janus kinase/Signal Transducer and Activator of Transcription (JAK/STAT) and the 
Mitogen Activated Protein Kinase (RAS/MAPK) (Cooper 2000, Rawlings et al. 2004, 
Dhillon et al. 2007, Plaza-Menacho et al. 2007).  
 
The JAK/STAT pathway comprises three main steps: 1) Juxtaposition and trans-
phosphorylation of two JAK molecules in the extracellular membrane. 2) 
Phosphorylation of STATs, a familiy of transcriptional factor located in the cytoplasm 
and 3) Hetero- or homo-dimerization of STATs which allow them to be translocated into 
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the nucleus and control gene expression (Rawlings et al. 2004, Maj und Chelmonska-
Soyta 2007, Decker und Kovarik 2000). Since JAK/STAT cascade is involved in the 
regulation of implantation and maternal immune response in early pregnancy, and its 
deregulation is associated of malignancy, several molecules are responsible for modulate 
the signal or turning it off. Three major regulator families have been identified: 
Suppressors Of Cytokines Signalling (SOCS), Protein Inhibitors of Activated Stats 
(PIAS) and protein tyrosine phosphatases (PTPs), but the inhibition mechanism differs 
between them. In the cytoplasm, PTPs lead to dephosphorylation of JAKs or the cytokine 
receptor, SOCS inhibits activation of STATs, while PIAS bind to STAT dimers 
preventing them from binding DNA (Rawlings et al. 2004, Fitzgerald et al. 2005a) 
(Figure 3). 
 
 
 
Likewise, JAKs are also able to trigger Ras activation. Ras is a GTP-binding protein 
kinase that alternates between an active and an inactive state when bound to GTP or 
GDP, respectively. By doing so, ras proteins activate RAF kinases. Consecutively, Raf 
activate Mitogen-activated protein kinases 1/2 MEK1/2), which in turn phosphorylate 
Extracellular signal-Regulated Kinases 1 and 2 (ERK1/2). ERKs are translocated into 
the nucleus where they phosphorylate some transcription factors including Elk-1, 
resulting in the control of gene expression (Landes Bioscience., Dhillon et al. 2007). 
Activation of MAPK pathway is terminated mostly by GTP-ase activating proteins 
 
Figure 3. Schematic diagram of pathways activated by LIF. Left panel: JAK/STAT cascade, right 
panel: RAS/MAPK pathway. Negative regulators are displayed in black. (Design by Morales-
Prieto 2011) 
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(GAPs), which inactive Ras causing the hydrolyzation of active Ras-GTP into inactive 
Ras-GDP (Dhillon et al. 2007). For the study of MAPK pathway, however, some 
compounds chemically synthesized have been found to interfere in the signaling trough 
this cascade. U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene) 
inhibits MEK1/2 in a highly specific manner by suppressing their kinase activity and is 
one of the most widely used inhibitors in the study of ERK1/2 effects (Figure 3). 
 
Although the mechanisms of signaling in JAK/STAT and MAPK pathways may appear 
to be simple, the biological effects are complicated by cross-talks between them. These 
interactions permit to enhance the effect of a specific stimulus or conversely, inhibit its 
signal. For instance, STAT3 activation and translocation results in the expression of 
SOCS3, a terminating molecule in the JAK/STAT cascade. SOCS3, however, has the 
ability to bind RasGAP, a negative regulator of Ras signaling, thus promotes activation 
of the MAPK pathway. Likewise, MAPKs specifically phosphorylate a serine near the C-
terminus of most STATs enhancing their transcriptional activation, and thereby 
increasing the effects mediated by STATs (Rawlings et al. 2004, Plaza-Menacho et al. 
2007). There is still conflicting evidence about the kinase responsible for this 
phosphorylation. Specifically, ERK1/2, p38, the Protein kinase C (PKC), Jun N-terminal 
kinase (JNK), and the mammalian target of rapamycin (mTOR), may have the ability to 
activate STAT3 Ser727 phosphorylation, but this interaction seems to be dependent on 
the cellular context and the stimuli and therefore, needs to be particularly investigated 
(Schuringa et al. 2000b, Schuringa et al. 2000a, Liu et al. 2008) .  
The possible cross-talk between ERK1/2 and STAT3 will be analyzed in this work, using 
the JEG-3 choriocarcinoma cell line as model. The activation of both cascades mediated 
by LIF, and the implication of ERK1/2 inhibition on the cell proliferation and invasion 
will be investigated. Finally, it is aimed to find changes on STAT3 phosphorylation and 
transcriptional activity after abrogation of ERK1/2 activation and thus, to establish the 
molecular “dialogue” between these cascades. 
 
1.2.2 Novel regulatory molecules: MicroRNAs 
 
Numerous scientists seek regulatory molecules with the potential to control JAK/STAT 
and MAPK cascades simultaneously, mainly because of their implications on the 
regulation of trophoblast behavior, but also because this information may also be 
extrapolated to cancer research.  
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A novel group of regulatory molecules are the micro-RNAs (mi-RNAs), endogenous small 
RNA sequences that do not code for proteins, but instead exercise control over those that 
do. Non-coding RNAs (ncRNAs) were characterized for the first time in 1965, but their  
physiological role was not investigated until 1993, when Lee and colleagues 
demonstrated for the first time the involvement of lin-4, a so called “small temporal 
RNA” (stRNA), in the developmental timing in C. elegans (Lee et al. 1993). Seven years 
after, a genetic analysis of the C. elegans heterochronic gene pathway revealed that let-
7, also a 21-nucleotide stRNA, was able to regulate expression of several genes involved 
in the control of developmental events (Reinhart et al. 2000). Over the years, numerous 
21-25nt RNAs were cloned from different organisms confirming the existence of a new 
class of RNAs. This family was initially known as “tiny RNAs” and the term microRNA 
(miRNA) was introduced when the intracellular mechanisms started to be described 
(Ruvkun 2001).  
 
By 1998, the study of posttranscriptional gene silencing (PTGS) had described the 
phenomenon of RNA interference (RNAi) that refers to gene silencing caused by 
introducing double-stranded RNA into the cell (Fire et al. 1998). RNAi is a natural cell 
process  found in almost all eukaryotes and represents an antiviral defense mechanism 
against viruses and transposable elements  (Dillin 2003). Nowadays, it is used for 
numerous biological applications and even some RNAi-based approaches are being 
studied in preclinical and clinical trials as new strategies for the treatment of skin 
diseases, respiratory diseases and cancer (Davidson und McCray 2011). Two types of 
RNA molecules trigger their effects through the RNAi pathway: small interfering RNAs 
(siRNAs) and miRNAs. Although they share some similarities (e.g. small length 20-
25nt), they differ in a main feature that is their origin: siRNA are synthetic sequences 
whilst miRNAs are endogenous (Qavi et al. 2010, Prieto und Markert 2011).  
 
Mechanistically, miRNAs are transcribed from DNA as longer sequences known as pri-
miRNAs, which are then cleaved by the nuclear enzyme Drosha to form ~70 nucleotide 
precursors named pre-miRNAs. Pre-miRNAs associate with Exportin-5 and are exported 
to the cytoplasm.  Once in the cytoplasm, pre-miRNAs and external siRNAs are 
processed by a Dicer-containing complex and then associated with the RNAi-induced 
silencing complex (RISC). The guide strand (if siRNA was used) or the mature miRNA 
directs the complex to the target mRNA thus, it represses protein translation (Bueno et 
al. 2008, Qavi et al. 2010, Cheng et al. 2005, Davidson und McCray 2011, Prieto und 
Markert 2011). The grade of complementarity between miRNA and its target mRNA 
Introduction 
 
 10 
defines the mechanism used for gene repression. If alignment is perfect, the cascade 
ends in mRNA degradation, while partial complementarity and alignment lead to 
translational repression of the target mRNA (Cheng et al. 2005, Navarro und Monzo 
2010, Hamilton und Baulcombe 1999) (Figure 4). 
 
 
 
Since a perfect sequence match between miRNA and its mRNA target is not necessary, a 
miRNAs can regulate simultaneously more than one gene, but also different miRNAs 
target the same mRNA. This characteristic provides different grades of regulation and 
explains the current estimation that about 30% of the human genome may be regulated 
by miRNAs (Bueno et al. 2008). Since the introduction of the term microRNAs, 
numerous groups focused their investigation on this topic, mostly aimed to identify the 
location, regulation and function of these RNAs. Up to date, ~12000 reports have been 
published (Pubmed) and the number of miRNAs described arises approximately 1000 
(MiRBase V16), this rapid growth demonstrates the interest caused but also the 
importance of their study in numerous research fields including human reproduction. 
 
The signature of miRNAs expression, also known as miRNome, is regulated in a tissue- 
and developmental stage-specific manner and, thereby, their regulation is associated 
Figure 4. Principle mechanism of RNA interference. Inside the nucleus, pri-miRNA 
are cleaved by Drosha to pre-miRNA and transported into the cytoplasm by 
Exportin 5 (green arrows). The subsequent cascade is shared with exogenous siRNA 
(blue arrows). Processing by Dicer results in mature miRNA or functional siRNA 
which bind to RISC and to complementary RNA sequences. Perfect complementarity 
induces degradation whilst partial annealing leads to translational repression 
(Taken from (Morales Prieto und Markert 2011)) 
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with cancer (Navarro und Monzo 2010, Bueno et al. 2008, Zhang et al. 2007). This 
characteristic allows them to be used as a biomarker for the identification of certain 
physiological or pathological events including malignancies. Additionally, since miRNAs 
are known to participate in the control of several cellular processes, new therapies based 
on miRNAs are expected to be the future of cancer treatment. Their study in 
physiological processes like pregnancy is still incipient and their role in the control of 
pregnancy establishment remain unclear. In order to establish the “state-of-art” of 
miRNAs in pregnancy, we will summarize the current knowledge on miRNA biogenesis, 
targets and functions with relevance for pregnancy and placenta development.  
 
Furthermore, human placenta, mainly trophoblast cells, produces miRNA-containing 
exosomes which transport regulating signals into the maternal organism and may play a 
role in the establishment of maternal immune tolerance (Frangsmyr et al. 2005). It can 
be expected that these circulating miRNAs will be useful for the diagnosis of pregnancy 
disorders, such as preeclampsia. Altogether, these observations suggest the role of 
miRNAs as regulators of inflammation and immune responses induced by mechanisms 
that include control of transcriptional factors and relevant for embryo implantation and 
placentation. 
 
Additionally, the effect of LIF on the microRNA signature of trophoblast has not been 
studied and may provide crucial information about the molecular mechanisms involved 
in the regulation of LIF effects. Currently, the work of RNA signatures in primary cells 
represents a great challenge due to the limitations in obtaining these cells. Therefore, 
most of the work should be performed in trophoblastic cell lines before and after LIF-
treatment and only afterwards, they may be compared with the expression in primary 
cells.  
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1.3. Objectives and design of this work 
 
The objective of this work is to investigate the molecular mechanisms underlying the 
effects of LIF-stimulation o proliferation and invasion of trophoblastic cells with special 
regard on two main intracellular processes: a possible cross talk between LIF-induced 
JAK/STAT and RAS/MAPK cascades, and the identification of novel miRNAs involved in 
the LIF-response of trophoblastic cell lines.  
 
Due to the extension of the topic, this study will be divided into three parts in order to 
answer the following questions: 
 
1. What is known about LIF in pregnancy? 
2. Is there any cross-talk between JAK/STAT and RAS/MAPK cascades in 
trophoblastic cells and how does it affect cellular proliferation and invasion? 
3. Which miRNAs are associated with pregnancy or LIF responses in trophoblastic?  
 
Ten papers will be included in this work. Initially, the role of LIF and other related 
cytokines in pregnancy will be analyzed and summarized in two reviews. Afterwards, the 
LIF-induced cross-talk between ERK1/2 and STAT3 in JEG-3 and HTR-8/svneo cells will 
be examined, as well as its implication in the cell proliferation and invasion. 
Subsequently, the state of art of miRNAs in pregnancy will be reviewed followed by an 
analysis of some miRNAs in LIF-induced JEG-3 cells. Finally, the microRNA expression 
signature (miRNome) of four cell lines will be analyzed and compared with that of 
isolated trophoblast cells before and after LIF stimulation (Figure 5), with the aim to 
find novel miRNAs involved in the control of trophoblast behavior. 
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The following techniques should be established or optimized for this study: 
 
 Western blot  
 DNA-binding capability assay 
 Matrigel Invasion Assay 
 RNA isolation and Array assays 
 qRT-PCR for miRNAs 
 Over expression and knock-down of miRNAs 
 Small-interference RNA 
 Primary trophoblast isolation protocol 
 
 
 
MiRNome 
(754 miRs) 
Cancer-derived 
cells 
Isolated  
trophoblast 
 
JEG-3 
 
AC1-M59 
 
ACH-3P 
 
3rd trimester 
Immortalized  
cells (SV-Neo) 
 
HTR8 
WT LIF WT LIF WT LIF WT LIF 
Figure 5. Experimental design of miRNome profiling in trophoblastic cells. Analysis of 754 
miRNAs will be performed for three choriocarcinoma-derived cell lines, an immortalized 
trophoblastic cell line (HTR8/svneo) and isolated trophoblasts of third trimester placentas. 
MiRNA profiles of cell lines will be repeated after LIF treatment.  
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  Chapter 2| Results 
 
2.1. LIF biological relevance in pregnancy 
 
Several investigations have been carried out during the last years in order to elucidate 
the specific role of LIF and other cytokines in the establishment and maintenance of 
pregnancy.  Two works are presented here, both of them summarizing the current 
knowledge of cytokines in human reproduction. 
 
The first review was written in cooperation with young investigators belonging to eleven 
research groups from different continents. The main goal was to summarize cytokines 
that are vital for human reproduction, their distribution within the reproductive tract, 
source of expression and function. Since the number of studied factors was very high, we 
decided to organize them according to their receptor family aiming to elucidate the 
characteristic signal transducing pathways. I have contributed in the chapter 2 “Type I 
cytokine receptor” with special focus on the subchapter on the role and functions of LIF 
in reproduction. The entire manuscript has approximately 68 pages and more than 430 
cites. Therefore, in this thesis only the section on “Type I Cytokine Receptor” was 
included. 
 
Similar to the previous one, the second article summarizes current knowledge on IL-6-
like cytokines and their role in reproductive medicine. Additionally, their potential for 
future diagnostic and therapeutic applications in regard of new strategies in the 
treatment of reproductive pathologies was discussed. I contributed with the LIF 
subchapter and the revision of the manuscript.  
 
2.1.1. Publication 1. “Cytokines regulating trophoblast invasion”  
 
Authors: Fitzgerald JS, Abad C, Alvarez AM, Bhai Mehta R, Chaiwangyen W, Dubinsky 
V, Gueuvoghlanian B, Gutierrez G, Hofmann S, Hölters S, Joukadar J, Junovich G, 
Kuhn C, Morales-Prieto DM, Nevers T, Ospina-Prieto S, Pastuschek J, Pereira de Sousa 
FL, San Martin S, Suman P, Weber M, Markert UR.  
Journal: Advances in Neuroimmune biology (NIB)  
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Status: Accepted May 2011 
Impact Factor: Not yet, new journal (Online Date: August 2011) 
 
2.1.2. Publication 2. “Understanding the link between the interleukin-6 cytokine 
family and pregnancy: implications for future therapeutics” 
 
Authors: Markert UR, Morales-Prieto DM, Fitzgerald JS 
Journal: Expert Review of Clinical Immunology (Expet Rev Clin Immunol) 
Status: Published. Expert Rev Clin Immunol. 2011 Sep;7(5):603-9.   
Impact Factor: 0.593 
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2.2. Uncovering the crosstalk between JAK/STAT and RAS/MAPK cascades 
 
 
STAT3 and ERK1/2 are intracellular molecules relevant in the trophoblast response to 
extracellular stimuli. Based on current investigations that have suggested a possible 
crosstalk between these molecules, it was decided to investigate the activation of ERK1/2 
and STAT3 after stimulation with LIF, and the possible crosstalk between their 
pathways.  
 
Two different cell models were used in these works: JEG-3 and HTR8/SVneo cells. The 
first study included exclusively JEG-3 cells and aimed to analyze the cross-talk at 
cytoplasmic and nuclear levels, as well as their implications in trophoblast proliferation 
and invasion. Some of the experiments were assisted by Maja Weber, Sebastian Hölters 
and Stephanie Ospina and the adjustments and revisions were done by Prof. Dr. 
Ekkehard Schleussner, Dr. Justine Fiztgerald and Prof. Dr. Udo R. Markert.  
 
The second report was supported by an Indo-German exchange program between the 
Department of Science and Technology (DST), Government of India, and the German 
academic exchange service (DAAD), Germany. Aim of this study was to determine the 
significance of ERK1/2- and STAT3-dependent signaling pathways in LIF-mediated 
proliferation and survival of trophoblast cells using HTR-8/SVneo cells. The exchange 
program included a scholarship of three weeks in India. During this time, I presented 
the methodology and experimental design of our study and we performed the first 
experiments. After returning to Germany, my contribution was the peroxidase staining 
for ERK1/2 and STAT3 phosphorylation after stimulation with LIF, as well as the 
participation in the writing and revision of the manuscript.   
 
2.2.1. Publication 3. “Intranuclear, but not intracytoplasmic, crosstalk between 
Extracellular Regulated Kinase1/2 and Signal Transducer and Activator of 
Transcription3 regulates JEG-3 choriocarcinoma cell invasion and proliferation” 
 
Author: Morales-Prieto DM, Ospina-Prieto S, Weber M, Hoelters S, Fiztgerald JS, 
Schleussner E, Markert UR 
Journal: Journal of Cellular Biochemistry  
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Impact Factor: 3.122 
Status:  Submitted (July 2011)  
Re-submitted after reviewers modifications (March 2012)  
 
2.2.2. Publication 4. “Leukemia Inhibitory Factor mediated proliferation of 
HTR8/SVneo trophoblastic cells is dependent on Extracellular Regulated Kinase 
1/2 activation” 
 
Authors: Golla JP, Suman P, Morales Prieto DM, Markert UR, Gupta SK. 
Journal: Reproductive Fertility and Development (Reprod Fert Develop)  
Impact Factor: 2.553 
Status: Published. Reprod Fert Develop 23(5) 714-724  
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2.3. MicroRNAs regulating throphoblast behavior  
 
2.3.1. Publication 5. “MicroRNAs in pregnancy”.  
 
Authors: Morales Prieto DM, Markert UR. 
Journal: Journal of Reproductive Immunology  
Impact Factor: 2.204 
Status: Published. J Reprod Immunol. 2011 Mar;88(2):106-11  
 
 
This review provides a general overview of the current knowledge on miRNAs in 
pregnancy. The available information concerning profiles and functions of microRNAs in 
the peri-implantation period, embryonic stem cells, placentation and pregnancy, as well 
as in several pregnancy-related pathologies are summarized in this work. The main 
achievement is the description of a miRNA cluster (C19MC) that is highly expressed in 
placenta tissues and has been described in several independent studies. As first author, I 
carried out most of the investigation and wrote the first draft. Prof. Dr. Markert 
contributed with important ideas and a critical and academic review of the manuscript. 
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2.3.2. Publication 6. Reduction of miR-141 is induced by Leukemia Inhibitory 
Factor and inhibits proliferation in choriocarcinoma cell line JEG-3 
 
Authors: Morales-Prieto DM, Schleussner E, Markert UR. 
Journal: American Journal of Reproductive Immunology  
Impact Factor: 2.451 
Status:  Published.  Am J Reprod Immunol. 2011; 66S1:57–62 
 
 
Since the study of microRNAs and their functions in pregnancy is very incipient, we 
decided to analyze the function of some miRNAs in the proliferation of choriocarcinoma 
cells and their expression after LIF stimulation. We selected 5 miRNAs, which have been 
previously described to participate in the control of cancer development, to be implicated 
in pregnancy, or to be related with members of the signaling intracellular cascade of LIF, 
especially STAT3.  
Prof. Dr. Schleussner was involved in the project design; Prof. Dr. Markert is responsible 
for the design of the study and the revision and finalization of the manuscript. 
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2.3.3. Publication 7 . MiRNA expression profiles of trophoblastic cells  
Authors: Morales-Prieto DM, Chaiwangyen W, Gruhn B, Markert UR.  
Journal: Placenta  
Impact Factor: 2.985 
Status: Submitted (September 2011)  
 
The study of the miRNA signature (miRNome) in normal human tissues has revealed 
some universally expressed miRNAs and also several groups of miRNAs exclusively or 
preferentially expressed in a tissue-specific manner (Liang et al. 2007). MiRNA 
signatures are frequently altered in cancer (Selcuklu et al. 2009, Zhang et al. 2007), and 
they can be successfully used to distinguish between cancer and normal tissues 
(Murakami et al. 2006, Cohn et al.) or even to clarify poorly differentiated tumors (Lu et 
al. 2005). This part of the work was designed to analyze the miRNA expression profiles 
of different cell lines before and after LIF stimulation. Due to the vast amount of data, 
two manuscripts were written. The first one contains the information about the 
signatures of trophoblastic cells and the comparison with those of isolated third 
trimester trophoblast cells. The full set of data is published and accessible at NCBI Gene 
Expression Omnibus: GSE32346. The expression of some miRNAs, previously described 
to be involved in cancer development, was also analyzed. This work provides the first 
comprehensive miRNA encyclopedia of trophoblastic cells and may also be useful for the 
design of further experiments. Wittaya Chaiwangyen assisted in the isolation of primary 
trophoblast cells and contributed with some of the single assays. PD. Dr. Gruhn 
supported the qPCR studies, Prof. Dr. Markert is responsible for the design of the study 
and the revision and finalization of the manuscript. 
2.3.4. Publication 8. Leukemia Inhibitory factor alters miRNome of trophoblastic 
cells  
 
Authors: Morales-Prieto DM, Ospina-Prieto S, Chaiwangyen W, Gruhn B., Markert UR.  
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Journal: Placenta 
Impact Factor: 2.985 
Status: In preparation 
 
 
As mentioned above, two manuscripts were prepared to publish the miRNA signatures of 
trophoblastic cells and the alteration after LIF treatment. In this second manuscript, the 
miRNome of trophoblastic cells before and after LIF stimulation is compared. Here, some 
miRNAs were identified as possible mediators of LIF effects. It was also demonstrated 
that HTR8/svneo and JEG-3 cells differ in the expression of miR-141 and one of its 
putative targets (PIAS3). Since the relation between miR-141 and PIAS3 should be 
further confirmed, this manuscript has not yet been submitted. Some additional 
experiments carried out by Wittaya Chaiwangyen and Stephanie Ospina will be also 
included. PD. Dr. Gruhn supported the qPCR studies, Prof. Dr. Markert is responsible 
for the design of the study and the revision and finalization of the manuscript. 
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2.4. Additional Publications 
 
In addition to the manuscripts described above, several minor results of this thesis are 
included in two manuscripts that have been submitted recently. They are presented 
below but will be shorter discussed, because their focus is distinct from that of the 
others. 
 
2.4.1. Publication 9. AP-1 transcription factos, mucin-type molecules and MMPs 
regulate the IL-11 mediated invasiveness of JEG-3 and HTR-8/SVneo cells 
 
Authors: Suman P, Godbole G, Thakur R, Morales Prieto DM, Modi D, Markert UR, 
Gupta SK.  
Journal: PLOS one  
Impact Factor:4.411 
Status: Published . PLoS ONE 2012; 7(1): e29745. 
 
The cooperation with the group in India continued during this year in an Indo- The 
cooperation with the National Institute of Immunology in India continued during this 
year in an Indo-German exchange program between the Department of Science and 
Technology (DST), Government of India, and the German academic exchange service 
(DAAD), Germany. The focus of this program was the delineation of molecular 
mechanisms of HTR8/svneo cells, especially with regard to the IL-6 family of cytokines. 
Based on the previous results with LIF, the cooperation program has been focused on the 
regulation of trophoblastic cells mediated by IL-11, another cytokine of the IL-6 family. 
The aim of this publication was the analysis of the expression of matrix 
metalloproteinases and changes in the invasion capability of HTR8/svneo cells.  
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2.4.2. Publication 10. It’s a woman thing: Part II - The placenta under the 
influence of tobacco 
 
Authors: Fitzgerald JS, Morales-Prieto DM, Suman P, San Martin S, Poehlmann T, 
Gupta SK, Markert UR.  
Journal: Human Reproduction Update (Hum.reprod.update)  
Impact Factor: 8.755 
Status: Under revison 
 
This work is the second section of a two-part review concerning the clinical and 
pathophysiological effects of maternal tobacco during pregnancy. The first part was 
focused on the clinical effects including the histological and physiological modification of 
the placenta during pregnancy. In this manuscript, the literature on experimental data 
on smoke effects has been summarized in an attempt to correlate with the clinical effects 
reviewed in the first part.  
My contribution to the above mentioned manuscript is the overview on trophoblast 
behavior under the influence of toxic insults from the cigarette. The effects of some 
molecules, e.g. nicotine, cadmium and some antioxidants are summarized in this section. 
The entire manuscript has approximately 47 pages and more than 160 cites. Therefore, 
in this thesis only the section on “Maternal smoking and trophoblast cells” is included. 
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  Chapter 3| Discussion 
 
3.1. LIF biological relevance in pregnancy (Publications 1-2) 
 
Trophoblast and cancer cells share several features including high proliferation, lack of 
cell-contact inhibition and the ability to escape from the host immune system (Fitzgerald 
et al. 2008). Trophoblast cells, however, exhibit a tightly time-regulated proliferation 
and invasion (Chakraborty et al. 2002, Fitzgerald et al. 2005a, Knofler 2010), which 
turns them into an excellent model for understanding the molecular mechanisms 
involved in this regulation. Numerous cytokines are expressed within the female 
reproductive track and regulate the trophoblast response to external stimuli. These 
cytokine patters are also responsible for the communication between fetus and mother 
during blastocyst implantation and therefore, their deregulation causes a variety of 
pregnancy disorders.  
 
Several studies have been performed in order to establish the intracellular mechanisms 
and the specific function of some cytokines. Since numerous models and experiments 
have been carried out, a large amount of information is available. By summarizing this 
information (Markert et al. 2011), it was found that dysregulation of some cytokines like 
IL-6, IL-10 and IL-11 is closely associated with infertility and recurrent miscarried (Lim 
et al. 2000, von Wolff et al. 2000, Gutierrez et al. 2004, Koumantaki et al. 2001, Murphy 
et al. 2005), while aberrant expression of G-CSF and IFN-γ is relevant in preeclampsia 
and preterm birth (Matsubara et al. 1999, Whitcomb et al. 2009, Szarka et al. 2011). 
Among the variety of cytokines considered for this work, Leukemia Inhibitory Factor 
(LIF) apperared to be one of the most extensively studied due to its implication in almost 
all processes associated with pregnancy.  
 
Even when LIF is associated with inflammatory cell responses and cell differentiation, 
during pregnancy, LIF expression is up-regulated by progesterone, one of the major 
hormones responsible for pregnancy establishment and maintenance (Markert et al. 
2011).  Moreover, the concentration of LIF in follicular fluids correlates with embryo 
quality, its concentration in flushing is a measure of uterine receptivity prior to 
blastocyst implantation (Arici et al. 1997, Laird et al. 1997) and finally LIF can also 
influence trophoblast behavior (proliferation, invasion and differentiation) (Fitzgerald et 
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al. 2005b, Fitzgerald et al. 2008). Altogether, these investigations demonstrate the vital 
role of LIF during ovulation, implantation and pregnancy outcome and therefore, 
emphasize the need to understand the molecular mechanisms associated to its function 
and regulation. 
 
It is expectable that LIF-based treatments will improve the outcome of IVF treatments 
in women with recurrent implantation failure or recurrent miscarriege. The first 
multicenter study failed in showing LIF as a therapeutic agent (Brinsden et al. 2009). 
However, the lack of prior assessment of LIF expression and its administration during 
the trial are discussed. LIF signaling is regulated through a negative feedback 
mechanism, meaning that both too much, as well as too little LIF will induce similar 
functional effects (Fitzgerald et al. 2009). Therefore, cytokine supplementation in IVF 
treatments may still be optimized. Currently, LIF is used as a supplement to culture 
media in embryo cultures previous to implantation, because the percentage of embryos 
that reach the implantation stage increases in presence of LIF (United States Patent 
5962321; Inventors: Gough, Nicholas Martin; Willson, Tracey Ann, Seamark, Robert 
Frederick (Beulah Park, AU), http://www.freepatentsonline.com/5962321.html). 
 
The possible applications of LIF in human reproduction are not only focused on the 
improvement of pregnancy achieving and maintenance but also on the contraception 
methodologies. Oral steroid contraceptives (OC) are the most common method of 
reversible contraception but their use is associated with several hormone withdrawal 
symptoms including bleeding, pelvic pain, breast tenderness, bloating/swelling, and 
increased use of pain medications (Sulak et al. 2006). Recent reports have even indicated 
that combined oral contraceptive containing drospirenone carries a higher risk of venous 
thromboembolism than do formulations containing levonorgestrel (Parkin et al. 2011).  
Despite the recent attempts to reduce the hormonal concentration, side effects are still 
high and numerous studies are carried out to reduce the frequency of menstruation and 
the acceptance of OC regimes (Coffee et al. 2007). The appearance of non-hormonal 
contraceptives, thus, represents an alternative to improve the quality of life for millions 
of women. Recently a new non-hormonal contraceptive has emerged. Known as 
PEGylated (conjugated to polyethylene glycol) LIF antagonist (PEGLA), this formulation 
has become a promising contraceptive which, by intra-vaginal application, may 
guarantee implantation block and simultaneously eliminate the systemic effect on bone 
(Menkhorst et al. 2011). The main concern about this new medication is the severe side 
effects of targeting IL-6-like cytokines, which include alteration in muscles, 
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cardiovascular development, immune system and nervous system development (Bauer et 
al. 2007). 
 
Summarizing, the potential to use LIF as biological marker for embryo selection, as 
medicatione to achieve and maintain pregnancy (Aghajanova 2010), or as a treatment in 
the control of pregnancy-associated diseases (Koehn et al. 2011) is enormous. However, it 
is crucial to understand the signaling mediators responsible for its regulation. For 
instance, the analysis of STAT3 and MAPK pathways may contribute to clarify the 
effects of LIF on trophoblastic cells and the future implications of a LIF-based therapy.    
 
3.2. Uncovering the cross talk between JAK/STAT and RAS/MAPK cascades 
(Publications 3-4) 
 
STAT3 is a well studied intracellular molecule which plays a crucial role in the 
regulation of trophoblast invasion mediated by LIF (Poehlmann et al. 2005, Fitzgerald et 
al. 2008). STAT3 becomes fully activated after phosphorylation at its tyr705 and ser727 
residues, which allows it to dimerize and translocate into the nucleus (Schuringa et al. 
2000b, Liu et al. 2008, Schuringa et al. 2001). A previous report of our group on JEG-3 
cells had demonstrated that LIF triggers STAT3 Tyr705 phosphorylation, and this 
activation correlates with an increase of cell proliferation and invasion (Fitzgerald et al. 
2005b). STAT3 Ser727 phosphorylation has been less studied but it is known that its 
inhibition decreases DNA binding activity of STAT3 after stimulation with IL-6 (Decker 
und Kovarik 2000, Boulton et al. 1995). The mechanisms involved in the activation and 
regulation of p-STAT3 Ser727 remain unclear and several studies are carried out to 
establish the kinase responsible for this phosphorylation, principally due to the potential 
to control STAT3-mediated cell responses. Since STAT3 contains a characteristic ERK-
MAPK phosphorylation site (-pro-X-ser/thr-pro-) (Chung et al. 1997), a possible cross-
talk between STAT3 and ERK activated by LIF may be expected.  
 
By using JEG-3 cells as model, we have demonstrated that LIF triggers phosphorylation 
of both STAT3 Ser727 and Tyr705 residues. In addition, activation of MAPK pathway, 
measured as phosphorylation of ERK1/2 was also observable within 5 min of 
stimulation. This rapid activation of both pathways provided the first evidence of an 
independent activation after LIF stimulation, which was lately confirmed by Western 
blotting and immunocytochemistry. The methodology included the pre-treatment of JEG-
3 cells with U0126, a specific p-ERK1/2 inhibitor, followed by LIF-stimulation and the 
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determination of STAT3 phosphorylation. Results demonstrated a successful inhibition 
of ERK1/2 activation in all experiments including a reduction of basal levels. Conversely, 
phosphorylation of STAT3 Ser727 and Tyr705 was not altered by application of U0126 
and also no changes in the localization of the protein were observed by 
immunocytochemistry.  
 
As mentioned before, activation of STAT3 depends on the cell-type and the stimuli, and 
therefore, responses may vary among different trophoblastic subtypes or cell lines. In 
order to confirm the role of ERK1/2 in the LIF-mediated STAT3 activation, a parallel 
study was carried out in cooperation with the Reproductive Cell Biology Laboratory in 
New Dehli, India. In this study, HTR-8/svneo cells were used as a model. HTR-8/svneo 
cells were established through transfection of isolated first trimester trophoblast cells 
with a simian virus 40 (SV40), and represent a model for trophoblast study, as they 
share several characteristics with first trimester trophoblast cells (Graham et al. 1993). 
Nevertheless, the results were almost identical, with a fully abrogation of ERK1/2 
activation that does not change the LIF-mediated activation of STAT3. Interestingly, 
HTR-8 cells exhibit higher basal levels of p-STAT3 Ser727 and p-ERK1/2 in comparison 
with JEG-3 cells. This can be explained by the cellular transformation by SV40, which in 
other cell lines has been associated with an increase of ERK1/2 and STAT3 activation by 
a mechanism including inhibition of protein phosphatase 2A (Cheng et al. 2009, Sablina 
und Hahn 2008). Incubation with a low concentration of U0126 (10ng/ml) was sufficient 
to abrogate ERK1/2 phosphorylation, independently of the basal levels. There results 
demonstrate that the methodology was optimal and also confirm the efficiency and 
specificity of U0126. 
 
Altogether, our studies demonstrated that STAT3 Ser727 phosphorylation in 
trophoblastic cells is independent of ERK1/2 activation, and therefore, further 
experiments are needed to clarify the signaling mediator. Based on previous studies in 
our laboratories, in which mammalian target of rapamycin (mTOR) was found to be 
required for the constitutive, LIF-independent phosphorylation of STAT3 Ser727 in 
HTR8/svneo cells (Busch et al. 2009), and also in a recent publication of mTOR as likely 
responsible for the phosphorylation of STAT3 Ser727 upon IL-6 stimulation in the 
human hepatocarcinoma cell line HepG2 (Kim et al. 2008), one can hypothesize that this 
may be the major signaling pathway responsible for the activation of p-STAT3 Ser727 in 
trophoblast and choriocarcinoma cells.  
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A major finding of the present work is that after stimulation with LIF, ERK1/2 
inhibition does not influence STAT3 phosphorylation, but it does augment STAT3 
nuclear translocation in JEG-3 cells. Besides the numerous reports describing a positive 
regulation of cytokine-mediated STAT3 phosphorylation by ERK1/2 (Tian und An 2004), 
there is also cumulating evidence describing the negative regulation of STAT3 by 
ERK1/2 (Krasilnikov et al. 2003). In CHO (Chinese hamster ovary) cells, constitutive 
expression of MEK1 cells inhibited the activation of STAT3 and hampered the binding of 
phosphorylated STAT3 to DNA (Sengupta et al. 1998). In addition, a recent report 
demonstrated that hepatic stimulator substance (HSS)-induced ERK1/2 activation in 
human hepatoma HepG2 cells exerted negative modulation on STAT3 accumulation into 
the nucleus (Tian und An 2004).  
 
IL-6 family members induce STAT3 activation and translocation into the nucleus, which 
is essential for mediating invasion in trophoblast and choriocarcinoma cells (Poehlmann 
et al. 2005, Suman et al. 2009, Dubinsky et al.). In the current study, inhibition of 
ERK1/2 induces accumulation of STAT3 in the nucleus and thus, increases its 
transcriptional activity, resulting in an augmention of JEG-3 invasion. This cross-talk 
might be useful for the development of new therapies based on the regulation of 
trophoblast invasion. However, studies in vivo are required to clarify this potential 
therapy. 
 
On the other hand, proliferation of trophoblastic cells is a process mostly mediated by 
MAPK activation, rather than by JAK/STAT. LIF-treatment triggers activation of 
ERK1/2 and STAT3, and results in an increase of proliferation in both HTR-8/svneo 
(Prakash et al. 2011) and JEG-3 cells. As previously demonstrated, ERK1/2 has no 
intracytoplasmic crosstalk with STAT3, but it antagonizes STAT3 DNA-binding 
capacities in the nucleus. Hence, decrease in proliferation caused by U0126 addition can 
be attributed to the loss of ERK1/2 activation, independent of activation of STAT3. In 
JEG-3 cells treated with U0126, further addition of LIF rescues slightly cell 
proliferation, showing that STAT3 is also be involved. The proliferation of P19 
embryonal carcinoma cells following LIF stimulation is also independent of the 
activation of STAT3 (Schuringa et al. 2002), which supports our findings that ERK1/2 is 
the major mediator of trophoblast proliferation, even in absence of cytokine stimulation. 
 
It may be concluded that LIF is a major inducer of invasion and proliferation in 
trophoblastic cells, and triggers its effects through activation of JAK/STAT and MAPK 
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pathways. These cascades are connected by an intracellular cross-talk, in which ERK1/2 
is a negative regulator of STAT3 nuclear activity (Figure 4). This connection may explain 
the disorders observed when dysfunctions of the pathways occur, but also provides 
information for understanding the role of individual factors which may lead to the 
development of new therapeutic strategies. 
 
 
3.3. MicroRNAs regulating throphoblast behavior (Publications 5-8) 
 
MiRNAs constitute a novel group of regulatory molecules which play a pivotal role in the 
control of gene expression at post-transcriptional level, and it is thought that 30% of the 
human genome is regulated by these molecules (Bueno et al. 2008). The study of 
miRNAs in pregnancy is still incipient, albeit some pioneer studies in pregnancy-
associated diseases (e.g. preeclampsia) have been published (Noack et al. 2011). 
Therefore, it was important to investigate the state-of-art of miRNAs in pregnancy 
reviewing the current data of microRNAs in pregnancy and highlighting some 
perspectives of their study in human reproduction (Prieto und Markert 2011).  
 
Figure 6. Diagram of the proposed LIF signaling pathway in trophoblast 
cells. LIF trigger activation of JAK/STAT and MAPK independently. ERK1/2 
does not regulate STAT3 Ser727 phosphorylation but antagonize to STAT3 
translocation into the nucleus. JAK/STAT and MAPK activation result in 
different cell responses increasing proliferation and invasion, respectively. 
Taken from (Morales-Prieto et al. 2011). 
Proliferation Invasion
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This review article summarizes current reports that demonstrate participation of 
miRNAs in several processes associated with pregnancy achievement and maintenance. 
For instance, during the menstrual cycle, inflammation-like processes must occur to 
prepare the endometrium for implantation (Pan und Chegini 2008). However, altered 
endometrial gene expression is responsible for inappropriate tissue regeneration, 
resulting in dysfunctional uterine bleeding, failure in embryo implantation, as well as 
many other endometrial disorders (Kuokkanen et al. 2009).  MiRNAs participate in 
regulating dynamic changes in uterine gene expression patterns by controlling genes 
associated with inflammatory responses (Pan und Chegini 2008, Chakrabarty et al. 
2007), or  by repressing expression of immune tolerance-associated genes, such as HLA-
G (Veit und Chies 2009). Altogether, these observations support the role of miRNAs as 
regulators of inflammation and immune responses by mechanisms that include control of 
transcriptional factors. Therefore, they appear to be highly relevant for tuning of embryo 
implantation and placentation. 
 
The main goal of our miRNA review (Prieto und Markert) was to summarize the 
information relevant for the miRNAs exclusively expressed by placenta. Three recent 
reports have independently identified a cluster of miRNAs located in the chromosome 19 
and which constitutes the largest miRNA cluster ever reported (Bentwich et al. 2005, 
Bortolin-Cavaille et al. 2009, Liang et al. 2007). The chromosome 19 microRNA cluster 
(C19MC) comprises 54 predicted miRNAs, 43 of them already cloned and sequenced. Two 
main characteristics of C19MC demonstrate its importance in human embryonic 
development: the fact that it is conserved among eutherian species, and its imprinting 
expression exclusively  from the paternally inherited chromosome (Bortolin-Cavaille et 
al. 2009). Imprinting genes play important roles in the regulation of cellular 
differentiation and fate, and they are frequently expressed only in embryonic stages or 
placenta tissues, which revealed C19MC as a miRNA cluster involved in human 
embryonic development (Tsai et al. 2009). Located close to C19MC, a second cluster has 
been identified. It maps to chromosome C19q13.42 and comprises only three miRs (miR-
371, miR-372 and miR-373). These miRNAs are found exclusively expressed by human 
embryonic stem cells hES (Laurent et al. 2008) and their study may provide information 
about the regulatory mechanisms involved in the embryonic development. 
 
The next step was to investigate the miRNome of isolated trophoblast cells and compare 
them with the miRNA signatures of several trophoblastic cell lines, which share 
characteristics with isolated trophoblast cells but differ in the proliferation and invasion 
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rates. In this study we demonstrated that the miRNome signature of the 
choriocarcinoma and choriocarcinoma-like cells (JEG-3, ACH-3P and AC1-M59) was very 
similar, but it differs significantly from that of HTR8/svneo cells. Surprisingly, it was 
also demonstrated that the miRNA signature of isolated trophoblast cells from term 
placentas is more similar to that of choriocarcinoma-derived cell lines than of the 
immortalized cell line HTR-8/svneo. A recent report focused on the mRNA signature of 
several cell lines has also described more similarities of the mRNA expression of isolated 
trophoblast cells with choriocarcinoma-derived cell lines than with HTR-8/SVneo cells 
(Bilban et al. 2010). In conclusion, these results suggest that cell lines derived from 
choriocarcinoma preserve large parts of the mRNA and miRNAs expression of 
trophoblast cells, while the immortalization process of HTR-8/svneo generates changes 
in the gene expression that result in a less appropiate model for trophoblast gene 
expression analyses.  
 
Furthermore, our study emphasized the importance of the C19MC because of its high 
expression in primary trophoblast cells and also in JEG-3 and their hybrids, but more 
significantly, because here it was demonstrated that these miRNAs confer the identity to 
the trophoblastic cells. It is to expect thus, that dysregulation of their expression may be 
associated with pregnancy disorders.  A recent report in serum of pre-eclampsia versus 
normal pregnant women has confirmed partially this hypothesis, as an aberrant 
expression of some members of the C19MC was observed in the pre-eclamptic women 
(Yang et al. 2011).  
 
Recent studies have also reported alterations in the expression of some miRNAs in 
choriocarcinoma cells when compared to normal trophoblast (Chao et al. 2010). 
Similarly, some miRNAs were reported to be altered in placentas injured or exposed to 
toxic agents versus normal tissues (Maccani et al. 2010). Here, the complete miRNAs 
signature of the most studied trophoblastic cell lines is provided and is compared with 
the expression of normal isolated trophoblasts. When used as a data bank, this 
information will be of value to design experiments related to gene expression and 
functional analyses. As an example, over-expression experiments on miR-519e, which is 
located within C19MC, can be carried out in HTR-8/svneo cells, while downregulation 
experiments can be performed in JEG-3 cells, as no basal expression in HTR-8 is 
observable. 
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3.3.1. MiRNome after LIF 
 
By reviewing the investigations carried out during the last decade, it was established 
that there were no studies published on LIF-induced miRNA in any cell type, albeit 
several miRNAs have been described as regulators of some members of JAK/STAT or 
MAPK pathways (Meng et al. 2007, Taganov et al. 2006, Bazzoni et al. 2009). As LIF 
plays an important role in the achievement, maintenance and regulation of pregnancy, 
the study of miRNAs expression in response to LIF is imperative for understanding 
cellular processes associated with pregnancy.  
 
The number of miRNAs already described arises 1000, but initially only five miRNAs 
were selected for the study (miR-9, miR-21, miR-93, miR-141 and let-7g). They were 
previously published to correlate with tumor-grade, to be implicated in pregnancy or to 
be related with members of the intracellular signaling cascade of LIF. Three miRNAs 
were identified to be significantly altered after LIF-treatment: miR-21, miR-93 
(upregulated) and miR-141 (downregulated). Interestingly, the strongest effect was 
observable in the expression of miR-141, which was downregulated by far more than 
50%(Morales-Prieto et al. 2011). MiR-141 was found significantly elevated in plasma 
from pregnant women in comparison with non-pregnant women (Gilad et al. 2008), and 
therefore, may be expected to display a specific or even crucial role during pregnancy. On 
the other hand, our finding of increased miR-21 expression in trophoblastic cells after 
LIF stimulation coincides with previous reports in head and neck carcinoma, 
osteosarcoma, ovarian carcinomas and others, and in which miR-21 promotes 
proliferation, migration and invasion (Zheng et al., Lou et al., Ziyan et al.).  
 
As previously mentioned, LIF increases proliferation of trophoblastic cells. Therefore, an 
effect of miR-141 over-expression or silencing on proliferation was expectable. Due to the 
small sequences used for transfection and the low cell viability after transfection, this 
methodology should be initially optimized. Two different small chemically altered RNA 
molecules were used for transfection: dsRNAs that mimic endogenous miRNA 
(overexpression) or single-stranded RNAs that inhibit specific miRNA (down-regulation). 
By using these methods, we were able to establish that silencing of miR-141 results in a 
reduction of JEG-3 proliferation. This finding goes in line with a report in 
nasopharyngeal carcinoma, where miR-141 positively correlates with proliferation, 
migration and invasion (Zhang et al.), but differs from the observed in gastric cancer 
cells (Du et al. 2009), reinforcing the idea of a cell-type specific response of miRNAs. 
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Finally, the effect of LIF on the miRNome of four trophoblastic cell lines was 
investigated. We identified three miRNAs dysregulated in all cell lines after four hours 
of LIF-treatment and therefore, which may contribute tor the LIF-response in 
trophoblast cells: miR-511, miR-550 and miR-885-5p. Among those, miR-511 has been 
more intensively studied because of its significantly lower expression in 
adenocarcinomas compared with normal tissues (Tombol et al. 2009) and its potential 
role as modulator of human immune responses (Tserel et al.). MiR-885-5p was also found 
down-regulated in primary neuroblastoma and seems to have a tumor suppressive role 
interfering with cell cycle progression and cell survival (Afanasyeva et al.). These 
associations allow us to hypothesize that these miRNAs may be involved in the 
trophoblast response to LIF stimulation. In future, research on their target genes may be 
of great importance to understand the LIF-mediated invasion and proliferation of 
trophoblast cells and thus, to generate novel therapeutical strategies. 
 
Summarized, this thesis describes the molecular mechanisms involved in the LIF-
response in trophoblastic cells. Starting with the intracellular processes occurring within 
the cytoplasm, when the cytokine receptors allow the activation of MAPK and JAK/STAT 
cascades, through the cross-talk between STAT3 and ERK1/2 and their association with 
proliferation and invasion, and finally, reporting for the fist time miRNAs specifically 
expressed by some trophoblastic cells and their implication in the proliferation of 
trophoblast cells.  
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3.4. Final Comments and future prospects 
 
Working with trophoblast primary cells represents a challenge due to some problems 
including the relatively low yield of isolation and the small life expectative of these cells. 
Several models have been established with the aim to avoid these disadvantages 
allowing the study of intracellular regulatory mechanisms including proliferation, 
migration and invasion. However, in this thesis we could demonstrate that these models 
differ significantly in their behavior and responses on stimuli, such as LIF, as in our 
focus. Therefore, we recommend to use generally more than one cell line in order to 
distingiush molecular mechanisms which are cell-type dependent and which are not. 
 
Among the cell models analyzed in this study JEG-3 and HTR-8 are the most different 
cell lines, as previously demonstrated in studies on their mRNA and protein expression. 
Our work describes an intracellular cascade shared by these cell lines, which includes 
activation of STAT3. Some additional works in our group have found further 
dissimilarities in the LIF-response between these cells lines including large differences 
in the expression of protein inhibitors of activated STAT3 (PIAS3), a negative regulator 
of the STAT3 cascade. Therefore, a deeper study of the expression of PIAS3, its possible 
control through miRNAs and the implications in the proliferation and invasion of 
trophoblast cells should be further carried on.  
 
Furthermore, since trophoblast cells release miRNA into the maternal circulation 
(Frangsmyr et al. 2005), placenta-specific miRNA expression in serum changes during 
the course of pregnancy and thereby, reflects the physiological state (Pinzani et al. 2010, 
Gilad et al. 2008). This association revealed miRNA profiling in serum as a future tool 
for diagnosis of pathological conditions, including pre-eclampsia or intrauterine growth 
restriction (IGR). MiR-141 has been already reported to be higher in serum from 
pregnant women and we found that it is involved in the regulation of trophoblast 
proliferation and LIF-responses. It may be hypothesized that miR-141 may be useful as 
biomarker for pregnancy disorders associated with trophoblast dysfunction.  
 
Likewise, this thesis reveals miR-511, miR-550 and miR-885 as possible mediators of 
LIF-responses in trophoblast cells and therefore, we propose to further investigate their 
functions and targets. In this study, a miRNA encyclopedia is provided, which contains 
key information about the expression and regulation of miRNAs in primary trophoblast 
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cells and different trophoblstic cell lines. This information may be useful for designing 
new strategies in order to establish the full functionality of miRNAs in pregnancy and 
their application as biomarkers or for new therapeutical strategies.    
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  Chapter 4| Summary 
 
 
The present Ph.D. thesis is a cumulation of ten mostly published or accepted scientific 
papers on Leukemia Inhibitory Factor (LIF) and trophoblastic cells.  
 
In contrast to what may be thought, human beings are not very fertile. About 70% of the 
fertilized eggs are lost within the first 12 weeks of pregnancy and the main reason seems 
to be dysregulation during the blastocyst implantation. In this process, the trophoblast 
cells of the outer layer of the blastocyst invade the decidua connecting maternal and fetal 
bloodstreams. In a “dialogue” between maternal and fetal cells, several molecules are 
released in order to control trophoblast proliferation and invasion. The group of secreted 
molecules includes hormones, enzymes, cytokines, chemokines and growth factors and 
their dysregulation can result in miscarries or pregnancy associated diseases like pre-
eclampsia or choriocarcinoma. One of those cytokines is LIF. 
 
LIF is a pleiotropic cytokine which belongs to the IL-6 family of cytokines. It is known for 
mediating cellular responses including proliferation and invasion and therefore, it plays 
a critical role in pregnancy establishment and maintenance. In this thesis, two review 
articles are included which summarize LIF production, and LIF-induced effects and 
molecular processes in trophoblastic cells. Likewise, the information about the potential 
clinical applications of LIF, its role in pregnancy and its association with pregnancy 
disorders was reviewed. 
 
Despite the fact that LIF has been studied for several years, the molecular mechanisms 
controlling LIF-induced cell-responses have not been analyzed in detail. On the cell 
membrane, transmembranal receptors recognize LIF and activate several intracellular 
pathways. One part of this thesis was focused on the JAK/STAT and MAPK cascades, 
due to their implications in the control of trophoblast cell behavior. STAT3 is a molecule 
downstream LIF receptor (LIFR) that plays a pivotal role in the signaling of 
extracellular stimuli to the nuclei. STAT3 is activated by phosphorylation at its ser727 
and tyr705 residues, which allows it to dimerize and cross from the cytoplasm to the 
nucleus. STAT3 tyr705 has been more extensively studied previously, while the 
relevance of ser727 was not yet known. Recent reports highlighted the importance of 
STAT3 ser727 in the cell response and new investigations are carried out to identify the 
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kinase responsible for this phosphorylation. ERK1/2, a molecule of the MAPK cascade, 
was predicted to be involved in the control of STAT3 ser727 phosphorylation and a cross-
talk between these molecules was hypothesized. In this thesis, it was demonstrated that 
ERK1/2 plays an important role in the proliferation of trophoblast cells, which is not 
dependent on STAT3 activation. We have also defined a cross-talk between ERK1/2 and 
STAT3, which, conversely to the expected, does not occur in the cytoplasm, but in the 
nucleus: ERK1/2 is not responsible for the STAT3 ser727 phosphorylation, but it has a 
negative effect on the translocation of STAT3 into the nucleus, which results in a 
decrease of trophoblast invasiveness.  
 
Recently discovered, microRNAs constitute a group of regulatory molecules that can 
control gene expression at post-transcriptional level. About 30% of the human genome is 
regulated by these molecules and their dysregulation is associated with cancer and 
malignancy. This thesis summarizes in a published review article the studies on 
miRNAs and placenta with special emphasis on those miRNAs specifically expressed by 
trophoblast cells. Additionally in this work, the miRNA expression profiles, also known 
as miRNome, of four different trophoblastic cell lines were analyzed and compared with 
that of isolated term trimester trophoblast cells. Some miRNAs were identified as 
potential markers responsible for the differentiation of trophoblast cells. Finally, the 
effect of LIF treatment on the miRNome of the same cell lines was investigated. Four 
miRNAs were found to be altered in all cell lines: miR-511, miR-550 and miR-885-5p 
(down-regulated), and miR-641 (up-regulated), suggesting an association between their 
expression and the LIF-induced cell response. The analysis of the putative targets 
suggested an association with the control of cell proliferation.  
 
Altogether, this work analyzes intracellular signalling mechanisms involved in the 
regulation of LIF-responses in trophoblastic cells and highlights some novel miRNAs 
which may be responsible for the control of trophoblast proliferation and invasion and, 
therefore, may contribute to new strategies for future treatments and clinical approaches 
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 Chapter 5| Zusammenfassung 
 
 
Die vorliegende Doktorarbeit ist eine Zusammenstellung („kumulative Arbeit“) von zehn 
Manuskripten, die in den meisten Fällen bereits veröffentlicht oder angenommen sind, 
und das Thema „Leukemia Inhibitory Factor und trophoblastäre Zellen“ bearbeiten.  
 
Im Gegensatz zur allgemeinen Meinung, sind die Menschen nicht sehr fruchtbar. 
Ungefähr 70% der befruchteten Eier werden innerhalb der ersten 12 Wochen der 
Schwangerschaft verloren. Der Hauptgrund scheint die Fehlregulation während der 
Implantation der Blastozyste zu sein. In diesem Prozess invadieren die 
Trophoblastzellen von der äußeren Zellschicht der Blastozyste in die Dezidua und fügen 
den mütterlichen und fetalen Blutkreislauf zusammen. In einem "Dialog" zwischen 
mütterlichen und fetalen Zellen werden zahlreiche Faktoren freigesetzt, welche die 
Trophoblastenproliferation und -invasion kontrollieren. Die Gruppe der sezernierten 
Moleküle enthält Hormone, Enzyme, Zytokine, Chemokine und Wachstumsfaktoren, 
deren Fehlregulation im Verlauf der gesamten Schwangerschaft  zu Erkrankungen wie 
Wachstumsretardierungen, Präeklampsie, vorzeitigen Wehentätigkeiten bis hin zu 
Aborten führen kann. Eines der entscheidenden Zytokine ist Leukemia Inhibitory Factor 
(LIF). 
 
LIF ist ein pleiotropes Zytokin, das zur IL-6-Familie der Zytokine gehört. Es induziert 
zelluläre Antworten wie Proliferation und Invasion. Außerdem spielt es eine 
entscheidende Rolle zu Beginn und im Verlauf der Schwangerschaft. In diese Arbeit 
werden zwei Übersichtsartikel einbezogen, welche die LIF Produktion, die LIF-
induzierten Effekte und die molekularen Prozesse in den Trophoblasten 
zusammenfassen. Auch Informationen in Bezug auf die mögliche klinische 
Anwendungen von LIF, seine Rolle in der Schwangerschaft und seine Verbindung zu 
Schwangerschaftsstörungen wurden zusammengestellt. 
 
Trotz der Tatsache, dass LIF seit mehreren Jahren untersucht worden ist, wurden die 
molekularen Mechanismen, welche die LIF-induzierten Zell-Antworten kontrollieren 
noch nicht in allen Details analysiert. Transmembrane Rezeptoren auf der Zellmembran 
erkennen LIF und aktivieren daraufhin mehrere intrazelluläre Signalwege. Ein Teil 
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dieser Dissertation hat sich auf die JAK / STAT-und MAPK-Kaskaden konzentriert, 
welche aufgrund ihrer Auswirkungen auf die Kontrolle des Trophoblastverhaltens von 
Bedeutung sind. STAT3 ist ein „downstream“ Molekül des LIF-Rezeptors (LIFR), das 
eine zentrale Rolle in der Signalübertragung von extrazellulären Stimuli auf den Kern 
spielt. STAT3 wird durch Phosphorylierung an seinen Ser727- und Tyr705-Resten 
aktiviert, wodurch es die Fähigkeit erlangt Dimere zu bilden und in den Zellkern zu 
wandern. Die aktivierten Dimere regulieren die Expression spezifischer Zielgene.  
 
Während STAT3 Tyr705 schon ausführlich untersucht wurde, ist über die 
Phosphorylierung und Funktion von Ser727 noch relativ  wenig bekannt. Jüngste 
Berichte hoben die Bedeutung von STAT3 Ser727 in der Zellantwort hervor und neue 
Untersuchungen wurden durchgeführt, um die Kinase zu identizifieren, welche für diese 
Phosphorylierung verantwortlich ist. Es wurde erwartet, dass ERK1/2, ein Molekül der 
MAPK-Kaskade, an der Kontrolle der STAT3-Ser727-Phosphorylierung beteiligt sein 
sollte. Daher wurde die Möglichkeit eines „cross-talk“ zwischen diesen beiden Molekülen 
als Hypothese aufgestellt. In dieser Dissertation wurde gezeigt, dass ERK1/2 eine 
wichtige Rolle bei der Proliferation von Trophoblastzellen spielt, die nicht abhängig von 
STAT3-Aktivierung ist. Wir haben auch einen „cross-talk“ zwischen ERK 1/2 und STAT3 
beschrieben, welcher  nicht im Zytoplasma, sondern im Zellkern auftrat: ERK1/2 ist 
nicht für die STAT3-ser727-Phosphorylierung verantwortlich, hat aber einen negativen 
Effekt auf die Translokation von STAT3 innerhalb des Zellkerns, was eine 
Verminderung der Trophoblast-Invasivität zur Folge hat. 
 
 
Vor einigen Jahren wurde entdeckt, dass microRNAs eine Gruppe von regulatorischen 
Molekülen darstellen, welche Genexpressionen auf post-transkriptioneller Ebene 
steuern können. Über 30% des menschlichen Genoms wird durch diese Moleküle 
reguliert und deren Fehlregulation sind unter anderem mit malignen Erkrankungen 
verbunden. Diese Dissertation fasst in einer veröffentlichten Übersichtsarbeit die 
Studien über miRNAs und Plazenta zusammen, mit besonderer Betonung auf die 
speziell durch Trophoblastzellen exprimierten miRNAs. Zudem wurden in dieser 
Dissertation die miRNA Expressions-Profile, auch als miRNom bekannt, in vier 
verschiedenen trophoblastären Zelllinien analysiert und mit denen von isolierten 
primären Trophoblastzellen des dritten  Trimenon verglichen. Einige miRNAs wurden 
als potenzielle Marker für die Differenzierung von Trophoblastzellen identifiziert. 
Schließlich wurden die Effekte von LIF auf die miRNA-Profile der selben Zelllinien 
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untersucht. Dabei fanden wir vier miRNAs, welche in allen Zelllinien signifikant 
verändert wurden: miR-511, miR-550 und miR-885-5p (herunterreguliert) und miR-641 
(hochreguliert), was auf ihre besondere Bedeutung hindeutet. Die Datenbank-Analyse 
der möglichen Zielgene legt einen Zusammenhang mit der Regulation der Zellteilung 
nahe.  
 
Zusammengefasst wurden in dieser Arbeit intrazelluläre Signalmechanismen 
untersucht, die an der Regulation der LIF-Reaktionen in Trophoblasten beteiligt sind. 
Außerdem wurden miRNAs identifiziert, die zur Regulation von 
Trophoblastzellproliferation beitragen. Diese miRNAs bieten daher das Potenzial zur 
Entwicklung neuer Strategien für die Erkennung oder Behandlung von 
Schwangerschaftsstörungen. 
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Abstract. Pregnancy is personally special to every woman expecting a child, but is also interesting from the perspective of an
immunologist. During a physiological pregnancy, the mother’s immune system decides to tolerate and foster an incorporated,
non-self, non-dangerous organism. Whether the maternal reaction stems from deciphering the foreigness or safeness of this new
individual, it is the general consensus that there is a foeto-maternal, bidirectional “dialogue” occurring and that the “messages”
that are “spoken” are relayed through signaling mediators, which are capable of transmitting a functional command to a target
cell. Much information dedicated to this theme has been gleaned in the past decade; however, the complex nature of cytokine
networks jeopardizes clarity.
In this review, we touch upon a list of mediators that are vital for reproduction. These factors are divided according to their
receptor family, because this elucidates the characteristic signal transducing pathway, which is expected to mediate their signal
within the target cell. The target cells of interest are the trophoblast, upon which we focus for several reasons: 1. the trophoblast
represent the foetal compartment while participating in foeto-maternal interplay (e.g. while invading the decidua, trophoblasts
are in constant communication with uterine, maternal immunocytes, which check and contain this function), 2. trophoblasts
are responsible for foetal well-being (e.g. nutrition, protection from the environment) and 3. dysfunctional trophoblast function
results in several pregnancy complications (e.g. preeclampsia, intrauterine growth retardation, miscarriage, preterm delivery).
We summarize what is described in the literature on how these mediators are distributed within the reproductive tract, which
cells are expressing their respective receptors (especially which trophoblast subsets) and how they modify trophoblast function
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(namely invasion, proliferation, differentiation and apoptosis). Furthermore, we unearth for which mediator the signal transducing
pathway is verifiably used in trophoblast (ic) cells. Finally, we correlate actual biological importance of the mediator for
reproduction by comparing murine knockout phenotypes and known positive and negative associations of these mediators with
human pregnancy pathologies (as listed above). We expect this concise review to be useful to both basic researchers and clinicians
who wish to obtain an overview of the reproductive cytokine network in respect to the trophoblast.
Keywords: Placenta, pregnancy, trophoblast, cytokines, cytokine receptors, chemokine receptors, immunoregulation
INTRODUCTION
The immunological situation found during preg-
nancy is of special importance. Most often, pregnancy,
although generally accepted as a miraculous milestone
in the lifeline of a woman, is not perceived as a crit-
ical condition in which the mother is incorporating a
complex organism of foreign origin. Indeed, normal
and physiological pregnancies are usually concluded in
an uncomplicated fashion without the maternal organ-
ism reacting in any adverse way toward the foetus or
placenta inside the gravid uterus, so that the accom-
plishments of this non-reaction are quite ignored [1].
During pregnancy, it is of utmost consequence that
the so-called foreign object, the foetus, is not rec-
ognized as such, but instead accepted as a “friend”.
There are two most prominent theories committed
to explaining this physiology. One maintains that an
active induction of tolerance of the foetal allograft is
initiated through bidirectional dialogue between the
foetus (or placenta) and the mother during physiologi-
cal pregnancies [2]. Another, newer hypothesis, which
proposes that the immune system is more concerned
with damage than with foreignness, describes that
without a so-called “danger signal” stemming either
directly from the pregnancy or from a precarious set-
ting during pregnancy, the foetus will not be recognized
as anything that requires an aggressive immunological
response [3, 4]. The discussion between both of these
fields is quite controversial and does not promise to be
resolved completely in the near future (reviewed in [5,
6]). However, both sides realize that a major contribu-
tor to any immunological reaction that might be seen
during pregnancy would be identified, amongst others,
per cytokines [5, 7].
Cytokines, being the main mode of communica-
tion between immunological cells and their targets,
would be instigators of tolerance, rejection or any other
immunological reaction toward a pregnancy. When
these signals are intercepted, blocked or amplified,
dire consequences can be expected. During pregnancy,
communication between the foetus (placenta) and the
mother (decidua) is an intricate network intercalated
with that of the hormonal network. Cytokines are
produced by immunocytes that are in dialogue with
their environment, and these immunocytes are in turn
responsive to other cytokines. Many of these cytokines
are produced in a spaciotemporal fashion, indicat-
ing that they are in cinque with maternal pregnancy
homeostasis, and are responsible for the fine tuning of
specific functions within the placenta.
In this review, we focus on a spectrum of cytokines
which are known to be important for reproduction.
We are mainly interested in their effects on the tro-
phoblasts, a main subset of cells that constitute the
placenta and which are of foetal origin. Maternal,
uterine immunocytes come into direct contact with tro-
phoblast cells, thus initiating a bi-directional transfer
of information.
In short, there are three main trophoblast subsets
in the placenta: the villous cytotrophoblast (CTB),
the syncytiotrophoblast (STB) and an intermediate
trophoblast subset that is also termed extravillous tro-
phoblast (EVT). The first two subsets are found coating
the villous tree of the placenta. The STB layer is found
on the outside coating, and comes into direct contact
with maternal blood of the intervillous space (and with
maternal immunocompetent cells), and thus is also
responsible for such jobs as transportation of nutri-
tion and oxygen to the foetus. It is also important in
metabolic changes including detoxification and pro-
tection from microbes. The layer just underneath the
STB consists of CTB, which are often considered a sort
of trophoblast stem cell that replenishes the STB layer
when areas of the villous tree thin out and are exhausted
[8, 9]. STB consist namely of fused CTBs, which after
fusion, have become aproliferative, meaning that the
only manner in which the STB layer can grow, is
through a constant replenishment from the below CTB
layer [9]. The CTB however have several functions:
they either differentiate to replenish STB or they dif-
ferentiate along the invasive pathway. This situation
occurs in areas where the floating villi are attached
to the basement membrane. Upon doing so, some
CTB differentiate first to anchor the villi to the base-
ment membrane, but some further differentiate into an
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invasive trophoblast phenotype, coined EVT due to its
location or intermediate trophoblast due to its size.
These EVT proceed to invade the maternal decidua
and, mainly during first trimester, the myometrium
[10]. A part of these EVT has the main goal of reach-
ing maternal uterine spiral arteries [11, 12]. These
arteries are important to supply the intervillous space
with maternal blood (containing nutrients and oxygen),
which is then rerouted into the intervillous space. When
EVT reach these arteries, the endothelium is eroded by
the EVT and replaced with EVT which then differen-
tiate into the so-called endovascular EVT (endEVT),
which are not capable of producing vasotension in
reponse to vasoreactive substances. In this manner, the
spiral arteries are transformed into low-resistance ves-
sels that supposedly allow for optimal blood flow into
the intervillous space [12]. EVT invasion, although
very similar to cancerous invasion, is also spaciotem-
porally controlled. Currently, it is deemed that EVT
come into contact with decidual/ uterine immunocytes,
which communicate with each other, and thus, EVT
invasion is controlled in terms of intensity and direction
[13].
Insufficient EVT invasion is hypothesized to lead
to faulty spiral artery transformation and thus to a
situation within the placenta that promotes placen-
tal insufficiency, and secondary to that intrauterine
growth retardation (IUGR) and/or preeclampsia [14].
Faulty trophoblast invasion into the decidua at ear-
lier points of pregnancy could lead either to infertility
(due to implantation failure) or to miscarriage [15].
In some situations, trophoblast invasion is not under
adequate control. This could result in benign, but life-
threatening, diseases such as placenta accreta, increta
and percreta. Some trophoblast cells dedifferentiate.
This situation can lead either to benign molar disease,
but also malign trophoblastic disease, choriocarci-
noma. All of these settings are dire for reproductive
success in the least, and in the most for the mother and
the foetus.
We focus now on an assortment of mediators that
are known to play a role during reproduction. In this
review, we mainly summarize the available literature
on the interactions of these cytokines with trophoblast
cells (proliferation, invasion, differentiation and oth-
ers). Furthermore, we list:
• what is known about cytokine distribution within
the reproductive organs,
• which trophoblast subsets are known to express
their receptors,
• which signal transduction pathways are utilized
in trophoblast(ic) cells,
• the impact of murine cytokine deficiency on via-
bility and reproduction and finally
• how the cytokine is associated with human preg-
nancy pathologies.
The mediators are categorized here according to
their classical receptor family, although we stress
that this scheme might not necessarily hold true
for the trophoblast. We refrain from describing the
exact mode of signal transduction via these recep-
tors since this would far overreach the scope of this
topic. Further information on this cytokine catego-
rization principle in the immune system in general
can be found in Coico and Sunshine [16] as well
as http://en.wikipedia.org/wiki/Cytokine receptor and
http://de.wikipedia.org/wiki/Zytokin.
TYPE I CYTOKINE RECEPTOR
Interleukin-6 (IL-6)
IL-6 is a 26-kD pleiotropic protein that belongs
to the family of glycoprotein 130 (gp130) cytokines
along with leukemia inhibitory factor (LIF) and IL-11.
It is produced by a large numbers of cells, such as
fibroblasts, macrophages, dendritic cells, T and B
lymphocytes, endothelial cells, glial cells and ker-
atinocytes. In addition, IL-6 has been shown to be
expressed by STBs and EVTs (2).
Although most biological functions of IL-6 occur
by activation of its membrane receptor gp130, there
is a specific receptor (IL-6R) which forms a com-
plex agonist. Both IL-6 membrane receptor gp130
and the specific receptor IL-6R are present in the
maternal and foetal tissues (endometrium, decidua
and trophoblast) during implantation and placentation.
Within the human endometrium, IL-6 expression fol-
lows a regulated temporal pattern (3–5), indicating a
role in endometrial function and in implantation. Both
increase during secretory phase of menstrual cycle,
however, during the early first trimester pregnancy the
soluble form predominates over the membrane-bound
form until pregnancy week 10. At pregnancy week
11, the longer membrane-bound form increases. This
increase proceeds during the second trimester [17].
It is also implicated in the prevention of recurrent
abortion in mice and humans [18–20], and it has been
demonstrated that deficient IL-6 mice show a reduc-
tion in fertility and a decrease in viable implantation
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sites [21]. Abortion in mice can be prevented by rIL-6
treatment [20].
IL-6 activates the Janus kinase/ signal transducer and
activator of transcription pathway (JAK/STAT) [11,
12]. IL-6 has been shown to stimulate system A (but
not system L) amino acid transporter activity in pri-
mary trophoblast cells through STAT3 and increased
expression of Na(+)-coupled neutral amino acid trans-
porter (SNAT)2 isoform. STAT3 was phosphorylated
at Tyr705 in these experiments. The importance of
the JAK/STAT signal-transduction pathway in embryo
implantation has been demonstrated by the embry-
onic lethality of STAT3 deficient mice [22]. The role
of STAT3 activity in trophoblast invasion suggests a
potential participation of IL-6 in this process [12, 13].
On the other hand, the invasive CTB cells express
high levels of IL-6 [23] which increases the activity
of matrix metalloproteinase-9 (MMP-9) and MMP-2
[24]. Moreover, transwell migration and Matrigel inva-
sion of JEG-3 cells have been significantly reduced by
transfection with IL-6 siRNA (small inhibitory RNA),
while silencing of both IL-6 receptors was able to
significantly decrease trophoblastic cell proliferation
[25]. In addition, IL-6 enhanced the invasiveness of dif-
ferent tumor cells in an extracellular matrix membrane
system [17, 18]. Furthermore, recent researches has
shown that IL-6 increased the invasion ability of human
pancreatic cancer cells [26] and that serum levels of
this cytokine correlate with the extent of tumor inva-
sion, lymph node metastasis, distant metastasis and all
aspects of breast cancer [27]. These findings indicate
that tumor cells tend to invade and metastasize in an
environment rich in IL-6. In the context of reproduc-
tion, an increased ratio of soluble gp130/soluble IL-6R
(sIL-6R) and/or reduced sIL-6R production combined
with down-regulation of IL-6R occur in placentas from
pre-eclampsia women [28].
Taken together these data suggest a contributing role
for IL-6 in stimulation of trophoblast invasion, regula-
tion of endometrial function and in implantation.
Interleukin-11 (IL-11)
IL-11, an IL-6 group cytokine, is present at the site
of implantation and has been observed to be indis-
pensable for the murine embryonic development [29].
It transduces its signal through the IL-11 receptor 
(IL-11R; IL-11 specific receptor) and gp130 (com-
mon co-receptor for IL-6 family of cytokines) through
activation of JAK1/2 and STAT3 mediated signaling
pathway. IL-11 has pleiotropic effects on cells depend-
ing upon the cellular microenvironment. It is involved
in regulation of biological functions, such as cellular
proliferation and differentiation as well as in pro-
gression of several carcinomas [30–32]. The IL-11R
knockout female mice, though physiologically normal
are infertile because of defective decidualization of the
endometrial stromal cells [33, 34]. Defective decidu-
alization leads to lack of critical endometrial signals
essential for normal proliferation and differentiation
of trophoblastic cells of the developing embryo. In
humans, IL-11R has been found to be expressed con-
sistently in the endometrium from proliferative and
secretory phase to 7–9 weeks of gestation [35]. In con-
trast to this, IL-11 expression is barely detectable in
the proliferative and secretory phase of endometrium,
but was found to be significantly higher in the chori-
onic villi as well as in decidua [35]. The endometrium
of rhesus monkey shows maximum immunoreactiv-
ity for both IL-11 and IL-11R during the secretary
phase of the menstrual cycle and their co-localization
at the site of implantation [36]. From the foetal side,
immunoreactive IL-11R is expressed by subpopula-
tions of interstitial and endEVT cells of first trimester
human placenta as well as by JEG-3 choriocarcinoma
cells [37, 38]. Furthermore, a defective production of
IL-11 correlates with a reduced fertility rate in humans
[35]. The plasma level of IL-11 was found to be low
in women suffering from spontaneous abortion [39].
Another study on human endometrial cells confirmed
that IL-11, in either an autocrine or paracrine man-
ner, works in conjunction with progesterone to bring
forth their differentiation into a functional decidua
[40]. Though IL-11 plays a defined role in endometrial
decidualization, its role in trophoblastic cell invasion
has been held in controversy. Exogenous treatment
with IL-11 of JEG-3 choriocarcinoma cells and a cell
line derived from the hybridoma of human EVT and
JEG-3 cells led to an increase in the invasion and
migration respectively through activation of STAT3
Tyr705 phosphorylation [37]. In contrast to these, treat-
ment of HTR-8/SVneo trophoblastic cells with IL-11
decreases their invasion through activation of STAT3
Tyr705 [41].
Granulocyte Macrophage-Colony Stimulating
Factor (GM-CSF)
Among the colony-stimulating factor family mem-
bers, GM-CSF is an hematopoietic cytokine secreted
by macrophages, mast cells, endothelial cells,
T cells, fibroblasts and bone marrow stromal cells [42].
GM-CSF affects the proliferation, differentiation and
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survival of myeloid leukocytes and their precursors
[43]. The receptor of GM-CSF consists of  (GM-R)
and  subunits. The  subunit is shared with receptors
for GM-CSF, IL-3 and IL-5 [44]. On the cell membrane
of choriocarcinoma cell lines such as BeWo, JEG-3 and
JAR and of primary trophoblast cells (CTB and EVT;
only weak expression on STB), GM-R protein can
be detected [45]. Researches demonstrate, also, a role
in the modulation of Th1 and Th2 immune responses
for this cytokine [46, 47]. Studies of in vitro angio-
genesis assays and in vivo Matrigel plug assays with
endothelial cell of mice indicated that GM-CSF and
monocytes play a key role in angiogenesis through
the regulation of vascular endothelial growth factor
(VEGF) [48]. Acting as an immunoregulatory agent,
GM-CSF, which is regarded as an important determi-
nant of pregnancy outcome, contributes to regulation
of placental morphogenesis and maternal immune tol-
erance [49]. Furthermore, as an embryotrophic factor,
it is indispensable for providing ideal foetal evolu-
tion after implantation, such as foetal and post-natal
growth, and the likelihood of obesity in adult descen-
dants and it regulates the morphological and functional
development of the placenta [50]. It contributes as
a driving force in a tightly regulated sequence of
events involving CTB cell proliferation and terminal
differentiation to generate STB cells [51]. By accom-
modating these trophoblastic functions, it is believed
to be involved in invasion of maternal decidual tissues
and blood vessels, although actual in vitro data is yet
to be generated.
GM-CSF seems relevant to human reproductive
medicine, since its deficiency is associated with
placental insufficiency, as well as immunological dis-
orders, and it is shown to be involved in miscarriage,
low birth weight, pre-term delivery and preeclamp-
sia [49]. According to other studies concerning these
complications, GM-CSF expression is increased in the
decidua of preeclamptic women and mice [52]. Dur-
ing the post-conceptional period, the GM-CSF which
is secreted into the uterus and the salpinges is impli-
cated as a regulator of the growth and development
of the pre-implantation embryo [53]. One study of
women suffering from recurrent miscarriage showed
that an increase in serum GM-CSF content, which is
seen in normal pregnancy, did not occur in the mis-
carriage group [54]. Researchers have demonstrated
that the outcome of gestation is radically modified
by the administration of exogenous GM–CSF to mice
[55]. Other studies in mice with a null mutation in
the GM-CSF gene show that fertility and the num-
ber of surviving pups are impaired in the absence of
GM-CSF [56–58]. These studies reveal that a GM-CSF
deficiency leads to growth retardation and small lit-
ter sizes probably secondary to placental anomalies,
including a diminished proportion of glycogen cells in
the spongiotrophoblast layer [56].
Uterine and placental tissues are recognised as
potent sources of hematopoietic colony stimulating
activity [59, 60]. GM-CSF is produced by uterine
epithelial cells, and GM-CSF is found in the lumi-
nal and glandular epithelium. GM-CSF synthesis by
uterine epithelial cells is predominantly stimulated
by estrogen; its expression stays high for the first
few days after conception, but then declines around
the time of embryo implantation, which occurs under
the inhibitory influence of progesterone [61]. Once
implantation begins, cell lineages in the chorionic villi
of the early developing placenta contribute to GM-CSF
production including the invading CTB cells [62], vil-
lous fibroblasts [63], and placental macrophages [64].
Other analyses also demonstrated that in women and in
mice, GM-CSF synthesis by reproductive tract epithe-
lial cells is responsive to ovarian steroid hormones and
to male seminal fluid factors (59, 60).
Several identified polymorphisms in the genes that
encode GM-CSF are identified conferring endogenous
variability in GM-CSF bioavailability and signaling
networks [65–67]. At least three signaling path-
ways have been described for this cytokine: the
mitogen-activated protein kinase (MAPK) pathways,
the JAK/STAT pathway and the phosphatidylinositol 3-
kinase pathway (PI3K) [68–72]. Furthermore, there is
one study that supports the idea that STAT5 is recruited
to the membrane from the cytosol upon GM-CSF stim-
ulation and is tyrosine-phosphorylated by JAK2 [44],
but it is yet to be discovered which pathway is used for
signal transduction of GM-CSF in the trophoblast. Our
own unpublished results indicate that at least STAT3
is not involved in mediating its signal. At least in the
inner cell mass it has been demonstrated that GM-CSF
signaling occurs independent of its ß common sub-
unit [53]. Considering the relevance of GM-CSF in the
early stages of pregnancy, a complete understanding of
its role represents an opportunity for developing inter-
ventions for achieving favorable obstetrical outcomes.
Leukemia Inhibitory Factor (LIF)
LIF, a member of the IL-6 family, is a widely known
pleiotropic cytokine which posseses a pivotal role in
human reproduction [73, 74]. LIF was first identified in
1987 by Metcalf and colleagues as a factor that induced
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the differentiation of mouse myeloid leukemic M1
cells into macrophages [75]. Currently, LIF is known to
be expressed in numerous cell types including neurons,
hepatocytes, and kidney and breast epithelial cells [76,
77] and its main role is the mediation of inflamma-
tory cell responses [78, 79]. Nevertheless, LIF is also
recognized to control uterine receptivity for blastocyst
implantation, or to influence trophoblast behavior by
promoting proliferation, invasion and differentiation
[80, 81].
LIF appears to be an important modulator of preg-
nancy in humans. Both granulosa-lutein cells and
ovarian stromal cells expressed LIF mRNA and pro-
tein. Furthermore, LIF concentration in follicular fluids
correlates with the embryo quality suggesting an
important role of LIF in the physiology of ovula-
tion and early embryo development [82]. On the other
hand, LIF is expressed by the endometrium, predomi-
nantly in the glandular and luminal epithelium, and its
concentrations reach maximal levels during the secre-
tory/postovulatory phase of the menstrual cycle, when
the implantation is expected to commence [80, 83].
During the implantation window, trophoblast cells also
express mRNA for the LIF receptor which maximizes
interaction with the endometrium. After adhesion, the
blastocyst is able to produce LIF mRNA by itself,
which leads to an increase in cell proliferation and trig-
gers differentiation into CTBs and STBs, and enhances
invasive behavior of trophoblast cells. [81, 84–86]. The
LIF receptor is expressed by both villous as well as
EVT cells throughout pregnancy. EVT express the LIF
receptor as they pass decidual leukocytes which secrete
LIF, and thus they come into dialogue [87].
LIF’s crucial role during embryo implantation is evi-
dent in LIF deficient female mice, which albeit being
infertile by the inability of the blastocyst to attach,
could recover fertility by LIF infusion into the uterus
[88]. Conversely, LIF receptor knockout mice implant,
but exhibit impaired placenta function, which results in
death within 24 h of birth [89]. In humans, LIF expres-
sion levels are diminished in endometrial cell cultures
from infertile women with repeated abortions or unex-
plained infertility [90, 91]. In fact, women wearing
a copper T380A intrauterine device (IUD), one of
the most effective anticonceptive devices, showed also
lower expression of LIF compare with control [73].
But it is not only LIF protein expression deregulation
which may have a negative impact on the pregnancy
outcome, functionally relevant mutation of the LIF
gene are found higher in infertile women in compari-
son with fertile controls resulting in poor outcome in
IVF treatment [92].
LIF triggers its effects by induction of a signaling
heterodimer consisting of the specific LIF receptor
(LIFR) and the subunit gp130 [74]. This causes the
activation of the RAS/MAPK (RAt Sarcoma/ MAPK)
and JAK/STAT cascades [93–95]. STATs are a fam-
ily of transcription factors located in the cytoplasm,
which after activation can form hetero- or homo-dimers
and be translocated into the nucleus to control gene
expression [96, 97]. STATs are associated with regula-
tion of implantation and maternal immune response in
early pregnancy [98]. Furthermore, we have demon-
strated that STAT3, a member of the STAT family,
plays a crucial role in the regulation of trophoblast
invasion mediated by LIF. LIF induces alteration of
proteases such as tissue inhibitor of metalloproteinase
1 (TIMP1) and Caspase4 via STAT3, which elevates
trophoblast(ic) proliferation and invasion, and STAT3
knockdown annuls these functions even in the presence
of LIF [81, 86, 99]. LIF has been patented as a supple-
ment to culture media to promote the development of
mammalian embryos to the implantation stage, since
growth in the presence of LIF increases the percent-
age of embryos that reach the implantation stage than
growth without LIF (United States Patent 5962321;
Inventors: Gough, Nicholas Martin; Willson, Tracey
Ann, Seamark, Robert Frederick (Beulah Park, AU),
http://www.freepatentsonline.com/5962321.html).
Granulocyte-Colony Stimulating Factor (G-CSF)
G-CSF is a macrophage- and granulocyte-inducing
(MGI) protein, mainly produced by macrophages,
which induces the proliferation and differentiation of
macrophage and granulocyte precursor cells. Further-
more, G-CSF is able to induce terminal differentiation
in murine leukemic cells and thereby suppress
leukemic cell populations. The murine and human
G-CSF protein show almost complete cross-reactivity
regarding biological effects and receptor-binding in
human or murine normal and leukaemic cells [93–97].
The molecular weight of G-CSF amounts 19.6 kDa,
consist of 174 amino acids and is o-glycosylated at
Thr-133 [100–102]. The encoding gene of G-CSF is
located at chromosome 17, 17q11.2–21 [103]. The G-
CSF receptor is a 150 kD single subunit protein [104].
G-CSF is produced by those decidual cells that are
in contact with anchoring villi but not by trophoblast
cells of the chorionic villi [105]. G-CSF-receptor (G-
CSFR) is expressed in human placental membranes
as well as CTBs and STBs and decidual stromal
and endometrial gland cells [104, 105]. G-CSFR is
intensely expressed in first and third trimester, but not
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expressed in second trimester placental tissue. The
strongest expression was found in invasive, extravil-
lous CTBs, and differentiated STBs but expression was
weak in undifferentiated CTBs. Furthermore, G-CSFR
positive interstitial trophoblasts were found in decidual
tissue, distal and proximal to the materno-foetal inter-
face and in dense maternal connective tissue. Thereby,
the G-GSFR expression was weak in first, strongest in
second, and weak or absent in third trimester. These
data suggest a possible role of G-CSFR in decidual
invasion of CTBs [106, 107].
The immortalised first trimester trophoblast cell
line HTR-8/SV neo increase G-CSF expression after
lipopolysaccharide (LPS) incubation, suggesting a
participation of trophoblast cells in cytokine based
immune signaling [108]. G-CSF is able to increase pro-
liferation of CTB cells derived from human chorionic
villous tissue [105], but inhibits the proliferation of two
choriocarcinoma cell lines [109], which the authors
cannot presently specify due to inavailability of the
full publication.
G-CSF activates the JAK/ STAT and MAPK sig-
naling pathway in chorioncarcinoma cell line JEG-3.
G-CSF had no positive effect on JEG-3 prolifera-
tion, but protects JEG-3 cells from serum starvation
[110]. All these data suggest a potential role of G-CSF,
secreted by decidual cells, in controlling trophoblast
invasion, but in vitro experiments substantiating this
notion are yet to be published.
Follicular fluid G-CSF has recently been described
as a new biomarker identifying the competent oocyte,
and this concentration correlated in positive predic-
tion of live birth in assisted reproduction techniques
(ART) [110, 111]. In a recently published pilot study,
administration of G-CSF during ART in patients who
suffered from repetitive implantation failure (and were
also lacking killer-cell immunoglobulin-like recep-
tors) elevated the pregnancy rate to a stunning ca
73%, albeit the abortion rate was also high (ca 39%)
[111]. Women suffering from primary recurrent mis-
carriage also profited from G-CSF treatment (ca 83%
versus 39% in control group for live birth rate)
[112]. G-CSF is also associated with other immune-
related pregnancy complications such as preeclampsia
[113] and spontaneous preterm birth [114]. Taking
the above into consideration, it is no surprise that
G-CSF has been patented as an intervention to pre-
vent abortion, implantation failure during ART or
to treat or prevent preeclampsia or preterm labor
(United States Patent 7615531, inventor: Carter, Dar-
ryl (Owings Mills, MD, US) Nora Therapeutics;
http://www.freepatentsonline.com/7615531.html).
Leptin
Leptin is a hormone that was originally thought to
be produced only by adipocytes to aid in modulating
satiety and energy homeostasis [115, 116]. However,
this cytokine is now known to be produced by placental
tissues [117] and secreted to both maternal and foetal
circulations during the pregnancy [118, 119].
Expression of the leptin gene was found abundantly
in the human first trimester chorionic villi, and slightly
in the third trimester chorion laeve, and amnion.
Immunohistochemical experiments demonstrated that
both STBs and CTBs were stained positively for leptin
[120].
Leptin receptors have been described in trophoblast
cells of several species [121–125] as well as in the JAR
and BeWo derived trophoblast cells lines [126]. Bod-
ner et al. [127], showed that theleptin receptor mRNA
was expressed in the cytoplasm of the STB. Moreover,
throughout immunohistochemistry technique, the lep-
tin receptors produced a strong reaction in the STB
of placental villi at term. The apical membranes were
continuously stained, whereas basal membranes and
cytoplasm lacked reactivity with both antibodies. CTB
cells, stroma cells and endothelial cells were not
labeled. EVT display high expression of the leptin
receptor [128].
The role of this cytokine during pregnancy was con-
firmed in ob/ob mice, which lack a functional leptin
protein. These animals are infertile, however, leptin
treatment promoted embryo implantation and initial
placental development in these mice [129]. Trans-
lated to human pregnancy pathologies, it can be stated
that leptin is associated with gestational hypertension,
IUGR and gestational diabetes. The polymorphism of
the leptin receptor is related with severe preeclamp-
sia [130]. Leptin has been found to be associated with
maternal hypertension that may or may not proceed
to preeclampsia [131, 132]. In IUGR decrease of pla-
cental leptin and mRNA leptin in umbilical cord was
observed [133]. Pregnancy associated with diabetes is
linked with an increase in the placental and circulatory
leptin [134, 135].
During embryo implantation and the development of
the placenta, trophoblast invasion is currently consid-
ered as the most limiting factor for the establishment
of normal pregnancy. There is evidence suggesting
that leptin produced by the maternal endometrium
plays an important role in the signaling necessary to
these processes [136]. In particular, leptin has been
proposed to play a relevant role in implantation and
trophoblast invasion by virtue of its stimulatory effect
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on MMP expression in CTB [137]. Leptin increases,
in a dose-dependent manner, the secretion of MMP-2
and enhanced the activity of MMP-9 in cytotrophoblas-
tic cells [137]. Moreover, Magarinos et al, illustrated
the antiapoptotic and proliferative effects of leptin in
trophoblastic cells lines [138].
Leptin seems to promote trophoblast invasiveness in
primary cultures of mouse trophoblasts. This cytokine
stimulated the phosphorylation of MAP or ERK kinase
(MEK, also termed MAP2K1), but not that of STAT3 in
the cultures, while it increased the concentration of the
suppressor of cytokine signaling 3 (SOCS3) protein,
and up-regulated metalloproteinase activity [139].
Leptin is now known to play a wide range of impor-
tant roles, which extend from pregnant physiology as
well as implantation and from paracrine effects in the
placenta to regulation of trophoblast invasiveness.
TYPE II CYTOKINE RECEPTORS
Interleukin-10 (IL-10)
IL-10 is an immunosuppressive cytokine that has
been shown to be produced by a wide variety of cell
types, including macrophages, dendritic cells, natu-
ral killer (NK) cells, T cells, B cells, as well as cells
found at the maternal-foetal interface, namely endothe-
lial, placental trophoblast and decidual stromal cells
[140–144]. Functionally, IL-10 binds to its cognate
receptor IL-10R and in turn activates the JAK and
STAT signaling pathways [145], but this is yet to be
demonstrated in the trophoblast.
In the context of pregnancy, IL-10 has been shown to
play a prominent role. The kinetics of IL-10 expression
in both mice and human placental trophoblast exhibit a
temporal pattern. IL-10 is expressed early in gestation
and remains elevated throughout the second trimester
[143].
As mentioned above, different cellular populations
are involved in its production at the maternal-foetal
interface. Particularly, CTBs produce IL-10. Studies
indicate that IL-10 can inhibit the activity of MMP-9,
an enzyme which increases CTB invasiveness [144,
146]. Furthermore, one publication illustrates how
infection of differentiating and invasive CTB with
cytomegalovirus (CMV) leads to production of both
cmv- and human IL-10. Both of these cytokines appar-
ently inhibited CTB migration (into an endothelial cell
wounding assay) and invasion (into a Matrigel) [147].
On the other hand, extrawillous trophoblast (EVT)
cells are poor producers of IL-10 (unpublished data),
thus possibly allowing MMP expression and invasion
capability. Additionally, in preeclampsia, a pregnancy
disorder associated with decreased trophoblast inva-
sion and remodeling of uterine spiral arteries, IL-10
production is significantly reduced [148].
In an in vitro model that recapitulates the interac-
tion between first trimester EVT and endothelial cells,
exogenous IL-10 could rescue the polychlorinated
biphenyls (PCBs)-induced disruption of endovascular
activity and restored impaired spiral artery remodeling
in vivo [149] implying its role in vascular activ-
ity. Additional evidence, from the lab of Surrendra
Sharma suggests that IL-10 may play a protective
role in preeclampsia. In this context, unlike the IL-10
proficient wild-type mouse, pregnant IL-10−/− coun-
terparts were sensitive to human preeclampsia serum
treatment that impaired spiral artery remodeling and
precipitated the full spectrum of clinical features of the
disease [150]. Importantly, recombinant IL-10 reversed
the hypoxia induced preeclampsia-like features in
pregnant IL-10−/−mice providing further evidence to
the pleiotropic vascular role of IL-10 [151, 152]. Like-
wise, IL-10canpromote trophoblast invasion indirectly
by disrupting macrophages that inhibit trophoblast
invasion [153] or protect against LPS and angiotensin
II-induced vascular dysfunction [154, 155].
IL-10 is not essential for normal pregnancy outcome
in mice [156] and reviewed in [157]. When IL-10−/−
females are mated with IL-10−/−males, implantation
sites are increased with more viable foetuses than preg-
nant wild-type IL-10+/+mice [158]. However, IL10
is vital in protecting pregnancy during inflammatory
alterations as seen during LPS-confrontation. In these
instances (IL-10 deficiency), LPS mediates an elevated
incidence of miscarriage [159] and preterm labor [160]
and predisposes to growth retardation [157], while
administration of IL-10 on E9.5 of gestation to these
mice reduced foetal loss and growth restriction [157].
Single nucleotide polymorphisms of IL-10 are asso-
ciated with the development of preeclampsia [161].
Some IL-10 gene promoter polymorphisms associated
with cytokine down-regulation seem to be consti-
tutional risk factors for early embryonic pregnancy
failure [162]. An increase in the production of IL-
10 early after implantation is related to the success
of pregnancy [163].
Taken together, IL-10 plays an important part in the
regulation of trophoblast invasion and vascular activity
at the maternal-foetal interface.
Interferon-gamma (IFN-γ)
IFN - is a type II proinflammatory cytokine
involved in the activation of innate and adaptive
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immune response via receptor (IFN - Rs)-mediated
JAK/STAT1 signaling pathway [164]. It has also potent
anti viral activity, as all other IFNs.
IFN - is expressed in the reproductive tract in
implantation and in pregnancy [165]. Histochemical
analyses in human trophoblast cells have shown a
stronger expression of IFN - during the first trimester
as compared to term [166]. In mice IFN - has been
detected in giant trophoblast cells [167]. However, the
majority of the human [168] and mice [169] endome-
trial IFN - stems from CD56bright CD16- uterine
natural killer (uNK) cells homing in from the sys-
temic circulation. IFN -Rs are known to be expressed
throughout the pregnancy by trophoblast cells (namely
villous CTBs) and in the CTB cell columns [168]) and
in uterine epithelium and stroma [170], and is in par-
ticular localized to those areas adjacent to attaching
trophoblast [171].
IFN - and IFN- R null mice have a large num-
ber of undifferentiated uNK cells causing wide spread
necrosis in the decidua suggesting the significance of
the IFN - pathway during early pregnancy [169].
IFN -was shown to decrease excessive trophoblast
invasion in a Matrigel assay using first trimester extrav-
illious trophoblast cells and JEG-3 choriocarcinoma
cells. The effect was mediated via down regulation of
MMP-2 and MMP-9 mediated by STAT1 and IFN-
-inducible class II transactivator (CIITA) [172–174].
Also, IFN-induced and regulated genes were found
to be upregulated in decidualized endometrial cells
cultured in the presence of the human trophoblast
conditioned medium, suggesting a role for IFN - in
regulating the maternal side of the foetal maternal inter-
face [175]. However, harmful effects of IFN - can also
be anticipated since the inhibition of IFN- signaling
in human trophoblast cells, exerted by protein tyrosine
phosphatase, prevented transplant rejection directed
against the foetus [176].
A shift towards a Th1-type immunity, as expressed
either through an increased IFN-gamma/IL-4 ratio in
maternal serum or elevated placental concentrations of
IFN - levels, is observed during preeclampsia [170,
171]. Although IFN- polymorphisms do not seem to
be associated with preeclampsia, a higher frequency
of a specific IFN - polymorphism was observed in
a Brazilian population of eclamptics [177, 178]. In a
China-based study, some IFN- receptor 1 polymor-
phisms are associated with the development of PE
[179]. Umbilical cord serum levels of IFN -was asso-
ciated with a decreased risk of small for gestational age
(SGA) birth, especially amongst preterm babies [180].
In terms of miscarriage, systemic levels of IFN-were
not associated with implantation rate or miscarriage
rate in women undergoing IVF treatment. However,
high levels of IFN - correlated with elevated levels
of activated NK cells and this may subsequently exert
a negative impact on reproduction [181]. Two South
American based studies, including a meta-analysis,
reported an association between IFN- gene poly-
morphisms and (unexplained) recurrent, spontaneous
pregnancy loss [182, 183]. However among an Iranian
population, the studies of IFN - gene polymorphisms
did not show any association with the pathology [184].
IMMUNOGLOBULIN SUPERFAMILY
Interleukin-1beta (IL-1ß)
IL-1ß is a potent inflammatory mediator produced
by monocytes, dendritic cells and a variety of other
cells. An experimental study suggests that IL-1ß effects
depend on inflammatory conditions.
IL-1ß−/− mice had reduced acute-phase response
in a model of local, sterile inflammation (without
microbial stimulus) but presented a normal reaction
when LPS was added [185]. It was viable to generate
homozygous IL-1b KO mice, they developed normally
and they were healthy and fertile [186].
Besides its role in autoimmune diseases and inflam-
matory disorders [187, 188], IL-1ß seems to play
a relevant role during human embryo implantation
[189]. IL-1ß was weakly expressed in epithelium and
stroma of human endometrium, but highly expressed
in first trimester decidua and in term placental mem-
branes. It seems that progesterone can regulate the
IL-1ß expression, since IL-1ß mRNA was detected in
the late secretory endometrium, when progesterone is
high, but not in proliferative endometrium, when the
progesterone level is low [190–192]. Despite IL-1ß
seeming to be a potent inhibitor of decidualization, IL-
1ß mRNA increases in cultures of endometrial stroma
cells during decidualization [193]. The expression of
IL-1 receptor type I (IL1RI) had three phases trough
the menstrual cycle, low expression in the proliferative
phase, moderate during ovulation and the implantation
phase, and intense at the end of the cycle [190, 194].
Furthermore, IL-1 receptor type II (IL1RII) mRNA
expression was low in the early-to mid-proliferative
phase, increased in the late proliferative/ early secre-
tory phase, decreased in mid-secretory phase and
increased again in late secretory phase [195]. IL-1ß
and IL-1R tI are detected in human placentas and IL-
1ß is expressed both in CTB and STB of chorionic villi
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[196]. IL-1ß was also detected in foetal and maternal
blood cells from placenta samples [197], while IL-
1R tI was present in STB of chorionic villi and in
the endometrial glands of maternal decidua [196]. It
seems that IL-1ß controls human placental trophoblast
growth. Recombinant human IL-1ß inhibited JAR and
BeWo (choriocarcinoma cell lines) proliferation and
this effect can occur by induction of apoptosis [198,
199]. An experiment to investigate the molecular inter-
actions on EVT differentiation showed that IL-1ß had
no effect in TCL1 cell differentiation into an invasive
phenotype (human EVT cell line) [200].
It has been suggested that IL-1ß plays a rele-
vant role in trophoblast invasion. First trimester CTB
and EVT stimulated by IL-1ß increased invasiveness
by approximately 50% on a Matrigel system [201,
202]. Moreover, stimulation with IL-1ß increased the
invasion of human placental choriocarcinoma cells
(JEG-3) and immortalized trophoblast cells (HTR-
8/SVneo) [202, 203], but did not affect the invasiveness
of trophoblastic SGHPL-4 cells in the same sys-
tem [204]. Different studies suggest that IL-1ß’s
tissue invasiveness effect is due to its regulatory
role on the production of MMPs, including MMP-
2, MMP-3, MMP-9 and monocyte chemoattractant
protein-1 (MCP-1) [204–209]. This inductor process
apparently occurs via MAPK and AKT (RAC-alpha
serine/threonine-protein kinase) signalling, given that
inhibitors of theses kinases decrease MMP-3 expres-
sion in SGHPL-4 cells [204]. Moreover, low molecular
mass polypeptide-2 (LPM2) may be necessary for IL-
1ß-induced trophoblast invasion, because it seems to
regulate the expression and activity of MMP-2 and
MMP-9 in HTR-8/SVneo. Additionally, LPM2 knock-
down in HTR-8/SVneo inhibited IL-1ß cell invasion
in Matrigel system [203, 210]. Therefore, these data
suggest that IL-1ß seems to have an important role in
trophoblast invasion, through the activation of MMPs.
There seems to be no apparent difference in the
maternal serum levels of IL-1ß in preeclamptics versus
control [170, 211]. However, the placental expression
of this cytokine seems to be increased in preeclampsia
patients [212]. Furthermore, placental levels of IL-1ß
were not altered in between pregnancies with or with-
out foetal growth retardation [213]. Increased amniotic
fluid levels of IL-1ß (as measured after amniocentesis)
was correlated with an increased risk for delivery <34
weeks gestation [214, 215]. In women threatening to
abort, elevated serum levels IL-1ß were correlated to an
adverse outcome [216]. Reduced intra-amniotic IL-1ß
concentrations and an increased occurrence of sponta-
neous abortions in previous pregnancies are associated
with the foetal carriage of polymorphic IL-1 receptor
antagonist allele 1 [217]. Furthermore, in contrast to
older study results, newer studies indicate that combi-
nations of polymorphisms for the promoter region of
the IL-1ß gene with other polymorphisms or homozy-
gotous polymorphisms of this promoter region seems
to confer a risk for recurrent pregnancy loss through
TH1 immunitiy to trophoblast [218–220].
Colony Stimulating Factor-1 (CSF-1)
CSF-1, also known as M-CSF (macrophage- colony
stimulating factor) [221] or MGF (macrophage growth
factor [222]) is one of a group of at least 18 glyco-
proteins, collectively known as hematopoietic growth
factors [223], which implies membership to the type
I cytokine receptor group, however, CSF-1 classi-
cally belongs to the immunoglobulin superfamily (in
terms of receptors), which shares structural homology
with immunoglobulins. The CSF-1 homodimer is pro-
duced in a variety of adult tissues and influences the
proliferation and differentiation of numerous of cell
types [224]. Ninety-five percent of circulating CSF-1
is cleared by sinusoidally-located macrophages, pri-
marily Kupffer’s cell in liver [225]. CSF-1 and its
receptor are an important receptor/ligand pair in the
biology of breast cancer and tumors of the female
reproductive tract [226]. They are initially implicated
as essential to normal monocyte development and tro-
phoblastic implantation [227] and it is one of the
important cytokines for the function of monocytes and
macrophages [228].
CSF-1 bioactivity is high in the uterus, placenta
and amniotic fluid [229]. CSF-1 is secreted by
human trophoblast as well as endometrial cells [228].
CSF-1 and endothelin-1 are co-localized in same cells
in the amniotic membrane [230]. Female sex steroids,
progesterone and estradiol, regulate CSF-1 synthe-
sis by luminal and glandular secretory epithelial cells
of the uterus [225]. CSF-1 mRNA and protein fac-
tors of its receptor c-fms are identified in the human
placenta and decidua; both are expressed by normal
human 1st trimester invasive EVT (217). The expres-
sion of CSF-1 and c-fms also possess intrinsic tyrosine
kinase activity which suggests that this is another fac-
tor playing a potentially important role in regulating
trophoblast function (218). CSF-1 is present in uterine
glandular epithelium (as mentioned above), vascu-
lar endothelium and villous as well as in EVT, and
mRNA expression of CSF-1 is found in the placenta
and decidua but not in the non-pregnant endometrium
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[224]. The presence of CSF-1 and c-fms mRNA and
protein at human foetomaternal interface suggest that
CSF-1 may be involved in autocrine and/or paracrine
interactions which may regulate trophoblast and/or
decidual cell function [224]. Quantitative mRNA anal-
ysis showed that c-fms mRNA expression in placental
tissues was lowest in first trimester samples and highest
at the end of pregnancy [231]. It has been demonstrated
that the level of CSF-1 in the amniotic fluid of term
gravidas is significantly increased compared to mid-
gestational controls [232]. These results suggest that
elevated levels of M-CSF in amniotic fluid have an
important immunological function in the maintenance
of pregnancy and foetal growth.
There exists some unclearness in the exact func-
tional effects of CSF-1 on trophoblast proliferation,
differentiation and invasion (commented in [233]).
While the two studies described here are congruent in
the aspects that EVT produce both CSF-1 and express
c-fms, the effects were disparate especially on EVT
proliferation and invasion. It seems that primary (inva-
sive) EVT react to CSF-1 supplementation with an
increase in growth (proliferation), but no difference
in Matrigel invasion. Furthermore, in these cells, both
MMP-9 (type IV collagenase) and TIMP-1 expres-
sion were up-regulated in response to this cytokine,
which could explain why no alteration in invasion was
detected [234]. In the study accomplished by Lewis
et al. [235], immortalized EVT cells, termed TCL-1
cell line, did not respond in a proliferative manner
to CSF-1, while blockage of CSF-1 promoted tro-
phoblast growth. The activity of MMP was unaltered
in this experiment. Thus, this group suggested that
CSF-1 may be a differentiation or maturation fac-
tor that suppresses the proliferation of trophoblasts.
The differences seen here are probably explainable by
the cell types used in both experiments. Lala com-
ments that in their HTR8/SVneo cell line, another
immortalized EVT cell line, proliferation was not
altered through CSF-1 treatment (unpublished data
mentioned in reply to comment [236]). However, in
a recent study, HLX (H20-like homeobox protein)
was found to be a regulator of CSF-1-dependent tro-
phoblast proliferation. The homeobox gene HLX is
expressed in proliferating and migrating human tro-
phoblast cells and HLX expression is significantly
decreased in human IUGR. CSF-1 apparently stim-
ulated HLX expression, and silencing of HLX in
the presence of the cytokine resulted in a signif-
icant decrease of trophoblastic proliferation. These
experiments were accomplished on SGHPL-4 and
HTR-8/SVneo trophoblast cells [237, 238].
Studies of osteoporotric (op/op) mice show the cru-
cial role of CSF-1 in pregnancy. These mice experience
severely reduced fertility, largely due to a male defi-
ciency to mate, but also related to low implantation
rates and greater embryonic wastage compared with
the wild-type female [221]. However, CSF-1 deficient
embryos (op/op) can develop normally. Infertility of
op/op×op/op matings, and lower implantation rates
and higher resorption rates in op/op females mated to
+/op or +/+ males, clearly indicate a role for CSF-1 in
both pre- and post-implantation embryos [239]. Many
effects of op/op mutation could be rescued by injec-
tion of neonatal mice with human recombinant CSF-1
[225].
Data suggest that the success of human pregnancy
is associated with the production of the Th2-type
cytokines LIF and CSF-1 (M-CSF) by T cells at
maternal-foetal interface [240]. There are also sig-
nificant increases in M-CSF and GM-CSF levels in
the placenta as well as in the serum of preeclampsia
patients which is bound to have various physiological
effects on tissues at the maternal-foetal interface [230].
The serum level of CSF-1 is significantly elevated
not only in preeclampsia, but also in normotensive
pregnancies with IUGR compared with those in nor-
mal pregnancy [230]. Paradoxically, excess decidual
macrophage infiltration has been linked to preeclamp-
sia and IUGR in the human, and studies also showed
that TNF and IL-1ß induced CSF-1 output by cultured
first trimester and term decidua cells [221]. CSF-1,
or M-CSF, is a potent inducer of Th2-type cytokines,
as well as LIF production, by T cells [240]. Defec-
tive IL-10, LIF and M-CSF production by decidual
CD4+ T cells were detectable in women with unex-
plained recurrent abortion at the time of miscarriage
[240]. Thus, it seems that CSF-1 is important in the
pathogenesis of human pregnancy pathologies as well.
TUMOR NECROSIS FACTOR RECEPTOR
SUPERFAMILY
Tumor Necrosis Factor-alpha (TNF-α)
The tumor necrosis factor (TNF) superfamily is
involved in several physiological functions, such
as immune response and morphogenesis. It has
also been implicated in tumorigenesis, transplant
rejection, septic shock and viral replication [241].
TNF- is a non-glycosilated protein with potent pro-
inflammatory activity which is required for a normal
immune response, but its overexpression has severe
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pathological consequences. TNF- is associated with
many autoimmune diseases [242] and anti-TNF-
drugs have been used in arthritis rheumatoid treatment.
Actually, anti-TNF- active immunization with a vac-
cine started the clinical phase of development [243].
In the reproductive field, TNF production is involved
in the balance of trophoblast turnover and renewal
[242]. TNF- reduces proliferation in EVT [244] and
primary trophoblast cultures [245]. During pregnancy,
several decidual cells types, EVT and villous CTB
produce TNF-. Recently, two receptors have been
detected in the placental bed: TNF-RI and TNF-RII.
Immunostaining for TNF-RI was greatest in intramu-
ral EVT and for TNF-RII in endEVT [244].
To investigate the individual role of TNF- in
the regulation of immune response, a TNF- −/−
mouse strain was generated. This strain was viable
and fertile, indicating that TNF- is not required for
normal embryo development [246]. However, another
model demonstrated that the association TNF-/INF-
was related with miscarriage in mice, demonstrat-
ing how Th1-type cytokines are involved in abortion
[247].
The TNF- effect on cell invasion seems to be cell
type-dependent. The cytokine did not have any effect
on human CTB invasion [248] but had an inhibitory
effect on HTR8/SVneo cells in Matrigel assays [249,
250]. Recently, its inhibitory effect on EVT was
shown through an explant/matrigel invasion assay
[244, 251]. The mechanism for exerting this effect
remains unclear, but the Kno¨fler group concluded
that TNF- restricts trophoblast invasion through the
induction of plasminogen activator inhibitor-1 (PAI-
1) [249] and the study published by Otun speculates
that TNF- alters EVT invasion by regulation of tro-
phoblast apoptosis [244]. On the other hand, it has been
demonstrated that extracellular matrix remodeling, a
key process in invasion, is variable between several
cell types: TNF- exerts inhibition of matrix metalo-
proteinase MMP-2 and integrins in JEG-3 cells, [252]
but does not in EVT [251]. TNF- increases proMMP-
9 secretion in human chorionic trophoblast cells [253]
and EVT [244], but not over the MMP-9 in JEG-3
cells. The last findings suggest an inhibitory effect of
TNF- in trophoblast(ic) invasion, but it will be nec-
essary to develop new approaches to understand the
involved mechanisms better. The general consensus
is that the the MAPK pathway is involved in mediat-
ing the TNF signal in trophoblast cells: Erk1/2 (which
then initiates NF-KappaB), stress-activated protein
kinase/Jun N-terminal kinase (SAPK/JNK, which acti-
vates activator protein-1 or AP-1) [254, 255].
Circulating levels of the TNF-, amongst oth-
ers, were raised in preeclampsia compared with
healthy pregnancy [170], and these levels were sig-
nificantly higher in patients with severe preeclampsia
than in mild preeclampsia [256]. In this respect,
TNF- up-regulating gene variants are associated with
preeclampsia [257]. Furthermore, elevated maternal
serum levels of TNF-, in preeclamptic women cor-
relate with (low) foetal birth weight in the early third
trimester [256, 258]. Finally, an elevated umbilical
cord blood concentration of TNF- was associated
with an increased risk of preterm birth, especially
among babies who were appropriate for gestational
age [180]. Polymorphisms in the cytokine genes
TNF- (and IL1ß) is associated with an increased
risk of preterm birth, which possibly reflects a dys-
regulation of the immune system in pregnancy [259].
Maternal TNF- levels appear to be dependent on
maternal body mass index, since, although elevated
TNF- levels were associated with an elevated risk
for preterm delivery (34–36 weeks’ gestation) in gen-
eral, these elevated levels had disparate associations
for the under- and over weight. Elevated TNF- con-
centrations were associated amongst obese women
with a reduced, and in underweight women with an
elevated, risk for spontaneous preterm delivery <34
weeks’ gestation [260]. In terms of miscarriage (recur-
rent spontaneous abortion, recurrent pregnancy loss,
reproductive failure), it has been demonstrated that
serum levels of TNF- are higher in women suffer-
ing from reproductive failure than in fertile controls
[261]. Several studies have identified an association
between TNF- gene polymorphisms and this preg-
nancy pathology [181, 261, 262].
CHEMOKINE RECEPTORS
Interleukin-8 (IL-8)
IL-8 is an 8 kD protein member of the neutrophil-
specific subfamily of chemokines (CXC) with ELR
(Glu-Leu-Arg) motif. It is produced by multiple cell
types, including leukocytes, fibroblasts, trophoblast
and some tumor cells [263]. The 77-amino-acid pre-
dominant form of IL-8 is produced by endothelial
and anchorage-dependent cells. During early preg-
nancy, uNK cells constitute an important source of
decidual IL-8 [264]. IL-8RA (CXCR1) and IL-8RB
(CXCR2) receptors, which coupled to G-Protein, are
expressed in EVT, STB, CTB, Hofbaue¨r cells and
human endometrium among other multiple cell types
[265–268].
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IL-8 has been reported to be present in the human
reproductive tract, and is detected in the cervix, the fal-
lopian tubes [269], placenta [264], and endometrium
[270]. It has been associated with endometrial prolif-
eration, angiogenesis and apoptosis [271]. Moreover,
IL-8 is abundantly secreted by villous and extrav-
illous CTB during first trimester pregnancy, while
12–14 gestational weeks’ EVT cells produce higher
levels than 8–10 gestational weeks’ villous cells. IL-
8R is expressed by isolated first trimester trophoblast
cells, CTB and EVT. This cytokine seems to stim-
ulate trophoblast invasion and plays a role in spiral
artery remodeling, although the mechanism of action
has not been investigated yet [272]. IL-8 stimulates
EVT Matrigel invasion [267, 273, 274] by increasing
MMP-2 and MMP-9 gelatinase activity in EVT cells
[267, 274]. Moreover, it has been shown that IL-8
stimulates these gelatinases together with urokinase
plasminogen activator (uPA) in various different cancer
cell types [275–277], and in such cases this situation is
associated with an increased tumor growth and metas-
tases. Enhanced tumoral growth is completely blocked
by IL-8 or FosB gene silencing which also reduced
microvessel density [278]. Moreover, Matrigel tumor
invasion is decreased by down-regulating IL-8 protein
production with the use of IL-8 targeted siRNA or by
blocking CXCR1 receptor [279]. In EVT, IL-8 neutral-
ising antibody partially abrogated uNK cell stimulated
invasion of these cells [267]. In terms of proliferation,
exogenous IL8 increases the proliferation of the EVT
cell line HTR-8/SVneo, but did not affect proliferation
of BeWo cells [280].
Currently, no data is available about IL-8KO mice,
so that it is difficult to state how indelible IL-8 is for
mammalian reproduction. However, IL-8 aberrations
are correlated to some pregnancy pathologies. Elevated
mRNA of IL-8 was found in chorionic villous samples
derived from women at ca. 11 gestational weeks’ and
later developed preeclampsia, although patient size in
these experiments indicate the preliminary nature of
the study [281]. Furthermore significantly higher lev-
els of this cytokine were found in preeclampsia patient
and in umbilical cord serum as compared to healthy
controls [256]. There are also indications that an ele-
vated production of IL-8 is associated with intrauterine
growth reduction (IUGR), since IL-8 mRNA was ele-
vated in the placentae of term-born IUGR cases in
comparison to their normally developed counterparts
[213]. The cervical mucous of patients (with a history
of recurrent miscarriage), who subsequently miscar-
ried contained significantly higher of IL-8, so that
IL-8 has been put forward as a possible predictor of
miscarriage [282]. Therefore, IL-8 appears to play a
role at the foeto-maternal interface and dysregulation
of this chemokine may contribute to some complica-
tions of pregnancy.
TRANSFORMING GROWTH FACTOR-
(TGF-) (OR SERIN/
THREONINKINASE)RECEPTORS
Transforming Growth Factor-beta (TGF-ß)
Cytokine mediators of tissue growth and remod-
eling, such as TGF-, are important regulators of
implantation and placentation. Members of the TGF-
 superfamily involved in these processes are TGF-
1-3 as well as activins [283]. TGF-1, -2, and -3
each consist of a homodimeric structure of 25 kD and
are stored in the extracellular matrix until activation,
when a covalently-bound propeptide is cleaved from
the molecule [284–286]. TGF- was first shown to
induce anchorage-independent growth in rat kidney
cells [287] and mouse fibroblast cells [285] in the pres-
ence of epidermal growth factor (EGF) [287], but it can
either induce or inhibit cell growth depending on the
cell type and its environment [284].
TGF-1 and -2 are expressed in human CTB [288]
and active TGF- has been detected on epithelial cells
at the maternal-foetal interface in the pig [289], sug-
gesting a role in maternal-foetal cross-talk. TGF-
receptors in trophoblast cell lines suggest a possible
autocrine signaling as well [290]. TGF- receptors
have been detected on murine trophoblast giant cells,
spongiotrophoblast and maternal decidua [291, 292]
and on human microvillus membrane, STB and CTB
[293, 294].
On binding TGF-, the TGF- receptor induces a
hetero-tetrameric complex of serine/threonine kinase
transmembrane receptors, which then phosphorylate
Smad, a signaling molecule which then translocates
to the nucleus[295]; this pathway is known to be uti-
lized in trophoblast cells [296]. TGF- can also utilize
the MAPK and Rho-A/Rho-associated kinase (ROCK)
signaling pathways [297]; the latter two have been sug-
gested to be involved in trophoblast migration and are
detected in CTB and syncytia [296]. Smad ubiquiti-
nation regulatory factor 2 (Smurf2) is an E3 ubiquitin
ligase which can target Smad for degradation; its over-
expression in the human trophoblast cell line HTR8
enhances migration and invasion [298]. While TGF-
 and macrophage inhibitory cytokine (MIC-1), a
TGF- superfamily member, inhibits MMP-2 and
MMP-9 production and trophoblast migration in vitro
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[288, 299, 300], activin A promotes CTB invasion by
stimulating MMP production [301]. Inhibition of TGF-
3 or the ROCK pathway increases invasion and MMP
production in human trophoblasts [172, 302, 303], and
exogenous TGF- decreases invasion of trophoblasts
in vitro [172, 303–305]. However, it has been shown
to increase invasion in a rat placental cell line [306];
controversial findings in this area have been reviewed
by Karen Forbes and Evangelia Pardali [297, 307].
In general, however, TGF-ß is understood to contain
physiological trophoblast invasion, while choriocar-
cinoma (JAR, JEG-3) is impervious to this cytokine
[308]. TGF-ß has been described to maintain tro-
phoblast stem cell proliferation, which is unusual, since
this cytokine is often considered an inhibitor of epithe-
lial cell proliferation [309]. Indeed, TGF-ß has also
been described as inhibiting EVT proliferation [310].
Knockout models are not commonly utilized
because most TGF-or TGF-R knockouts are embry-
onic lethal on gestational day 10.5 in mice due to a
defective yolk sac vasculogenesis [297, 311, 312]; in
humans, TGF- gene defects are associated with the
Camurati-Engelmann disease [297]. One Korean based
study indicated that a TGF-beta1 polymorphism may
be a genetic risk factor for PE and IUGR-complicated
PE [313], and maternal plasma concentrations of TGF-
ß1 were significantly higher in PE patients than in
healthy, pregnant controls [314]. In terms of recur-
rent spontaneous abortion, no association with TGF-ß1
gene polymorphism could not be traced [315].
TYROSINE KINASE RECEPTORS
Insulin-like Growth Factor (IGF)
IGF is a hormone and key growth factor and is
one part of a huge family of proteins, which all can
be summarized as the IGF family or the “IGF axis”.
In general the IGF axis includes the receptor ligands
for IGF1 and IGF2, six different high-affinity bind-
ing proteins (IGFBP1-6), several more low-affinity
binding proteins, known as IGFBP-related proteins
(IGFBP-rPs) and finally receptors type-1 IGF receptor
(IGF1R) and type-2 IGF/mannose-6-phosphate recep-
tor (IGF2R/M6PR) (reviewed in [307, 316–321]). All
of these members, expressed ubiquitously in tissue-
specific ratios and amounts, regulate important cellular
functions like proliferation, survival, differentation,
cellular metabolism and others [316]. For this reason,
more or less all IGF axis proteins play crucial roles in
a wide variety of cellular processes in normal phys-
iology and pathophysiology including growth [322],
tumorgenesis [316] and many reproductive events such
as follicular development [323, 324], oocyte matura-
tion [325], preimplantation- and embryo development
[326] and finally placental function/placentation and,
associated with that, foetal growth [307, 317].
Within human placental regions IGF1 and IGF2
mRNAs are expressed with a similar tissue distribution
and primarily by foetal tissues including CTB, EVT
for IGF1- and 2 and the chorionic plate, mesoderm
and leave (IGF2). The IGF2 mRNA was abundant at
all gestational ages. In contrast to this, IGFBP mRNAs
are expressed almost exclusively by maternal tissues
(decidual cells) and were identified in variable abun-
dance [327, 328]. Generally, IGFBPs are modulatory
regulators of IGF proteins, which means they have con-
troversial functions and they can inhibit or stimulate
IGFs [329].
The classical and preferential mode of action of
the two IGF ligands is through the two IGF recep-
tors, but they can also bind to the insulin receptor
(IR). Conversely, insulin can also bind to IGF recep-
tors, which results finally in a complex interacting
receptor network [316]. IGF1 and IGF2 mostly pre-
fer the IGF1R and IGF2 the type-2 IGF receptor and
the insulin receptor IR-A [316, 317, 330]. The IGF1R
mRNA is expressed in all cell types of the placenta
and [327], for this, IGF1Rs are localized in villous
endothelium and stroma, trophoblast and decidua [331,
332]. The activation of the tyrosine kinase receptor,
IGF1R, by ligand binding leads to the activation of a
complex signaling network across the two major sig-
naling pathways PI3K-AKT and RAS-RAF-MAPK
[318, 333–335]. The IGF2R/M6PR like IGF1R are
expressed primarily on the maternal-facing microvil-
lous membrane of the STB [331]. The type-2 IGF
receptor has no intrinsic kinase activity and is con-
sequently regarded as non-signaling [336] and it was
suggested that the primary function of this receptor is
to clear IGF2 from circulation and to prevent excessive
IGF2 effects on the placenta (293). However, McKin-
non et al. [337], showed in transwell migration assays
with HTR8/SVneo cells that IGF2 stimulates EVT
cell migration by signaling through IGF type-2 recep-
tors independently of IGF1R and IGFBPs and further
involves signaling via inhibitory G proteins and the
MAPK pathway.
It is well known that placental development cor-
relates with foetal growth and that alterations in the
placental structure and function leads to infants with
intrauterine growth restriction (IUGR) [338]. The
involvement of IGF axis proteins, especially the lig-
ands and the receptors, in placentation can be supported
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by the fact that null-mutations and knockout of IGFs
and/or IGF receptors in mice mostly lead to IUGR
[330]. However, IGF2R/M6PR knockout mice present
foetal overgrowth and higher perinatal lethality, which
leads to the conclusion that IGF axis proteins, espe-
cially the receptors, are crucial for the regulation of
normal growth [339]. For a good overview of mice
with many different null mutations of the IGF family,
please refer to the review of Nakae et al. [330].
Besides many functions including proliferation,
migration, nutrient exchange and amino acid uptake,
as well as inhibition of apoptosis of IGF axis pro-
teins during placentation [317, 340], many authors
showed that IGF proteins, especially IGF2 via the type-
2 receptor and IGFBP1, stimulate EVT cell migration
and enhance the invasion of EVT cells to the mater-
nal decidua [337, 341–344]. To underline and detail
this statement, Hamilton et al. [342] conclude that
after transwell migration and additional Matrigel inva-
sion assays with human first trimester EVT cells,
that trophoblast-derived IGF2 and decidua-derived
IGFBP1 provide autocrine/paracrine enhancement of
trophoblast invasiveness largely by stimulation of
migration. Furthermore Hamilton and his colleagues
showed that EVT cell proliferation was unaffected by a
wide range of IGF1, IGF2 and IGFBP1 concentrations
and they also showed that blocking of the type-1 recep-
tors by antibodies did not affect the IGF2-mediated
invasion, indicating that IGF1R was not responsible
for the IGF2 effect. The migration stimulatory action
of IGFBP1 occurs by binding of its RGD (Arg-Gly-
Asp) domain to the5ß1 integrin (fibronectin receptor)
on the EVT cell surface, leading to activation of focal
adhesion kinase (FAK) and stimulation of the MAPK
pathway [337, 344].
While IGF2 and the IGF2R play an important
role for placenta development, this is also the case
IGF1, which promotes CTB differentiation and IGF1R
are crucial for normal placenta function [292]. For
example decreased maternal serum IGF1 levels were
found in women who developed preeclampsia [345]
and also mutations in the human IGF1R gene are
associated with intrauterine and postnatal growth retar-
dation [346]. A G1125A mutation was identified which
resulted in a kinase-deficient IGF1R, which likely
caused the phenotype of intrauterine and postnatal
growth retardation in a girl and members of her
family who had a history of this phenotype [347].
Maternal diabetes resulted in inverse changes of circu-
lating foetal IGF-1 and IGFBP-1 at birth. A decrease
in circulating IGFBP-1 and to a lesser extent an
increase in circulating IGF-1 may present an important
mechanism that contributes to increased birth weight
in diabetic pregnancies [348].
Epidermal Growth Factor (EGF)
The CTBs, as mentioned in the introduction section,
are a progenitor stem cell population of trophoblast
which continuously proliferate and differentiate into
EVTs or STBs. EVT invasion play an important role
for placental growth and successful pregnancy, espe-
cially during the first trimester [349, 350]. Previous
investigations have revealed that the trophoblast cell is
strongly influenced by cytokines and growth factors, of
which one of the most relevant is EGF. Fourteen differ-
ent ligands comprise the EGF family [351], including
heparin-binding EGF-like growth factor (HBEGF)
[352] and Transforming growth factor alpha (TGF-)
[350]. Binding of EGF to its receptor (EGFR) stim-
ulates intrinsic tyrosine phosphorylation activity and
transautophosphorylation [353], which results in the
activation of a variety of intracellular pathways, com-
prising of the Ras/MAPK, PI3K/Akt, phospholipase
C-/protein kinase C (PLC/PKC), transcription fac-
tor AP-2 and STAT [354–357]. In the human placenta,
it has been established that MAPK11/14 and AP-2
are important for EGF-mediated functions in the tro-
phoblast.
The importance of EGF has been demonstrated
using in vitro or in vivo studies, in which human pla-
cental cell lines, isolated primary trophoblasts, and
explant tissues are the most widely used [350]. EGF
is able to influence positively or negatively a variety
of fundamental (trophoblast) cell properties, such as
proliferation [358–360], differentiation [358], apop-
tosis [361–364], motility [355, 356, 365], secretion
[355, 366] and invasion/migration [367–370]. CTB
proliferation and differentiation into syncytial units can
be stimulated in culture by EGF [358]. Interestingly,
EGF-stimulated differentiation requires MAPK11/14
activation, while EGF-driven trophoblast proliferation
is enhanced when MAPK11/14 is inhibited [358]. AP-
2 has been found to promote EGF-dependent EVT
invasion, probably through alteration of MMP-2, uPA
and PAI-1 activity [371]. EGF also induces MMP-9
and TIMP-1 secretion in the trophoblast through acti-
vation of both PI3K and MAPK signalling pathways
[355]. It should be noted here though, that differences
in EGF effects have been seen between primary tro-
phoblasts and cell lines (SGHPL-4) – gene silencing
of AP-2 had no effect on SGHPL cells, while the
invasive capacity of primary EVT was reduced [371].
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EGF and its receptors are expressed both in decidual
and trophoblastic cells. CTB, STB, and foetal connec-
tive tissue cells in first-trimester tissues stained positive
for both the EGF binding domain of the human EGF
receptor or to the activated (tyrosine-phosphorylated)
human EGF receptor. In contrast, staining of third-
trimester placentae for both targets yielded only a
sparse staining of either trophoblast cell layers but an
intense staining of the foetal connective tissue cells
[372]. EGF was localized immunohistochemically in
the human endometrium throughout the menstrual
cycle, in gestational decidua, and in first, second,
and third trimester placenta. Stromal cells, but not
glandular epithelium localisation suggested that EGF-
production occurs in the proliferative endometrium and
this secretion seemed more intense during the secre-
tory phase especially in those stromal cells surrounding
the spiral arterioles. Immunostaining for EGF in stro-
mal cells is again moderate in gestational decidua, but
intense in the surface epithelium. EGF immunostaining
was intense in STB of first trimester placenta, with a
moderate staining of CTB, but decreased in both layers
of trophoblast as pregnancy progressed [373].
Despite the above, the role of this growth fac-
tor in foetal growth regulation is still only partially
understood. Animal models have been able to confirm
that EGFR is required for numerous developmental
and physiological processes Conditional knock-out of
EGFR (sometimes termed HER-1 or erbB-1) cause
embryonic or perinatal lethality of the affected mice
due to growth retardation, smaller placentas and
impaired epithelial development of several organs
[374, 375]. However, EGF −/− mice show no effect
of genotype or background strain on litter size, gen-
der ratio, pup body weight, and survival of foetuses in
utero [376].
Investigations in humans have found that a poly-
morphism in the 59 untranslated region of EGF that
results in increased EGF expression is associated with
lower birth weight and foetal growth restriction in
pregnant women from Western Europe [377, 378]. In
the human placenta, an altered expression of the EGF
receptor is associated with preeclampsia, intrauterine
growth restriction (IUGR), persistent trophoblastic dis-
ease and pathological trophoblast invasion [379].
Vascular Endothelial Growth Factor (VEGF)
VEGF is a heparin-binding homodimeric glycopro-
tein of 30–40 kD which is involved in many processes
related to reproductive physiology [380, 381]. It is a
potent mitogen of endothelial cells which promotes the
remodeling of the early vasculature and stimulates the
formation of a capillary network of the placenta [382].
This cytokine also positively regulates the proliferation
of trophoblast [383–385] (probably through better vas-
cularisation) and its expression is altered in recurrent
abortion [386, 387].
The VEGF family is an important mediator of angio-
genesis and consists of six members: VEGF-A-E and
placenta growth factor (PlGF) [388-393] have been
identified up to date. The angiogenesis function is reg-
ulated by the receptors VEGFR-1 (flt-1 or FMS-like
tyrosine kinase), VEGFR-2 (KDR or kinase domain-
containing receptor), VEGFR-3 which have tyrosine
kinase activity [394]. VEGF and its receptors have
been detected in giant trophoblast cells, early yolk
sac [395], human endometrium [396], human and ani-
mal placentae [397, 398], fallopian tube and ovary
[399] suggesting a role for this factor in the induction
of vascular growth in decidua, placenta and vascular
membranes [400]. In the ovary, VEGF is produced by
both thecal and granulosa cells [401, 402]. In fact, in
situ hybridization studies in rat ovary provided the first
evidence that VEGF may be a regulator of physiolog-
ical angiogenesis [403]. Post-implantation embryos in
VEGF± mice have shown several malformations in
the vascular system resulting in lethality on days 11
and 12 of pregnancy, strongly suggesting a regula-
tion of foetal vascular development by VEGF [404].
Furthermore, results of targeted gene disruption in the
mouse have revealed that the two VEGF receptors, Flt-
1 and KDR/fetal liver kinase-1 (Flk-1), are functionally
important for embryonic vasculogenesis. Heterozy-
gous VEGF-deficient mouse embryos show impaired
or abnormal blood vessel formation, leading to embry-
onic death by mid-gestation [404, 405]. Homozygous
Flk-1/KDR deficient mice died in utero as a result
of early defects in the development of hematopoietic
and endothelial cells, which are necessary for yolk-
sac blood island formation and vasculogenesis [406].
Homozygous Flt-1 gene-deficient mice also died in
utero, most likely because of deficient cell-cell or cell-
matrix interactions, causing endothelial cells to form
abnormal vascular channels [407].
VEGF mRNA has been detected in human preim-
plantation embryos at the blastocyst stage supporting a
possible role in others reproductive events [405]. The
receptor for VEGF, Flt-1, is produced in the decidua
by chorionic vascular endothelium and especially by
invasive EVT and, in vitro, by BeWo choriocarci-
noma cells [408]. However, VEGF seems to mediate
proliferation rather than invasion/migration in EVT
[408]. In the trophoblastic cell line JEG-3, cultures
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containing VEGF showed that in vitro migration of
JEG-3 cells through a transwell membrane was sig-
nificantly reduced by silencing of VEGF. Therefore, a
role of VEGF was postulated in the regulation of tro-
phoblast migration [25]. It is also known that VEGF
acts via autocrine stimulation loop in trophoblastic
cells [409]: in normal human CTB, TGF-beta1 induced
an hypoxia inducible factor-1 (HIF-1)-mediated
VEGF secretion (and a TGF-ß1-stimulated-ERK1/2
activation may be involved in this process) [410].
Moreover, both the PI3K–AKT–mTOR (mammalian
Target of Rapamycin)–HIF-1 and ERK–HIF-1 sig-
naling pathways are crucial for increasing VEGF and
endoglin expression in response to hypoxia in BeWo
cells [411].
It has been shown that VEGF is predominantly
expressed in tumour cell lines derived from female
reproductive organs [412]. In tumors, VEGF is
known to significantly contribute to pathological
angiogenesis, tortuosity of tumor vasculatures and
vasculogenesis, which all together lead to acceler-
ated growth rates of tumors, invasion and metastasis
[413]. VEGF family members regulate CTB survival
and expression of a subset of its family members is
dysregulated in severe forms of preeclampsia [414].
Currently, assays have been implemented clinically to
detect the concentration of soluble Flt-1 (sFlt-1), which
binds and inactivates VEGF, and PlGF in maternal
serum at mid-gestation. Unfavorable ratios of sFlt-
1/PlGF can predict the development of PE [415].
Considering all these data, VEGF is most likely
involved in many processes related to reproductive
physiology, and which are essential for correct implan-
tation and placentation.
Hepatocyte Growth Factor (HGF)
HGF is a pleiotropic cytokine whiuch was first
defined as a potent mitogen for hepatocytes in vitro
[416, 417]. HGF acts through binding to the recep-
tor, c-Met, causing tyrosine kinase activation and
autophosphorylation at tyrosine residues [418]. Fol-
lowing auto- phosphorylation, the PI3K and MAPK
pathways are two main signaling cascades involved
in mediating the HGF signal [419]. HGF is associ-
ated with cell proliferation, differentiation, invasion
and angiogenesis in other cell systems [420].
The placenta has been shown to express a significant
amount of HGF [416]. Serum of HGF levels increase
throughout the first, second and third trimesters
of pregnancy, respectively [417]. Furthermore, the
second trimester period displays the highest HGF level
in amniotic fluid, but the rate of HGF production from
placental tissue is not significantly different between
the three periods [417]. Mesenchymal cells of the villi
express HGF mRNA in situ and CTB express HGF
receptor, c-Met [421, 422]. In addition, c-Met protein
is expressed in choriocarcinoma cell lines [423, 424].
In vivo “gene knockout” studies in mice lacking
the HGF gene show placental defects and embryonic
lethality which were identified as a complete lack of
development of labyrinthine trophoblast at 13.5–14.5
([425] and reviewed in [426]). A single injection of
HGF/SF at embryonic day 9.5 (E9.5) into the amniotic
cavity of HGF/SF −/− embryos rescued the placental
defect [427]. In c-Met mutant mouse embryos, iden-
tical placental and additional liver abnormalities were
found [428]. Transgenic mice that overexpress HGF,
seem to have lower tumor yields or a lower incidence
of hepatocellular cancers [429].
HGF stimulates nitric oxide (NO) synthesis involved
in the human EVT cell line SGHPL-4 invasion of fibrin
gel [430]. HGF regulates trophoblast invasion through
the activation of c-Met and consequent secretion of 92-
kDa collagenase as determined by the Boyden chamber
invasion assay [431]. Trophoblast motility is an impor-
tant step for the invasive process. Cartwright et al found
that HGF stimulates SGHPL-4 motility and invasion
by activation of the PI3K pathway [432]. Inhibition
of the MAPK pathway also inhibited HGF-induced
motility of primary human EVT, whereas not effect
on basal motility [432]. The homeobox gene HLX
is expressed in proliferating and migrating (but not
invading) human trophoblast cells and HLX expres-
sion is significantly decreased in human IUGR. In
SGHPL-4 and HTR-8/SVneo cells, HGF stimulated
the production of HLX mRNA and protein expression,
which resulted in increased trophoblast cell migration.
Reciprocally, HLX inactivation significantly decreased
trophoblast migration, thus the HLX gene is also a key
of trophoblast cell migration via HGF/c-Met signaling
pathway [238]. Finally, although much attention has
been dedicated to HGF and its effects on trophoblast
invasion, only little to no attention is paid to its effects
on trophoblast proliferation.
As to be expected from the above studies, HGF
seems to be associated with IUGR. HGF and c-
met expression are reduced in IUGR placentae [433].
Recently, plasmatic HGF measurements at around
mid-gestation (14–20 gestational weeks) were success-
fully implemented as a predictive marker for small-
for-gestational age foetuses, but not for preeclampsia
[434]. In this context, no direct information can
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Table 1
Selected Type I receptor cytokines in reproduction
Cytokine Distribution in Trophoblast effects Murine KO model Positive/or Signal Effector
reproduction Receptor Invasion/ Proliferation Differenttiation other negative transduction
expression migration effects association • trophoblast(ic) cells
with human ◦ other cells
pregnancy
pathology
IL6 E: EM, STB, EVT JEG-3: + JEG-3: + + into thee Reduced fertility Human and • STAT3 ↑ MMP-9, -2
decidua, EVT, (indirect (indirect proof, invasive and viable mice recurrent
STB, CTB, proof, since since siRNA of phenotyp implantation sites abortion,
human and siRNA of IL6 IL6 and its rec infertility, PE
animal placenta and its rec resulted in ↓
resulted in ↓ proliferation)
invasion)
IL-11 E: chorionic IT, endEVT, JEG-3: + No effect Not known Infertility due Reduced fertility, ◦ JAK1/2 Not known
villi, decidua R: EM, JEG-3 HTR-8/SVneo: - to defective spontaneous ◦ STAT1
implantation site deciualization abortions ◦ ERK1/2
• STAT3
GM-CSF E: chorionic villi, JEG-3 JAR Not known CTB: + + terminally Impaired fertility PE, recurrent ◦ MAPK Not known
placental macrophage, Invading CTB, EVT, into STB and offspring miscarriage, ◦ JAK2/
villous fibroblast, (weak on STB) survival, IUGR, placental ◦ STAT5
epithelial cells small litter sizes, insufficiency, ◦ PI3K
of reproductive diminished IUGR, preterm
tract, EM-glands glycogen cells delivery
in placenta
LIF E: endometrial Trophectoderm, JEG-3: + + into CTB, LIF−/−: fertile, but ↓ endm. LIF ◦ RAS/ ↑TIMP
glands, blastocyst, villous trophoblast, EVT + (Matrigel) STB, EVT no implantation; expression in ◦ MAPK ↓ Casp4
granulose-lutein cells, LIFR −/−: impaired recurrent abortion, • STAT3
ovarian stromal cells, placental function unexplained infertility;
↑ LIF gene
mutation in
infertile women
G-CSF E: decidual EVT, ST, CT Not known CTB: + Not known Not known PE, preterm birth, • JAK/STAT Not known
cells in contact Chorio-Ca cell biomarker for • MAPK
with anchoring lines:-JEG-3: 0 competent oocyte
villi (not chorionic
trophoblast)
R: decidual
stromal + EM
gland cells
Leptin E: 1st trim EVT, STB, Mouse Cell line: + Not known Anti-apoptotic Infertility due PE, IUGR, • MEK/ ↑ MMP-9, 2
chorionic villi, IT, JAR, BeWo, trophoblast: + JEG-3 to implantation gestational • SOCS3
3rd trim. (weak in CTB) CTB: + JAR( in presence problems and diabetes (mouse trophoblast)
chorion leave, of 25 mM glucose) placental
amnion, STB, anomalies
CTB
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Table 2
Selected Type II cytokine receptors in reproduction
8, 5 Distribution in Trophoblast effects Murine KO model Positive/or Signal Effector
reproduction Receptor Invasion/ Proliferation Differentiation Other negative transduction
expression migration effects association • trophoblast(ic)
with human cells
pregnancy ◦ other cells
pathology
IL10 E: CTB, CT EVT (little) CTB:↓ Not known ↓ to invasive - implantation sites production in PE, ◦ JAK/STAT ↓ MMP-9
decidual stroma Also indirectly phenotype are increased + ↑ single nucleotide
cells by disrupting more viable foetuses, polymorphism
macrophage - higher rates of in PE, early
LPS-mediated pregnancy
miscarriage, preterm failure
birth, IUGR,
- human PE-serum
mediated impaired
spiral artery
remodelling and
PE-like symptoms
IFN-γ E: uNK Villous CTB, CTB 1st trim EVT: - Not known Not known Large number of ↑ production in • STAT1 ↓ MMP2/9
R: uterine cell columns JEG-3: - undifferentiated PE, ↑ levels in • CIITA
epithelium and (both Matrigel) uNK cells umbilical cord
stroma (especially causing necrosis serum associated
adjacent to with decreased
attaching risk for IUGR;
trophoblasts) gene polymorphisms
associated with
recurrent
pregnancy loss
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Table 3
Immunglobulin receptor. Tumor necrosis factor receptor, Chemokine receptor and TGF-ß receptor cytokine families
A: Immonoglobulin receptors
Cytokine Distribution in Trophoblast effects: Murine KO Positive/or Signal Effector
reproduction Receptor Invasion/ Proliferation Differentiation Other effects model negative transduction
expression migration association • trophoblast(ic) cells
with human ◦ other cells
pregnancy
pathology
IL-1 E: CTB, STB, STB, CTB, CTB, EVT: + JAR:- Bewo:- No effect toward Induction of Normal, ↑ in placenta • MAPK ↑ MMP-2, -3, -
1st trimester EVT by 50% (Matrigel) invasive phenotype apoptosis healthy, fertile of PE (not IUGR), • LPM2 and -9, MCP-1
decidua, JEG-3: + ↑ level in
secretory EM HTR8: + amniotic fluid
R: decidual SGHPL-4: 0 of preterm birth
EM- glands, STB EVT cell line: - pregnancies, ↑
maternal level
in miscarriage
CSF1 E: EM-glands, 1st trim EVT EVT: 0 EVT: + Not known Not Reduced PE, IUGR, • TK EVT:
placenta, (Matrigel) TCL-1: 0 described fertility due recurrent • HLX ↑ MMP-9,
decidua into HTR8/ to low abortion ↑ TIMP-1
uterus +amniotic SVneo: 0/ + implantation TCL-1:
fluid, vascular BeWo: - rates; normal 0 for MMP
endothelium. SGHPL-4: + phenotype
R: EVT, decidua
B: Tumor necrosis factor receptor
TNF- E: deciduas,: Intramural CTB: 0 EVT: - Apoptotic Viable, fertile; PE, IUGR, • ERK 12 PAI-1
EVT, villous EVT, endEVT EVT: - HTR8/ Other primary (EVT) however, TNF- preterm birth • SAPK/JNK ↑ pro-MMP-9,
CTB R SVneo: - trophoblast: - and IFN- (however risk but not active
(all Matrigel) needed for V14 alterations MMP-9 (EVT)
NKT-cell according to ↓ MMP-2
mediated maternal BMI), (for JEG-3,
abortion reproductive not EVT)
failure
C: Chemokine receptors
IL-8 E: villi, EVT, 1st trimester EVT: + HTR-8/SVneo: + Not known Not known PE, IUGR, ◦ FosB ↑ MMP-2, -9
uNK cells, CTB, EVT (Matrigel) Bewo: 0 miscarriage ↑ uPA (in
Hofbaur cells, other tumors)
EM into cervix,
Fallopian tubes,
placenta
D: TGF- receptors (serine-threonine recptors)
TGF E: CTB, pig CTB, STB, CTB: + Trophoblast Not known Embryonic Increased • Smad, ↓ MMP-9, -2
placental epithelial HTR-8: + stem cell: + lethal E 10.5 TGF-1 gene • Rho-A/ production
cells R: EVT: - EVT: - due to defective polymorphisms ROCK
murine giant- JAR: 0 yolk sac in PE, elevated • Smurf2
and spongio- JEG-3: 0 vasculogenesis plasma levels
trophoblast, of TGF-1 in PE
human decidua
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Table 4
Tyrosine kinase receptors
Cytokine Distribution in Trophoblast effects: Murine KO model Positive/or Signal Effector
reproduction Receptor Invasion/ Proliferation Differenttiation Other negative transduction
expression migration effects association • trophoblast(ic) cells
with human ◦ other cells
pregnancy
pathology
IGF-1/2 E: CTB, EVT, STB EVT: + EVT: 0 IGF-1: Antiapoptotic IUGR or PE, IUGR, IGF-1: 51
chorion (Matrigel) CTB + foetal SGA • MAPK activation
R: villous endothelium, HTR8: + macrosomia IGF-2: • non
stroma, decidua signalling
• G-protein,
• MAPK
EGF E: EM (stroma STB, CTB EVT: + CTB: + CTB: + (into Midgestational PE, IUGR, ◦ Ras ↑MMP-2/9
surrounding JEG-3: + syncytial units) embryonic lethality, persistent ◦ MAPK uPA PAI-1
spiral aterioles), JAR: + IUGR and trophoblastic ◦ PI3K/Akt ↑TIMP-1
decidua, placenta (MAtrigel) placental disease, Gene ◦ PLCγ/PKC
(STB, later abnormalities polymorphism ◦ RhoA/C
CTB + STB) (small) for ↑ EGF ◦ JAK/STAT
R: foetal production: ↑ • MAPK11/-14
connective rate IUGR • AP-2
tissue
VEGF E:, placenta JEG-3, CTB, JEG-3: + EVT: + Not known Antiapoptotic Post-implantation Recurrent • HIF-1 
(+ animal), (indirectly, (indirectly (CTB) vascular abortion, PE • ERK
Fallopian tube, since silencing through better malformations • PI3K
ovary (thecal + of VEGF vascularization) with lethality • Akt
granulosa cells) resulted in at E11 + E12 • mTOR
R: giant ↓ invasion)
trophoblast, yolk
sac, human EM
HGF E: placenta, CTB, EVT: + Not known Not known Antiapoptotic Placenta defect PE, IUGR • PI3K ↑collagenase
mesenchymal chorio-ca (Boyden caused by • MAPK
cells of villi cell lines chamber) decrease of • Homeobox
SGHPL-4: + labyrinthine gene HLX
trophoblast
with homozygous
embryo lethality
between
E13.5–E15.5
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Table 5
ACRONYMS, ABBREVIATIONS & SYMBOLS/GLOSSARY
-: negative effect FosB: proteins encoded by the c-fos genes LPM-2: low molecular mass polypeptide RGD: Arg-Gly-Asp or Arginine- Glycine- Aspartat
+: positive effect
↑: up-regulation G-CSF: granulocyte-colony stimulating factor M6PR: mannose-6-phosphate receptor ROCK: Rho-A/Rho-associated kinase
↓: down-regulation
Akt: RAC-alpha serine/threonine GM-CSF: granulocyte macrophage- MAPK: mitogen activated protein kinase, pathway s: soluble, example: sIL-6R (soluble
protein kinase colony stimulating factor includes : Ras/ Raf/ / ERK/ MEK/ JNK IL-6 receptor)
AP: activator protein gp130: glycoprotein 130 MCP-1: monocyte chemoattractant protein-1 SAPK: stress-activated protein kinase
BeWo: a choriocarcinoma cell line HBEGF: heparin-binding EGF M-CSF: macrophage-colony stimulating factor SGA: small for gestational age
(synonomous with CSF-1 and MGF)
Ca: carcinoma HGF: hepatocyte growth factor MEK: MAP or ERK Kinase SGHPL-4: trophoblast cell line (primary EVT
transfected with SV40)
Casp.: caspase HLX: H2.0-like homeobox protein- a human MGF: macrophage growth factor (synonomous siRNA: short inhibitory RNA
protein encoded by the HLX gene with M-CSF and CSF-1)
CIITA: IFN-inducible class II HTR8/SVneo: a trophoblast cell line (HTR8) MIC: macrophage ihibitory cytokine Smad: a signal transducing protein; homologs of "
transactivator derived through transfection of EVT mothers against decapentaplegic" (MAD)
with simian virus neo and the C. elegans protein SMA
CMV: cytomegaly virus IFN: interferon MMP: matrixmetalloproteinase Smurf: Smad ubiquitination
regularory factor
CSF-1: Colony stimulating factor-1 IGF: insulin-like growth factor LPS: lipopolysaccharide SNAT: Na(+)-coupled neutral amino
(synonomous with M-CSF and MGF) acid transporter
CTB: cytotrophoblast IGFBP: IGF binding protein mTOR: mammalian Target of Rapamycin SOCS: suppressor of cytokine signaling
CXC: chemokine super family with four conserved IL: interleukin NK cells: natural killer cells STAT: Signal Transducer and Activator
cystine (C ) residues and X is any amino acid of Transcription
HIF: hypoxia inducible factor IT: intermediate trophoblast) NO: nitric oxide STB: yncytiotrophoblast
E: cytokine expression IUD: intrauterine device (for contraception PAI: plasminogen activator inhibitor TCL1: choriodecidua,immortalized through
transfection with a retrovirus gene coding
for the SV40 large-T antigencell line
EGF: epidermal growth factor IUGR: intrauterine growth retardation PCB: polychlorinated biphenyl TGF: transforming growth factor
ELR: Glu-Leu-Arg or Glutamic acid- JAK: Janus Kinase PI3K: phosphatidylinositol-3-kinase TIMP: tissue inhibitor of metalloproteinase
Leucine- Arginine
EM: endometrium JAR: a choriocarcinoma cell line PKC: protein kinase C TNF: tumor necrosis factor
endEVT: endovascular EVT JEG-3: a choriocarcinoma cell line PLC: phospholipase C Trim.: trimester
EVT: extravillous trophoblast JNK: Jun N-terminal kinase PLCγ: Phospholipase C gamma uNK cells: uterine NK cells
FAK: focal adhesion kinase KDR: kinase domain- containing receptor PlGF: placental growth factor uPA: Urokinase-Type Plasminogen Activator
Flk: fetal liver kinase LIF: leukemia inhibitory factor R: receptor expression VEGF: vascular endothelial growth factor
Flt: FMS-like tyrosine kinase MGI: macrophage granulocyte Ras: RAt Sarcoma; a protein subfamily of
(a VEGF receptor) inducing (protein) small GTPases
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be gleaned thus far from the literature on an associ-
ation between preeclampsia and HGF although HGF
is reported to have an effect on trophoblast invasion.
In this aspect, it is interesting that the hypothesis of
trophoblast invasion being causative for preeclampsia
has been challenged [435]. It has proposed instead that
trophoblast invasion is causative of IUGR and related
alterations of foetal growth, which is in line with the
information available thus far on HGF and its asso-
ciation to foetal growth retardation. Also in line with
the above findings, HGF seems to be associated with
trophoblastic disease [436]. Miscarriage, spontaneous
abortion and preterm delivery have also not been asso-
ciated with HGF yet.
CONCLUSION
It may be concluded that cytokines play a vital role
in mammalian reproduction, including during human
pregnancy. Much information has been unearthed in
terms of where and when these cytokines are produced,
and which cells possess receptors, indicating that spe-
cific cells within the reproductive tract are potentially
capable of reacting to its corresponding cytokine. In
the past decade, a tremendous array of data has been
generated concerning the functional actions of these
cytokines on trophoblast populations. This denotes the
vast interest and potential that many international sci-
entists believe this field of research occupies. This is
in part due to the impact that is supposed to emanate
from the results found in these studies in terms of
preeclampsia and IUGR, but also of cancer.
It must be stressed however, that we are not close yet
from reaching a therapeutic goal. This review exposes
several research gaps, especially in terms of factual
knowledge on signal transduction in the trophoblast.
It may not be assumed that the mode of signal trans-
duction for a specific mediator in a specific cell will be
the same in the trophoblast, or even between the tro-
phoblast(ic) subsets. It is vital to comprehend the exact
regulating mechanisms of signaling mediators if these
mediators are proposed for therapeutic interventions.
In the example of LIF, for instance, the negative feed-
back mechanism driven through the STAT signaling
system warrants caution in using LIF as a therapeutic
agent, since both low as well as high LIF concentra-
tions would results in an under-utilization of STAT3.
This would probably negatively regulate trophoblast
invasion. Therefore, understanding trophoblast(ic) sig-
naling functions well should help to enforce innovation
towards novel therapeutic approaches that will assist
in enhancing reproduction on the one side, and on the
other, combating cancer.
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Leukaemia inhibitory factor mediated proliferation of
HTR-8/SVneo trophoblast cells is dependent on activation
of extracellular signal-regulated kinase 1/2
Golla Jaya PrakashA,C, Pankaj SumanA,C, Diana M. Morales PrietoB,
Udo R. MarkertB and Satish K. GuptaA,D
AReproductive Cell Biology Laboratory, National Institute of Immunology,
Aruna Asaf Ali Marg, New Delhi 110 067, India.
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Abstract. Leukaemia inhibitory factor (LIF) is one of the cytokines that is indispensable for embryo implantation. The
aim of the present study was to investigate the role of activation of extracellular signal-regulated kinase (ERK) 1/2 in LIF-
mediated proliferation of HTR-8/SVneo cells. Stimulation of HTR-8/SVneo cells with LIF (50 ngmL1) resulted in an
increase in cell proliferation (P, 0.05) via increased transition of cells to the G2/M phase of cell cycle. Stimulation with
LIF resulted in the activation of both signal transducer and activator of transcription (STAT) 3 Tyr705 and ERK1/2, but
inhibition of ERK1/2 signalling by pretreatment of cells with U0126 (10mM) for 2 h resulted in abrogation of LIF-
mediated increases in G2/M transition, with a significant decrease (P, 0.05) in absolute cell numbers compared with
control. Although STAT3 silencing had no effect on LIF-dependent proliferation of HTR-8/SVneo cells, it did result in an
increase in cell apoptosis, which increased further upon inhibition of ERK1/2 activation irrespective of LIF stimulation.
Stimulation of cells with LIF increased the Bcl-2/Bax ratio, whereas ERK1/2 inhibition decreased the Bcl-2/Bax ratio,
even after LIF stimulation. Hence, it can be inferred that ERK1/2 activation is essential for LIF-mediated increases in
proliferation and that both STAT3 and ERK1/2 activation are important for the survival of HTR-8/SVneo cells.
Additional keywords: apoptosis, trophoblast.
Introduction
After fertilisation, implantation of the blastocyst is one of the
critical steps leading to establishment of pregnancy. This pro-
cess involves extensive cross-talk between the trophoblast cells
and the receptive endometrium through embryonic- as well as
endometrial-derived factors at the site of implantation. Lack
of any of the crucial embryonic or maternal signals at the site of
implantation may result into shallow implantation or failure of
implantation (Kno¨fler 2010).
During the first trimester of pregnancy, trophoblast cells
proliferate, invade and differentiate to establish contact with
the maternal circulation. Proliferation of trophoblast cells is
positively regulated by factors such as leukaemia inhibitory
factor (LIF), epidermal growth factor (EGF), insulin-like growth
factor (IGF)-1, vascular endothelial growth factor (VEGF),
granulocyte colony-stimulating factor, transforming growth
factor (TGF)-a, but is negatively regulated by decorin and
TGF-b1 (Li and Zhuang 1997; Athanassiades and Lala 1998;
Athanassiades et al. 1998; Miyama et al. 1998; Fitzgerald et al.
2005; Iacob et al. 2008; Dubinsky et al. 2010; Hambruch et al.
2010). Depending upon the cell type and the predominance of
cytokine/growth factors in the external milieu, cellular prolifer-
ation is regulated by activation of several signalling pathways,
including phosphatidylinositol 3-kinase (PI3K), protein kinase
C, mammalian target of rapamycin, wnt/b-catenin, Janus
tyrosine kinase (JAK)–signal transducers and activators of
transcription (STAT), p38 mitogen-activated protein kinase
(MAPK) and extracellular signal-regulated kinase (ERK) 1/2
(Davies et al. 2004; Meloche et al. 2004; Petersen et al. 2005;
Wu et al. 2005; Masckauchan et al. 2006; Busch et al. 2009;
Grivennikov et al. 2009; Fu et al. 2010; Keuling et al. 2010).
This suggests that cellular proliferation is under the tight
regulation of several external factors through the activation
of various downstream signalling pathways (Fitzgerald et al.
2010).
As one of the cytokines predominantly present during the
peri-implantation period, LIF plays a vital role in embryo
implantation (Harvey et al. 1995). It has been reported that
in LIF-knockout mice, embryos fail to implant, which can be
rescued by injection of LIF (Stewart et al. 1992; Chen et al.
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2000; Makrigiannakis et al. 2006). In primates, injection of a
monoclonal antibody against recombinant human LIF into the
uterine cavity during the peri-implantation period resulted in a
significant reduction in fertility (Sengupta et al. 2006). LIF
activates the JAK-STAT pathway and increases the prolifera-
tion and invasion of JEG-3 choriocarcinoma cells (Fitzgerald
et al. 2005; Poehlmann et al. 2005). However, LIF can transduce
its signal through activation of either JAK-STAT or the MAPK/
ERK pathways in different cell types like retinal cells, bronchial
epithelial cells and cardiac myocytes to bring out their effective
functions (Kodama et al. 2000; Hu et al. 2006; Rhee and Yang
2010).
Although both the JAK-STAT and MAPK/ERK pathways
have been implicated in the regulation of the proliferation of
trophoblast cells, the specific involvement of these pathways
in LIF-mediated proliferation of trophoblast cells has not been
deciphered. Hence, the aim of the present study was to deter-
mine the significance of ERK1/2- and STAT3-dependent sig-
nalling pathways in LIF-mediated proliferation and survival
of trophoblast cells using HTR-8/SVneo cells (derived from
human first-trimester placenta explant cultures immortalised by
SV40 large T antigen) as a model of first trimester trophoblast
cells (Graham et al. 1993; Busch et al. 2009).
Materials and methods
Culture of trophoblast cells
HTR-8/SVneo cells (kindly provided by Dr Charles Graham,
Queen’s University, Kingston, ON, Canada) were maintained
in RPMI-1640 medium (Sigma-Aldrich, St Louis, MO,
USA) supplemented with an antibiotic–antimycotic cock-
tail (100UmL1 penicillin; 100mgmL1 streptomycin;
0.25 mgmL1 amphotericin B; Biological Industries, Kibbutz
beit Haemek, Israel) and 10% heat-inactivated fetal bovine
serum (FBS; Biological Industries). The cells were grown under
a humidified atmosphere of 5%CO2 in air at 378C (Graham et al.
1993).
Cell proliferation assay
To investigate the role of LIF on cell proliferation, HTR-8/
SVneo cells were seeded onto 12-well cell culture plates
(1 104 cells per well; Greiner Bio-one, Frickenhausen,
Germany). After 24 h, cells were washed with plainmedium and
separately treatedwith increasing concentrations of LIF (Sigma-
Aldrich; 1, 5 and 50 ngmL1) in RPMI-1640 medium contain-
ing 1% FBS for 48 h under standard culture conditions of 5%
CO2 in air at 378C. After 48 h, cells were harvested using a
medium containing 0.5% trypsin and 0.2%EDTA andwere then
stained with 1mgmL1 propidium iodide (PI; Sigma-Aldrich)
and counted on a flow cytometer (BD FACS Calibur; Becton
Dickinson Biosciences, San Jose, CA, USA).
In another set of experiments, HTR-8/SVneo cells (1 104
cells per well), cultured as described above, were pretreated for
2 h with an optimised non-cytotoxic concentration (10mM)
of U0126 (Calbiochem, La Jolla, CA, USA), an inhibitor
of mitogen-activated protein kinase kinase (MEK) 1/2 or with
a vehicle control (dimethyl sulfoxide). After the 2-h incubation
period, both control and U0126-treated cells were stimulated
with an optimised concentration of LIF (50 ngmL1) for 48 h,
followed by cell counting as described above.
DNA cell cycle analysis
The HTR-8/SVneo cells were seeded onto six-well cell culture
plates (0.05 106 cells per well; Greiner Bio-one). After 24 h,
cells were washedwith plainmedium and pretreatedwith 10 mM
U0126 or vehicle control for 2 h. Then, 50 ngmL1 LIF was
added to both control and U0126-treated cells. Cells were
incubated for 48 h and then harvested using a medium con-
taining 0.5% trypsin and 0.2% EDTA. Cells were washed twice
with 50mM phosphate buffer, pH 7.4, with 0.9% NaCl (phos-
phate-buffered saline (PBS)) and fixed with 70% chilled etha-
nol. Subsequently, cells were kept for 20min on a roller rotator
at 48C. Then, cells were washed twice with PBS, followed by the
addition of RNase A (50 mgmL1) with 0.05% Triton-X to the
cell suspension and a further 20min on the roller rotator at 48C.
After this incubation period, PI was added to the RNase-treated
cell suspension at a final concentration of 50 mgmL1 and cells
were kept in the dark for 15–20min before DNA content was
analysed using a BD FCAS Canto II (Becton Dickinson
Biosciences). Cell cycle analysis was performed using FlowJo
software (Tree Star, San Carlos, CA, USA) and the Dean–Jett–
Fox model for fitting of cell cycle phases.
Western blot analysis of LIF-mediated activation
of downstream signalling pathways
The HTR-8/SVneo cells (0.1 106 cells per well) were seeded
into six-well cell culture plates (Greiner Bio-one) in RPMI-1640
medium supplemented with 10% FBS and cultured until 70–
80% confluency. Cells were serum starved for 4–6 h andwashed
once with plain medium. Cells were further cultured in plain
RPMI-1640 medium and treated with LIF (50 ngmL1) for 10,
30 or 60min with or without U0126 pretreatment (10mM, 2 h).
After each time point, cells were lysed by the addition of 100mL
lysis buffer (20mM TRIS-HCl, 10% glycerol, 0.2mM EDTA,
137mM NaCl, 1% Nonidet P-40, 1mM sodium orthovanadate)
supplemented with complete protease and phosphatase inhibitor
cocktails (Roche Diagnostics, Mannheim, Germany). The
lysates were centrifuged at 12 000g for 15min, the supernatant
collected and the protein concentration estimated by the BCA
colourimetric assay (Pierce, Rockford, IL, USA) using bovine
serum albumin (BSA) as the standard.
For gel electrophoresis, 40 mg whole-cell extract was solu-
bilised in gel-loading buffer (62.5mM Tris-HCl, pH 6.8, 2%
sodium dodecyl sulfate (SDS), 25% glycerol, 1% bromophenol
blue, 5% b-mercaptoethanol), boiled for 10min and resolved
by 0.1% SDS–10% polyacrylamide gel electrophoresis
(SDS-PAGE) essentially as described previously (Laemmli
1970). The resolved proteins were transferred onto nitrocellu-
lose membranes using the wet transfer method. After protein
transfer, membranes were blocked with 50mM Tris-buffered
saline (TBS; 50mM TRIS-HCl, 150mM NaCl, pH 7.4) with
3% BSA for 1 h. Blots were incubated at 48C overnight with
a 1 : 1000 dilution of rabbit polyclonal antibodies against
phosphorylated (p-) c-Raf (Ser338), p-MEK1/2 (Ser217/221),
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p-ERK1/2 (Thr202/Tyr204), p-p90RSK (Thr359/Ser363) and
p-STAT3 (Tyr705; Cell Signalling Technology, Danvers, MA,
USA) in TBS containing 0.1% BSA and 0.3% Tween-20
(TBST), followed by three washings with TBST and incubation
with a 1 : 2000 dilution of horseradish peroxidase (HRP)-
conjugated goat anti-rabbit IgG antibody (Cell Signalling
Technology) in TBST for 1 h at room temperature. Blots were
developed using the chemiluminescent substrate Immobilon
(Millipore, Billerica, MA, USA) and Hyperfilm-MP (GE Health-
care Bio-Sciences AB, Uppsala, Sweden) according to the man-
ufacturers’ instructions. All blots were then probed for b-actin,
as described previously (Suman et al. 2009). The intensity of the
bands on Western blots was quantified by LabWorks software
version 4.5 (Ultra-Violet Products, Cambridge, UK).
Immunocytochemistry
The HTR-8/SVneo cells were seeded onto sterile microscopy
slides and incubated in a drop of medium overnight at 378C to
allow them to adhere to the surface. Cells were starved in serum-
free medium for 4 h. Subsequently, cells were treated or not
treated with 10 mMU0126 for 2 h, followed by stimulation with
10 ngmL1 LIF for 15min (which was the time point with the
strongest phosphorylation on Western blot analysis). Immuno-
staining was performed using a Vectastain ABC Kit (Vector
Laboratories, Burlingame, CA, USA). Briefly, cells were fixed
in ethanol :methanol (1 : 1) for 5min, washed in 0.1M PBS and
non-specific sites blocked with normal goat serum for 20min at
room temperature. After blocking, slides were incubated for 1 h
with anti-p-ERK1/2 (Thr202/Tyr204) polyclonal rabbit antibody
diluted 1 : 100 in Dako antibody diluent (Dako, Glostrup,
Denmark) and then incubated for 30min with biotinylated
affinity-purified anti-rabbit IgG antibody (Vector Laboratories).
Thereafter, slides were treated for 30min with a solution of
avidin/biotinylated enzyme complex (ABC; Vector Laborato-
ries), followed by staining for 2min with diaminobenzidine
(DAB; Dako). Cell nuclei were counterstained with haematox-
ylin for 1min. Finally, slides were dehydrated with an alcohol-
to-xylol treatment, covered with Histofluid (Marienfeld,
Lauda-Ko¨nigshofen, Germany) and stored at 48C until used for
microscopy. Cells were analysed under a fluorescence micro-
scope (Axioplan 2; Carl Zeiss, Jena, Germany). Density analysis
of staining was performed using Scion Image software (Scion
Image, Frederick, MD, USA).
Silencing STAT3 expression by short interference RNA
HTR-8/SVneo cells were transfected with STAT3 short inter-
ference (si) RNA (Thermo Scientific Dharmacon, Lafayette,
CO, USA) as described previously with slight modification
(Suman et al. 2009). Briefly, cells were transfected with 250 nM
siRNA using Oligofectamine (Invitrogen, Carlsbad, CA, USA)
for 4 h in OPTI-MEM I medium (Invitrogen) and, after 4 h,
the medium was exchanged for RPMI-1640 supplemented with
10% FBS. Cells were retransfected after 48 h using half the
amount of transfection mixture. The extent of silencing of
STAT3 expression was ascertained by Western blot analysis
of cell lysates collected 24 h after the second transfection with
either non-genomic siRNA designed by scrambling the STAT3
siRNA (AAGCCACTTATAAATTCGTTC) or STAT3 siRNA
(AATGTTCTCTATCAGCACAAT; Poehlmann et al. 2005).
Blots were probed with a 1 : 1000 dilution of rabbit polyclonal
antibody against STAT3 (Cell Signalling Technology) as the
primary antibody and a 1 : 2000 dilution of HRP-conjugated
anti-rabbit IgG antibody (Cell Signalling Technology) as the
secondary antibody. Blots were reprobed for actin as an internal
control, as described above. Silenced and non-silenced cells
(24 h after the second transfection) were trypsinised and seeded
as per the protocol described for DNA cell cycle analysis and
assessment of apoptosis by annexin V staining. Briefly, cells
were pretreated for 2 h with U0126 or with vehicle, followed by
stimulation or not with LIF (50 ngmL1) for 12 h for annexin V
staining or for 48 h for DNA cell cycle analysis.
Apoptosis and death scoring of HTR-8/Svneo cells
following LIF and U0126 treatment
HTR-8/SVneo cells were treated or not with LIF (50 ngmL1)
for 12, 24 and 48 h in the presence or absence of U0126 (10 mM).
Cells were dislodged from the surface of six-well culture plate
using medium containing 0.5% trypsin and 0.2% EDTA before
being washed three times with PBS. Cells were then resus-
pended in binding buffer (10mMHEPES, pH 7.4, 140mMNaCl
and 2.5mM CaCl2) and stained with PE-Annexin V (BD
PharMingen, Franklin Lake, NJ, USA) for 15min in the dark. To
ascertain the specificity of cell death by apoptosis, cells were
counterstained with SYTOX-green DNA binding dye (10 nM;
Invitrogen). Stained cells were analysed using aBDFACSCanto
II flow cytometer (Becton Dickinson Biosciences) and data were
analysed using FlowJo software (Tree Star).
In addition, cells were stimulated for 12 and 24 h in the
presence or absence of LIF (50 ngmL1) and U0126 (10 mM).
After 12 and 24 h, cells were harvested for the preparation of
whole-cell lysates as described above or to prepare a mitochon-
drial fraction. For the preparation of a mitochondrial fraction,
cells were trypsinised and washed with cold PBS. Cells were
then resuspended in isolation buffer (0.2M sucrose, 0.1% BSA,
0.2mMEDTA,10mMHEPES, pH 7.4) and homogenised on ice
using a Dounce homogenizer (Sigma-Aldrich). Homogenised
fractions were centrifuged at 1000g at 48C for 10min and the
supernatant collected. The supernatant was further centrifuged
at 14 000g for 15min at 48C. The mitochondrial fraction, in the
form of the pellet, was washed twice with cold isolation buffer
and lysed in lysis buffer containing protease inhibitor cocktail
(Roche Diagnostics). Whole-cell lysates and the mitochondrial
fractions were used for Western blot analysis of the expression
of Bcl-2 and Bax, respectively. For Western blotting, mouse
monoclonal antibodies against Bcl-2 and Bax (Santa Cruz
Biotechnology, Santa Cruz, CA, USA; 1 : 1000 dilution
in TBST) were used as primary antibodies, whereas HRP-
conjugated goat anti-mouse IgG, (HþL) antibody (Pierce;
1 : 2000 dilution in TBST) was used as a secondary antibody.
Blots were developed and reprobed for actin as described above.
Statistical analysis
All experiments were performed at least twice and the results are
expressed as themean s.e.m. For different sets of experiments,
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such as proliferation assays and Western blot analysis (densi-
tometric analysis), statistical analyses were performed by
comparing mean values in control and experimental groups
using paired Student’s t-test and/orWilcoxon’s signed-rank test.
P, 0.05 was considered significant.
Results
Effect of LIF on proliferation of HTR-8/SVneo cells
HTR-8/SVneo cells were treated with increasing concentrations
of LIF and the extent of proliferation was assessed by counting
the number of viable cells after 48 h treatment. The addition of
1 ngmL1 LIF to the cells had no effect on proliferation, but a
significant increase in proliferation (P, 0.05) was observed
following treatment with 50 ngmL1 LIF (Fig. 1a).
Relevance of the ERK1/2 signalling pathway in LIF-mediated
proliferation of HTR-8/SVneo cells
U0126, a pharmacological inhibitor of MEK1/2 activation, was
used to investigate the relevance of ERK1/2-associated signal-
ling in LIF-mediated proliferation of HTR-8/SVneo cells.
Treatment of cells with a non-cytotoxic concentration of U0126
(10 mM) resulted in a significant decrease (P, 0.05) in prolif-
eration compared with vehicle control (Fig. 1b). Furthermore,
when cell were costimulated with LIF and U0126, a significant
decrease (P, 0.01) in proliferation was observed compared
with cells treated with LIF alone (Fig. 1b). In addition, evalua-
tion of the cell cycle phases by analysing the DNA content of
HTR-8/SVneo cells after 48 h LIF stimulation revealed an
approximate two-fold increase in the number of cells in the G2/
M phase of cell cycle compared with control, which is sugges-
tive of a greater number of proliferating cells in LIF-treated
samples (Table 1). Pretreatment of cells with U0126 in the
presence or absence of LIF had no significant effect on theG2/M
cell population compared with control (Table 1).
Effect of MEK1/2 inhibition on LIF-mediated activation
of the MAPK–ERK1/2 signalling pathway
HTR-8/SVneo cells were treatedwith 50 ngmL1 LIF for 10, 30
and 60min with or without 2 h pretreatment with 10 mMU0126.
Irrespective of the addition of U0126, treatment of HTR-8/
SVneo cells with LIF resulted in transient activation by phos-
phorylation of c-Raf and MEK1/2 as early as 10min, which
decreased by 60min (Fig. 2a–c). Furthermore, treatment of cells
with LIF resulted in the activation of ERK1/2 by 10min, which
was maintained at the same level until 60min. However, pre-
treatment of cells with U0126 abrogated ERK1/2 activation
following LIF stimulation. In addition, following the addition
of U0126, there was an absence of the basal phosphorylation
of ERK1/2 compared with untreated control (Fig. 2a, d).
Immunocytochemistry for p-ERK1/2 also suggested that
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Fig. 1. Effect of leukaemia inhibitory factor (LIF) on the proliferation of HTR-8/SVneo cells in the presence or absence of U0126. Cells
were treated with varying concentrations of LIF and processed for proliferation assay as described in the Methods. (a) Concentration-
dependent effects of LIF on the proliferation of HTR-8/SVneo cells. (b) Effects of LIF on the proliferation of cells in the presence and
absence of U0126. Data are the mean s.e.m. of cell proliferation as a percentage of control from three independent experiments
performed in duplicate. *P, 0.05 compared with control, yP, 0.01 compared with cells stimulated with LIF.
Table 1. Effects of leukaemia inhibitory factor andU0126, an inhibitor
of extracellular signal-regulated kinase 1/2 activation, on cell cycle
progression of HTR-8/SVneo cells
DNA content was measured after propidium iodide staining by flow cyto-
metry. The percentages of cells in different phases of the cell cycle are
shown as the mean s.e.m. of at least two different experiments. *P, 0.05
compared with control; LIF, leukaemia inhibitory factor
Treatment G0/G1 phase S phase G2/M phase
Control 52.5 2.5 35.0 2.1 9.4 1.4
LIF 40.5 1.9 29.8 3.4 18.6 2.6*
U0126 44.8 2.6 42.5 3.1 10.5 3.2
LIFþU0126 43.9 2.1 40.6 1.7 9.8 2.5
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stimulation of HTR-8/SVneo cells with 10 ngmL1 LIF could
increase the p-ERK1/2 levels, an effect that was abrogated
following U0126 pretreatment (Fig. 3). One of the downstream
molecular targets of activated ERK1/2 is p90 ribosomal S6
kinase (p90RSK), the phosphorylation of which was increased
10min after stimulation with LIF, but returned to basal levels
by 60min (Fig. 2a, e). As observed for ERK1/2 activation,
LIF-mediated activation of p90RSK was completely abrogated
in cells pretreated with U0126 (Fig. 2a, e).
Effect of U0126 on LIF-mediated activation of STAT3
in HTR-8/SVneo cells
HTR-8/SVneo cells were stimulated with 50 ngmL1 LIF for
10, 30 and 60min in the presence or absence of U0126. An
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Fig. 2. Effect of U0126 on leukaemia inhibitory factor (LIF)-mediated activation of the extracellular signal-regulated
kinase (ERK) 1/2 signalling pathway in HTR-8/SVneo cells. Cells were stimulated with LIF (50 ngmL1) for 10, 30
and 60min in the presence or absence of U0126 (10mM) and cell lysates were processed for Western blot analysis.
(a) Representative blots for phosphorylated (p-) c-Raf, p-mitogen-activated protein kinase kinase (MEK) 1/2, p-ERK1/2
and p-p90RSK. (b–e) Band intensities for p-c-Raf, p-MEK1/2, p-ERK1/2 and p-p90RSK, respectively, normalised
against actin. Data are given as the fold change compared with control (without LIF stimulation) and are expressed as the
mean s.e.m. of three independent experiments. *P, 0.05 compared with control (without LIF stimulation); yP, 0.05
compared with U0126-pretreated with otherwise unstimulated cells.
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increase in the phosphorylation of STAT3 was observed 10 and
30min after LIF treatment, which started to decrease at 60min
(Fig. 4). Despite treatment of HTR-8/SVneo cells with U0126,
LIF stimulation resulted in a significant increase in STAT3
Tyr705 phosphorylation (Fig. 4).
Role of the ERK1/2 pathway in the regulation of apoptosis
of HTR-8/SVneo cells
HTR-8/SVneo cells were stimulated with 50 ngmL1 LIF for
12, 24 and 48 h, with or without 2 h pretreatment with U0126
(10mM), and apoptotic cells were analysed by staining with PE-
Annexin V. Following LIF stimulation, there was no change in
the proportion of annexin V-positive cells compared with con-
trol at any time point, whereas pretreatment of cells with U0126
resulted in a progressive increase in the number of annexin
V-positive cells compared with control (Fig. 5). Even LIF
stimulation of U0126-pretreated cells resulted in an increase in
annexin V-positive cells over time (Fig. 5).
In another experiment, HTR-8/SVneo cells were stained for
death by PE-Annexin V (apoptosis) and SYTOX green DNA
binding dye (total death), to differentiate between apoptotic and
necrotic death, 12 and 48 h after LIF stimulation in the presence
or absence of U0126. At 12 h, there was an increase in the
number of annexin V-positive cells following U0126 treatment
in the presence or absence of LIF compared with control cells.
This was associated with an overall shift in the cell population in
the U0126 treatment group (see Fig. S1 available as an Acces-
sory Publication to this paper; Fig. 5). However, there was
no change in the proportion of double-positive cells 12 h after
LIF stimulation in the presence or absence of LIF. After 48 h
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Fig. 3. Peroxide staining for extracellular signal-regulated kinase (ERK) 1/2 phosphorylation in HTR-8/SVneo cells. HTR-8/
SVneo cells were pretreated or not for 2 h with 10mMU0126 in the absence of serum and then stimulated or not with 10 ngmL1
leukaemia inhibitory factor (LIF) for 15min. Slides marked with an asterisk are copies of the slides to their left. Strong staining has
been highlighted in red using Scion Image software (Scion Image, Frederick, MD, USA).
0
2
4
6
8
U0126 U0126
U0126 U0126
0 10 30 60 0 10 30 60
*
*
*
†
†
†
R
el
at
ive
 in
te
ns
ity
p-
ST
AT
3/
ac
tin
Time (min)
Actin
p-STAT3 Tyr705
0 10 30 60 0 10 30 60Time (min)
(b)
(a)
Fig. 4. Effect of extracellular signal-regulated kinase (ERK) 1/2 inhibition
on leukaemia inhibitory factor (LIF)-mediated activation of signal transducer
and activator of transcription (STAT) 3 phosphorylation. HTR-8/SVneo
cells were stimulated with LIF (50 ngmL1) for 10, 30 and 60min in the
presence or absence of U0126 (10mM) and cell lysates were processed
for Western blot analysis of phosphorylated (p-)STAT3 Tyr705. (a) Mean
( s.e.m.) band intensities compared with control (cells without LIF stimu-
lation) following normalisation against actin from three independent experi-
ments. (b) Representative blot for p-STAT3 Tyr705. *P, 0.05, as compared
with control (without LIF stimulation); yP, 0.05 compared with U0126-
pretreated with otherwise unstimulated cells.
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incubation, therewas an increase in SYTOXgreen-positive cells
in all groups, but compared with the control and LIF-stimulated
groups, there was significant increase in double-positive cells
following ERK1/2 inhibition irrespective of the addition of LIF
(Fig. S1).
Effect of LIF on the Bcl-2/Bax ratio in HTR-8/SVneo cells
HTR-8/SVneo cells were stimulated with LIF in the presence or
absence of U0126 as described above and cells were lysed using
lysis buffer after 12 and 24 h for Western blot analysis of
Bcl-2 (anti-apoptotic molecule) expression. In another series
of experiments, mitochondrial fractions were collected after 12
and 24 h for Western blot analysis of the expression of the pro-
apoptotic molecule Bax. A significant increase (P, 0.05) was
observed in the Bcl-2/Bax ratio 24 h after LIF stimulation
compared with control; however, there was no significant dif-
ference at the 12 h time point (Fig. 6). In contrast, there was a
significant decrease (P, 0.05) in Bcl-2/Bax ratio in cells pre-
treated with U0126 or both U0126 and LIF (Fig. 6).
Significance of STAT3 in the proliferation and apoptosis
of HTR-8/SVneo cells
HTR-8/SVneo cells were transfected with STAT3 siRNA and,
72 h after transfection, Western blot analysis was used to eval-
uated the expression of STAT3 in siRNA-transfected cells.
A significant decrease in STAT3 expression was observed in
silenced cells comparedwith expression in cells transfectedwith
scrambled siRNA (Fig. 7a).
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Furthermore, the proliferation of STAT3-silenced cells was
evaluated in the presence of LIF and after U0126 pretreatment.
An increase in the proliferating cell population (G2/M phase)
was observed following LIF stimulation in both scrambled
siRNA treated and STAT3-silenced cells, but no change was
observed following inhibition of ERK1/2 activation by U0126
in both the above groups (Table 2). Compared with control cells,
there was no change in the G2/M phase cell population in
scrambled siRNA-transfected cells treated with both U0126
and LIF, but there was an increase in the proportion of prolifer-
ating cells (G2/M phase) in the STAT3-silenced group treated
with both U0126 and LIF compared with untreated STAT3-
silenced cells, which was not statistically significant (Table 2).
Apoptosis was also evaluated in STAT3-silenced cells using
annexin V staining. An increase in apoptosis was observed
in STAT3-silenced cells compared with scrambled siRNA-
transfected cells (Fig. 7b). There was a further increase in
apoptosis in STAT3-silenced cells treated with U0126 or with
both U0126 and LIF for 12 h (Fig. 7d); however, this failed
to reach statistical significance compared with scrambled
siRNA-treated cells (Fig. 7c).
Discussion
During the peri-implantation phase of embryonic development,
controlled proliferation and self-renewal of trophoblast cells
play an important role in the successful establishment of preg-
nancy. This is facilitated by several cytokines and growth factors
present in the uterine microenvironment. For example, EGF
increases the survival of trophoblast cells by activating several
pathways, such as ERK1/2, PI3K and p38 (Johnstone et al. 2005;
Magarinos et al. 2007). Another growth factor present during
the peri-implantation phase, namely IGF-1, acts in an autocrine
and/or paracrine manner to regulate early placental growth and
function. IGF-1 has been reported to increase the proliferation
of primary trophoblast cells obtained from explant culture
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Table 2. Effect of signal transducer and activator of transcription 3
silencing and inhibition of extracellular signal-regulated kinase 1/2
activation on cell-cycle progression in the presence or absence of
leukaemia inhibitory factor
Propidium iodide staining was used to measure DNA content by flow
cytometry. The percentage of cells in different phases of the cell cycle are
shown as the mean s.e.m. of two different experiments. *P, 0.05 com-
pared with control. LIF, leukaemia inhibitory factor; siRNA, short interfer-
ence RNA; STAT3, signal transducer and activator of transcription 3
Treatment G0/G1 phase S phase G2/M phase
Scrambled siRNA
Control 51.6 4.2 36.5 3.1 8.9 1.2
LIF 50.4 2.6 33.1 2.9 15.7 2.5*
U0126 62.1 3.1 25.4 2.1 10.9 2.1
LIFþU0126 64.6 5.1 26.1 4.5 10.8 1.9
STAT3 siRNA
Control 52.1 2.8 39.2 1.1 8.1 1.9
LIF 49.8 1.9 32.3 3.6 17.4 2.4*
U0126 54.9 3.5 35.1 2.3 9.1 1.7
LIFþU0126 55.7 4.6 34.5 3.8 13.1 2.0
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(Maruo et al. 1995). Similarly, VEGF increases the proliferation
of trophoblast cells by activating the MAPK–ERK1/2 pathway,
which can be specifically inhibited by an MEK1/2 inhibitor
(Cha et al. 2001). As observed in mice, LIF is secreted by
the glandular epithelium of the human endometrium and is
expressed at higher levels in women with proven fertility during
the secretory and/or post-ovulatory phase of themenstrual cycle,
suggesting its importance in human reproduction (Cullinan et al.
1996). In the human first trimester trophoblast cell line (HTR-8/
SVneo), stimulation with LIF led to a concentration-dependent
increase in proliferation through enhanced transition of cells
from the resting to G2/M phase of the cell cycle. This observa-
tion is consistent with previous observations that LIF increases
the proliferation of JEG-3 choriocarcinoma cells, although the
increase in the proliferation of those cells was observed at
concentrations as low as 1 ngmL1 (Fitzgerald et al. 2005). This
may be due to differences in the cell lines used between the
studies.
In the human placenta, villous trophoblast cells show immu-
nolocalisation of p-ERK1/2 untilWeek 12 of gestation, which is
indicative of their involvement in the early phase of trophoblast
proliferation (Kita et al. 2003). It has been observed that
ERK1/2 activation controls the interleukin (IL)-11-mediated
proliferation of HT-29 cells (human colorectal adenocarcinoma
cell line) as well as the LIF-mediated increase in the prolifera-
tion of P19 (human embryonal carcinoma) cells (Schuringa et al.
2002; Yoshizaki et al. 2006). Furthermore, the increase in the
proliferation of P19 cells followingLIF stimulationwas found to
be independent of the activation of STAT3.Activation of ERK1/
2 also plays an important role in the leptin-mediated increase
in trophoblast cell proliferation (Magarinos et al. 2007). These
studies highlight the significance of ERK1/2 activation in the
proliferation of trophoblasts and other cell types. Stimulation of
HTR-8/SVneo cells with LIF resulted in the activation of both
STAT3 Tyr705 and ERK1/2 (Figs 2, 4). ERK1/2 is a serine/
threonine kinase that is activated by an upstream MEK1/2,
which is activated through another kinase upstream to that (i.e.
mitogen-activated protein kinase kinase kinase (MAPKKK) or
c-Raf). To investigate the significance of the activation of
the MAPK–ERK1/2 pathway, downstream signalling can be
abrogated using pharmacological inhibitors such as U0126
or PD98059 for MEK1/2, which can block the activation of
ERK1/2. In the present study, we used U0126, an inhibitor of
both MEK1 and MEK2, at a concentration of 10 mM, which is
non-toxic to the cells. Pretreatment of HTR-8/SVneo cells with
U0126 for 2 h resulted in complete abrogation of ERK1/2
activation, at the basal level as well as after LIF stimulation.
In contrast with observations that LIF was responsible for an
increase in the G2/M phase transition of HTR-8/SVneo cells,
after inhibition of ERK1/2 activation, irrespective of LIF
stimulation, there was no change in the proportion of cells
undergoing G2/M transition. This suggests that LIF-mediated
activation of ERK1/2 signalling pathways plays an important
role in trophoblast cell proliferation by promoting the G2/M
phase transition of cells. Activation of the ERK1/2 pathway has
been documented during the increased proliferation of cells
through an increase in the transition from the resting stage to the
G2/M phase. For example, leptin increases vascular smooth
muscle cell progression to the G2/M phase via activation of
ERK1/2 (Huang et al. 2010). In fibroblasts and epidermal cells,
activation of ERK1/2 regulates cell cycle progression by
increasing the expression of cyclins (Dumesic et al. 2009).
So, it can be suggested that activation of ERK1/2 is key to the
regulation of the proliferation of HTR-8/SVneo cells, which
may itself be regulated by the activation and expression of
several cell cycle-associated proteins.
Treatment of HTR-8/SVneo cells with LIF in the presence or
absence of U0126 led to the inhibition of activation of signalling
molecules such as ERK1/2 and p90RSK, although it had no
effect on the activation of STAT3 Tyr705 (Figs 2, 4). These
observations further suggest that the LIF-mediated increase
in proliferation of HTR-8/SVneo cells was brought about by
activation of the ERK1/2-mediated signalling pathway and not
through activation of the STAT3 Tyr705 pathway. Furthermore,
to verify the independent role of STAT3 on LIF-mediated
proliferation ofHTR-8/SVneo cells experimentally, we silenced
its expression using siRNA. Silencing of STAT3 expression in
HTR-8/SVneo cells did not affect the LIF-mediated increase
in proliferation because there was a comparable increase in the
level of the G2/M phase cell population, but inhibition of ERK1/
2 activation in STAT3-silenced cells inhibited the LIF-mediated
proliferation of cells. These observations further suggest that
although STAT3 has a role in increasing the invasion of
trophoblast cells, it does not have a significant role in LIF-
mediated proliferation (Fitzgerald et al. 2008).
Inhibition of the LIF-mediated increase in G2/M progression
by U0126 was associated with a decrease in the absolute cell
count after 48 h of treatment (Fig. 1b). One reason for this could
be the induction of apoptotic cell death following ERK1/2
inhibition because EGF and leptin enhance the survival of
trophoblast cells by activating ERK1/2-dependent MAPK
signalling (Garcia-Lloret et al. 1996; Magarinos et al. 2007;
Perez-Perez et al. 2008). Furthermore, activation of p90RSK,
downstream to ERK1/2, has been linked to the activation of
several anti-apoptotic proteins, such as Bcl-xL/Bcl-2 associated
death promoter, eukaryotic elongation factor-2 kinase and
glycogen synthase kinase-3, so it may have a role in cell survival
(Garcia-Lloret et al. 1996; Ticchioni et al. 2007; Quoyer et al.
2010). In addition, ERK1/2 activation has been reported to
trigger a survival mechanism by increasing the Bcl-2/Bax ratio
in TNF-related apoptosis-inducing ligand (TRAIL)-induced
stress in HeLa cells (Lee et al. 2006). In HTR-8/SVneo cells,
inhibition of ERK1/2 activation led to an increase in apoptosis,
with a concomitant decrease in the Bcl-2/Bax ratio. In the
present study, stimulation of HTR-8/SVneo cells with LIF after
blockade of ERK1/2 activation could not rescue the apoptotic
changes induced by U0126. However, LIF alone increased the
Bcl-2/Bax ratio in HTR-8/SVneo cells but, after ERK1/2 inhi-
bition, the ratiowas reversed, favouring an increase in apoptosis.
This change in the Bcl-2/Bax ratio was reflected by an increase
in cell death at 48 h compared with 12 h after treatment with
U0126 (Fig. S1).
Because STAT3 activation was not associated with the LIF-
mediated increase in proliferation, we wanted to investigate
whether this was associated with the regulation of apoptosis.
Silencing the expression of STAT3 brought about an increase in
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the apoptosis of HTR-8/Svneo cells, which increased further
after inhibition of the ERK1/2-mediated signalling pathway.
In conclusion, the findings of the present study suggest that
the LIF-mediated proliferation of HTR-8/SVneo cells is regu-
lated by a ERK1/2-dependent signalling pathway by increasing
G2/M transition and is not associated with activation of STAT3
Tyr705. In addition, LIF promotes survival of HTR-8/SVneo
cells by upregulating the Bcl-2/Bax ratio, whereas ERK1/2
inhibition increases apoptosis by decreasing the Bcl-2/Bax ratio.
Silencing STAT3 expression in HTR-8/SVneo cells had no
effect on their proliferation.
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Since the discovery of non-coding RNAs, several families of small regulatory molecules
have been described including small nucleolar RNAs, piwi-interacting RNAs and microR-
NAs (miRNAs). MiRNAs are small single-stranded RNAmolecules which play an important
role in the regulation of gene expression at the transcriptional level. Recent studies demon-
strated that about 30% of human genes are regulated bymiRNAs and their deregulation has
been associated with malignancies and poor outcome. Therefore, it is not surprising that
proﬁling ofmiRNAs expression and studies on their regulation became a great ﬁeld of inter-
est in the last decade. However, miRNA-mediated regulation in pregnancy remains poorly
investigated although several independent processes associated with placenta develop-
ment have been shown to be miRNA-regulated. This review provides a general overviewicro-RNA
ost-transcriptional gene silencing
regnancy
lacenta
of the current data on proﬁles and functions of microRNAs in the peri-implantation period,
embryonic stem cells, placentation and pregnancy, as well as in several pregnancy-related
pathologies. We conclude that miRNAs present in the maternal circulation may provide a
new promising diagnostic tool for pregnancy disorders.rophoblast
mmune tolerance
mbryonic stem cells
. Introduction
Small non-coding RNAs (ncRNAs) constitute a group of
NAs which do not code for proteins, but instead exercise
ontrol over those that do. The ﬁrst ncRNA was character-
zed in 1965 in baker’s yeast, but the physiological role
f ncRNAs was not manifest until 1993 when Lee and
olleagues described for the ﬁrst time the involvement
f lin4, a so called “small temporal RNA”, in control-
ing developmental timing in Caenorhabditis elegans (Lee
t al., 1993). It was only in the early 2000s that the term
icroRNA (miRNA) was introduced and the intracellu-ar mechanisms of RNA interference (RNAi) started to be
escribed. One of the ﬁrst identiﬁed characteristics of the
iRNAs was the highly conserved sequences throughout
pecies and the fact that they are expressed in a tissue-
∗ Corresponding author. Tel.: +49 3641 933763; fax: +49 3641 933764.
E-mail address:markert@med.uni-jena.de (U.R. Markert).
URL: http://www.placenta-labor.de (U.R. Markert).
165-0378/$ – see front matter © 2011 Elsevier Ireland Ltd. All rights reserved.
oi:10.1016/j.jri.2011.01.004© 2011 Elsevier Ireland Ltd. All rights reserved.
speciﬁc manner. However, their importance in the control
of genome expression became clear when the analysis of
miRNA sequences revealed the vast amount of recogni-
tion sites on many mRNAs, which suggested a potential
role of miRNAs in the control of transcription and trans-
lation of protein-coding-RNAs and provided information
about the still unexplained 98% of genes which do not pro-
duce proteins (Zhang et al., 2007; Buckingham, 2003). It
is hypothesised that miRNAs may be key factors in evolu-
tionary processes and particularly in the evolution of the
complexity of higher mammals (Bentwich et al., 2005).
During the last decade, about 800 miRNAs have been
described in humans and their function in the regula-
tion of cell proliferation and apoptosis in cancer has been
demonstrated (Zhang et al., 2007). Currently, most of the
miRNA-related studies compare cancer cells versus normal
cells, but the analysis ofmiRNAs in the control of physiolog-
ical processes including pregnancy is just incipient. Recent
reports demonstrate that speciﬁc patterns of miRNAs are
expressed only in embryonic stem cells and in early phases
of embryonic development and somemiRNAs are shown to
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Fig. 1. Theprincipalmechanismof RNA interference. Inside the nucleus, pri-miRNAare cleaved byDrosha to pre-miRNAand transported into the cytoplasm
xogenou
nces. Tw
ads to tr
s referreby Exportin 5 (green arrows). The subsequent cascade is shared with e
functional siRNA which bind to RISC and to complementary RNA seque
Complete complementarity induces degradation and partial annealing le
interpretation of the references to color in this ﬁgure legend, the reader i
be less strongly expressed in choriocarcinoma cells than in
normal trophoblast (Chao et al., 2010; Navarro andMonzo,
2010). More surprisingly, placental miRNAs seem to be
released into the maternal circulation and their concen-
tration and patterns in plasma raise the potential for them
to become markers for the detection of pregnancy disor-
ders such as fetal growth restriction (FGR) (Mouillet et al.,
2010a; Mincheva-Nilsson and Baranov, 2010; Frangsmyr
et al., 2005).
In this review,we summarize the current knowledge on
miRNAbiogenesis, targets and functionswith relevance for
pregnancy and placental development.
2. MicroRNA biogenesis and RNA interference
pathway
The phenomenon of RNA interference was ﬁrst
described in 1998 and refers to gene silencing caused by
introducing double-stranded RNA into the cell (Fire et al.,
1998). Two types of RNA molecules trigger their effects
through the RNAi pathway: small interfering RNAs (siR-
NAs) and miRNAs. While siRNA are synthetic sequences,
miRNAs are endogenous small sequences of RNA (∼22nt)
which have been shown to be highly conserved throughout
evolution (Qavi et al., 2010).
MostmiRNA are not complementary to a speciﬁcmRNA
and thereby regulate simultaneously more than one gene.s siRNA (red arrows). Processing by Dicer results in mature miRNA or
o major enzymes involved in the RISC complex are Ago2 and DP130.
anslational repression (modiﬁed after (Navarro and Monzo, 2010)). (For
d to the web version of the article.)
Additionally, different miRNAs can target the same mRNA
and have similar biological functions, which can intensify
or amplify their effects, also in case of their deregulation. It
is currently estimated that about 30%of thehumangenome
may be regulated by miRNAs (Bueno et al., 2008), which
explains the rapidly increasing number of studies and pub-
lications in the ﬁeld.
MiRNAs are transcribed from DNA as longer sequences
known as pri-miRNAs, which are then cleaved by the
nuclear enzymeDrosha to formhairpin pre-miRNAs before
being exported into the cytoplasm through Exportin-5.
Once in the cytoplasm, pre-miRNAs are further cleaved by
Dicer, an enzyme of the RNase III superfamily of bidentate
nucleases, to formmature single-strandedmiRNAs. Finally,
mature miRNAs are associated with the RNA-induced
silencing complex (RISC) and repress protein translation
(Buenoet al., 2008;Qavi et al., 2010; Cheng et al., 2005). The
mechanismused formiRNA-mediated translational inhibi-
tion depends on the complementarity grade between the
miRNA and its target mRNA. If alignment is complete, the
cascade ends in cleavage of the target mRNA, while par-
tial complementarity and alignment leads to translational
repression of the target mRNA (Cheng et al., 2005; Navarro
and Monzo, 2010) (Fig. 1).
The relevance of miRNA in reproduction is underlined
by theﬁnding that thecascadeof thepivotalmiRNAbiogen-
esis proteins Drosha, Exportin 5, Dicer, Argonaute 2 (Ago2)
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Table 1
MiRNA cluster C19MC on chromosome 19. Most members have been detected in the placenta (Liang et al., 2007; Bentwich et al., 2005; Bortolin-Cavaille
et al., 2009) or in maternal blood (Miura et al., 2010) as marked.
microRNA Bortolin-Cavaillé Bentwich Liang Miura microRNA Bortolin-Cavaillé Bentwich Liang Miura
miR-498
√ √ √ √
hsa-mir-519a-2
√
hsa-mir-512-1
√
miR-519b
√ √ √
hsa-mir-512-2
√
miR-519c
√ √ √
miR-512-3p
√
miR-519d
√ √ √ √
miR-512-5p
√
miR-519e
√ √ √
hsa-mir-515-1
√ √
miR-520a
√ √ √ √
hsa-mir-515-2
√
miR-520b
√ √ √
miR-515-3p
√ √
miR-520c
√ √ √
miR-515-5p
√ √
miR-520d
√ √ √
hsa-mir-516-1 miR-520e
√ √ √
hsa-mir-516-2
√
miR-520f
√ √ √
miR-516-3p
√ √
miR-520g
√ √
hsa-mir-516-4
√
miR-520h
√
miR-516-5p miR-521-1
√ √
hsa-mir-516b2-3
√
miR-521-2
√ √ √
miR-517a
√ √ √ √
miR-522
√ √ √
miR-517b
√ √
miR-523
√ √ √
miR-517c
√ √ √
miR-524
√ √ √
miR-518a
√ √ √
miR-525
√ √ √
hsa-mir-518a-1
√
miR-525-3p
√
hsa-mir-518a-2
√ √
miR-525-5p
√
miR-518b
√ √ √ √
miR-526a
√ √
miR-518c
√ √ √ √
miR-526a-1
√
miR-518d
√ √ √
miR-526b
√ √ √
miR-518e
√ √ √ √
miR-526c
√ √
miR-518f
√ √ √
miR-527
√ √
miR-519a
√ √
hsa-mir-1283-1
√
√
hsa
√
miR
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ghsa-mir-519a-1
nd DP103 is fully present and functional in trophoblast
ells (Donker et al., 2007). The expression of these proteins
oes not depend upon decidualization, normoxia/hypoxia
r culture medium composition. This shows the nonspe-
iﬁc basis of production of active miRNAs, and in part
lso accounts for the efﬁciency of exogenous siRNA when
pplied to trophoblasts (Wengenmayer et al., 2004).
Knockout studies of these pivotal miRNA biogenesis
roteins conﬁrm the requirement of functional miRNA in
eproduction. Loss of Dicer within ovarian granulosa cells,
uteal tissue, oocyte, oviduct and, potentially, the uterus
enders females infertile (Hong et al., 2008). Disruption of
he gene for Ago2 leads to a phenotype similar to the dis-
uption of Dicer1, but with embryonic lethality early after
he implantation stage (Morita et al., 2007).
. MiRNA in the peri-implantation period
During the menstrual cycle, inﬂammation-like pro-
esses occur aiming to prepare the immunological
eceptivity of the endometrium for implantation. These
rocesses are controlled by several proteins, enzymes and
ngiogenic factors which are differentially expressed and
ightly regulated. Altered endometrial expression of these
olecules seems to be responsible for inappropriate tissue
egeneration, resulting in dysfunctional uterine bleed-
ng, failed embryo implantation, and other endometrial
isorders. Current reports have demonstrated that miR-
As participate in regulating dynamic changes in uterine
ene expression patterns by controlling genes associated-mir-1283-2
-1323
√
with the inﬂammatory response (Pan and Chegini, 2008;
Chakrabarty et al., 2007).
A number of miRNAs are speciﬁcally expressed dur-
ing the peri-implantation and pre-implantation periods in
mice. Among the 32 miRNAs identiﬁed as up-regulated
during the receptive phase, miR-101 and miR-199a* were
shown to target cyclooxygenase-2 (Cox2) gene, which is
known for its critical role in implantation and also for
its abilities to promote inﬂammation and tumorigenesis
(Chakrabarty et al., 2007).
4. MiRNA expression in placenta
Current reports on miRNA expression patterns have
exposed a group of miRNAs almost exclusively expressed
by the placenta and fetal brain tissues (Miura et al., 2010).
Located in chromosome 19, C19MC represents the largest
miRNA cluster ever reported. It comprises 54 predicted
miRNAs, 43 of which have been cloned and sequenced
(Bentwich et al., 2005; Bortolin-Cavaille et al., 2009; Liang
et al., 2007) (Table 1).
Interestingly, this cluster is only present in primates
and seems to be the result of duplication and mutation
events unique to this taxonomical order, reinforcing the
hypothesis of miRNA development as a state of evolution.
Besides the current increasing knowledge about miRNA
clusters, it is still not clear whether all miRNAs located in a
miRNA cluster are co-regulated by the same cis-elements
and trans-factors (Tsai et al., 2009).
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The study of C19MC hypermethylation demonstrated
an association between their expression pattern and the
methylation status of a distal CpG-rich region at 17.6 kb
upstream. Imprinting genes play important roles in the
regulation of cellular differentiation and fate, and they
are frequently expressed only in embryonic stages or pla-
cental tissues, which revealed C19MC as a miRNA cluster
involved in human embryonic development (Tsai et al.,
2009).
Six miRNAs are up-regulated in hypoxic trophoblast
(miR-93, miR-205, miR-224, miR-335, miR-451 and miR-
491) and one is down-regulated in hypoxia (miR-424)
(Mouillet et al., 2010b; Donker et al., 2007). Analysis of the
potential mRNA targets of thesemiRNA revealed that miR-
424 controls FGFR1 and MAP2K1 while miR-205 silences
MED1 gene expression, which is essential for murine pla-
cental development (Mouillet et al., 2010b). MiR-205 is
expressed in the hematopoietic and reproductive systems
(Landgraf et al., 2007). It is highly expressed in primary
trophoblast cells, marginally expressed in trophoblast-
derivedcells, andundetectable in cancer cell lines (Mouillet
et al., 2010a,b) which suggests that miR-205 plays a role in
the adaptation of placental epithelium to injury.
Several further miRNAs are altered in placental injuries
or exposure to toxic agents. In cigarette smoke-exposed
placentas miR-16, miR-21 and miR-146a are down-
regulated after cigarette smoke challenge (Maccani et al.,
2010). In the immortalized cell line TCL-1, derived from the
choriodecidua, miR-146a was dose-dependently reduced
by nicotine and benzo(a)pyrene treatment (Maccani et al.,
2010). These observations insinuate a role of miR-146 in
the reaction on cell stress. Interestingly, strong effects on
miR-146 have also been found after bisphenole A exposure
of immortalized trophoblastic cells (TCL-1, HTR8), which
conﬁrms and underlines its role in answering cell stress
(Avissar-Whiting et al., 2010).
Recent studies have described changes of placental
miRNA proﬁles in preeclampsia. In one study expression of
miR-210, miR-1, a miRNA in the 14q32.31 cluster region,
miR-584 andmiR-34c-5p was affected (Enquobahrie et al.,
2010), while in another study the differential expression
of miR-15b, miR-181a, miR-200C, miR-210, miR-296-3p,
miR-377, miR-483-5p, and miR-493 has been reported
(Mayor-Lynn et al., 2010). Only miR-210 coincides in both
papers, which may conﬁrm its involvement in the path-
omechanism of preeclampsia.
Expression of some miRNAs is elevated in chori-
ocarcinoma cells compared with normal trophoblast
cells (miR-9*, miR-96, miR-203, miR-372 and miR-200a),
whereas others are down-regulated (miR-199a, miR-199-
s, miR-199s*, miR-154, miR-370, let-7b, miR-299, miR-134
and miR-199b) (Chao et al., 2010). Within this group, miR-
199b may display a key role in the control of trophoblast
proliferation as forced expression of miR-199b results in
inhibition of choriocarcinoma cell proliferation.
Thus far, very little is known aboutmiRNA expression in
individual cell types in the decidua and placenta surround-
ing the trophoblast cells. Let-7a and miR-320 are induced
by blastocysts and during decidualization of the uterus (Xia
et al., 2010a,b). MiRNA-222 has been described as a major
factor in differentiation of endometrial stromal cells dur-ctive Immunology 88 (2011) 106–111 109
ing decidualization (Qian et al., 2009). To the best of our
knowledge no reports have been published on miRNA in
decidual or placental immune cells.
5. MiRNAs in embryonic stem cells
Similar to C19MC, study of the expression signature in
human embryonic stem (hES) cells demonstrated a spe-
ciﬁc pattern of miRNA. Surprisingly, the majority of the
characterized miRNAs are also located in chromosomes 19
and X (Navarro and Monzo, 2010; Suh et al., 2004). Among
the 36 miRNAs identiﬁed, seven miRNAs were expressed
exclusively in hES cells (miR-200c, miR-368, mir-154*,
miR-371,miR-372,miR-373andmiR-373*) suggesting that
these miRNAs control speciﬁc functions of hES. Further,
this study also revealed a stage-speciﬁc group of miRNAs
involved in the regulation of development and differenti-
ation and comprising let-7a, miR-301, miR-374, miR-21,
miR-29b, and miR-29. The authors speculate that these
miRNAs may be the primary regulators of hES cell main-
tenance or differentiation. Therefore, identiﬁcation of their
target mRNAs will provide information about the complex
network of regulation in hES cells (Suh et al., 2004).
Additional studies on the involvement of miRNAs in
embryonic stem cell differentiation have been performed
in mice. MiR-17 family members, miR-17-5p, miR-20a,
miR-93, and miR-106a, are differentially expressed in
developing mouse embryos and function to control differ-
entiation of stem cells. MiR-93 andmiR-17-5p are strongly
expressed within the mesoderm of gastrulating embryos,
and speciﬁcally, miR-93 localizes to differentiating prim-
itive endoderm and trophectoderm of the blastocyst
(Foshay and Gallicano, 2009). A more recent study has
analyzed mouse pre-implantation embryos at each devel-
opment stage and has found that only a small number of
miRNAs are strongly induced or repressed at any given
stage. They further observed that several miRNAs showed
dramatic directional changes in expression between suc-
cessive stages of development and suggest that they are
strongly expressed only during narrow time windows.
They found nine miRNAs which are potentially involved
in trophectoderm development: miR-297, miR-96, miR-
21, miR-29c, let-7, miR-214, miR-125a, and miR-424 are
up-regulated while miR-376a is down-regulated upon
blastocyst formation (Viswanathan et al., 2009). During
blastocyst-derived stem cell differentiation, mainly mem-
bers of the let-7 family and miR-24 were induced. MiR-24
targets sdx2 which is a stem cell marker that declines
during this differentiation process (Viswanathan et al.,
2009).
6. Involvement of miRNA in regulation of
materno-fetal immunotolerance
Several miRNAs seem to repress expression of immune
tolerance-associated genes, including HLA-G, but without
altering trophoblast invasion. In different situations,
HLA-G is involved in developing immune tolerance, such
as in pregnancy, inﬂammatory and autoimmune diseases
or cancer (Veit and Chies, 2009). Abnormal HLA-G expres-
sion occurs in almost 70% of breast cancer lesions and
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s associated with poor outcome (Chen et al., 2010). A
ecent study demonstrated a relation between miRNAs
nd HLA-G. Among others, aberrant hypermethylation of
iR-148 and miR-152 was observed in primary human
reast cancer specimens, suggesting a regulatory role
or these miRNAs in HLA-G expression (Lehmann et al.,
008). This correlation was conﬁrmed by a study on
EG-3 choriocarcinoma cells. MiR-152 repressed HLA-G
xpression with no effect on JEG-3 invasion. In addition,
ver-expression of miR-152 increases NK cell-mediated
ytolysis implying that miR-152 has a role as an immune
esponse enhancer (Zhu et al., 2010).
. Pregnancy related miRNAs in maternal
eripheral blood
Placenta-derived miRNAs in the maternal circulation
eem to play a pivotal role in adaptation of the organism to
regnancy, especially in regard to inducing immune toler-
nce. Numerous members of the above mentioned C19MC
luster of miRNA have been detected in maternal blood
Miuraet al., 2010). Elevatedplasma levelsofplacentalDNA
nd RNA are associated with clinical conditions related to
lacenta dysfunction, such as preeclampsia and intrauter-
ne growth restriction (Alberry et al., 2009; Zhong et al.,
001), but little is known about the (placental) miRNA
atterns inmaternal blood during pregnancy and its corre-
ation with diseases.
Placenta-speciﬁc miRNA expression in serum changes
uring the course of pregnancy. SomemiRNA changemore
han 600-fold which has allowed researchers to distin-
uish accurately pregnant from non pregnant women by
nalyzing three miRNA that are highly expressed during
regnancy (miR-526a, miR-527 and 520d-5p) (Gilad et al.,
008). Among the signiﬁcantly elevatedmiRNAs in plasma
rompregnantwomen,miRNA-424andmiR-141havebeen
reviouslydescribedasuseful fordiagnosisofmalignancies
Mouillet et al., 2010a). MiR-141 belongs to the miR-200
luster, physiologically exclusively expressed in hES cells,
nd is involved in carcinogenesis in breast cancer (Neves
t al., 2010). MiR-424 regulates differentiation in human
eukemia cells (Kasashima et al., 2004).
Fetal growth restriction is the second leading cause of
erinatal morbidity andmortality. Recently, an association
etween FGR and increased circulating miRNA levels has
een described based on the hypoxic conditions which are
requently involved in the pathophysiology of fetal growth
estriction.
. Conclusions and perspectives
Pregnancy is a complex process which requires tightly
egulated gene expression in the placenta. MiRNA tune
nd control gene expression post-transcriptionally, but
anifold factors and situations tune and control miRNA.
herefore, their potential for becoming novel biomark-
rs and also drug targets is enormous. In pregnancy,
iRNAmay reﬂect disorders not yet detectable with other
ethods and contribute to understanding the underlying
athological mechanisms.ctive Immunology 88 (2011) 106–111
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Reduction in miR-141 is Induced by Leukemia Inhibitory Factor
and Inhibits Proliferation in Choriocarcinoma Cell Line JEG-3
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Introduction
Leukemia inhibitory factor (LIF) induces tyrosine
phosphorylation of signal transducer and activator of
transcription 3 (STAT3) in several trophoblast and
choriocarcinoma cell types and lines (summarized
in1). This event triggers several trophoblastic func-
tions, such as migration, invasion or induction and
suppression of expression of a variety of genes.2,3
Because functional effects have been observed after
several days, it cannot be excluded that parts thereof
are secondary or indirectly induced. We argue that
micro-RNA (miRNA) may be involved in the
regulation of these previously observed LIF-induced
functions. For this reason, we have selected a panel
of five miRNAs which have been described to influ-
ence STAT3 expression or which are known to be
expressed on full activation of STAT3.
MiRNAs constitute a novel group of regulatory
molecules that play a pivotal role in the control of
gene expression at post-transcriptional level. The
number of miRNAs described thus far arises approxi-
mately 1000 (MiRBase V16), which may regulate up
to 30% of the human genome.4 The signature of
miRNA expression is regulated in a tissue- and
developmental stage-specific manner, and thereby, it
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Problem
Starting from the peri-implantation period, leukemia inhibitory factor
(LIF) is a major regulator of trophoblast functions. Micro-RNAs (miRNA)
are short non-coding RNA sequences, which regulate expression of
genes at post-transcriptional level. The influence of LIF on miRNA
expression in trophoblastic cells has not yet been analyzed and was
focus of this investigation.
Method of study
JEG-3 choriocarcinoma cells have been stimulated with LIF for 1, 2, 4,
6, and 24 hr. The expression of miR-9, miR-141, miR-21, miR-93, and
let-7g has been analyzed by real-time PCR. Subsequently, miR-141 has
been silenced and over-expressed to test its role in the proliferation of
JEG-3 cells after 24 and 48 hr.
Results
MiR-141 has been significantly downregulated by more than 50% after
LIF stimulation, while miR-21 and miR-93 expression has been signifi-
cantly upregulated. Silencing of miR-141 completely inhibited the prolif-
eration of JEG-3 cells, while over-expression had no effect.
Conclusion
LIF regulates expression of miRNA in trophoblastic cells, which may be
responsible for several functional effects induced by LIF.
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may be used as a biomarker for the identification of
certain physiological or pathological events including
malignancies. Current reports have demonstrated
specific patterns of miRNAs regulating changes in
uterine gene expression5,6 or miRNAs that are specif-
ically expressed in embryonic stem cells and whose
expression is altered during embryonic develop-
ment.7 Likewise, some miRNAs are found less
expressed in choriocarcinoma cells than in normal
trophoblast, which suggests a role in carcinogenesis.8
We focused on five miRNAs previously published
to correlate with tumor grade, to be implicated in
pregnancy, or to be related with members of the sig-
naling intracellular cascade of LIF. For instance,
miR-141, belonging to the miR-200 cluster, is found
upregulated in nasopharyngeal and ovarian carcino-
mas in comparison with normal tissues and corre-
lates with poor prognosis.9,10 As biological marker,
levels of miR-141 are increased in plasma from preg-
nant women.11 Also, expression of miR-9 may serve
as a biomarker, which correlates with tumor grade
and metastatic status in breast and cervical can-
cer.12,13 Its inhibition results in increased levels of
phospho-STAT3 in embryonic stem cells.14 Among
the miRNAs selected for the present investigation, to
date, miR-21 is the most extensively studied.
Because of its over-expression in at least six different
solid cancers (lung, stomach, prostate, colon, pan-
creas, and breast), it has been considered an oncomir
(reviewed in15). MiR-21 can be induced by STAT3.7
Mir-93 seems to be related with the trophoblast
response to hypoxia as it is upregulated in hypoxic
trophoblast cells.16 MiR-93 shares some features
with miR-141 and miR-21 as they all are expressed
in human embryonic stem cells, but their effects in
cell maintenance or differentiation seem to be dis-
similar. While miR-93 expression remains similar
also in adult tissue, miR-141 attenuates differentia-
tion and miR-21 expression intensifies it.17–20
Finally, we selected let-7g, a member of one of the
currently most important miRNA families (let-7),
which is aberrantly expressed in human cancer.21
Let-7g and also miR-21 were expressed in vitro as
well as in vivo via STAT3 activation after IL-6 stimu-
lation.22
Although the LIF-induced STAT3 activation in
trophoblastic cells seems to be crucial for many cell
functions, thus far, the LIF-induced miRNA expres-
sion in these cells has not yet been investigated.
Therefore, in the present study, we aim to analyze
the kinetics of the expression of miR-9, miR-21,
miR-93, miR-141, and let-7g after LIF treatment in
JEG-3 cells. Being the most affected, influence of
miR-141 on proliferation has been analyzed by its
experimental over-expression and silencing.
Materials and methods
Cell Cultures
JEG-3 (DSMZ, Braunschweig, Germany) is an adher-
ent human choriocarcinoma cell line preserving sev-
eral trophoblast-like capacities including production
of pregnancy-related hormones and cytokines. JEG-3
cells cultures were performed at 106 cells ⁄175 cm2
flask and maintained under standard conditions
(37C, 5% CO2, humid atmosphere) in Ham’s F-12
Nutrient Mixture with l-glutamine (Gibco, Paisley,
UK) supplemented with 10% heat-inactivated fetal
calf serum (FCS; Gibco) and 1% penicillin ⁄ strepto-
mycin antibiotic solution (Gibco).
Quantitative Real-time PCR
JEG-3 cells were seeded in 12-well plates, allowed to
attach, and deprived of serum overnight. Thereafter,
cells were challenged with 10 ng ⁄mL LIF (Millipore,
Schwalbach, Germany) up to 24 hr, and total RNA
(containing miRNAs) was isolated with TRIzol (Invi-
trogen, Darmstadt, Germany). Mature miRNAs were
reverse-transcribed, and real-time PCR was per-
formed using TaqMan miRNA assays with specific
primers for the selected miRNAs (Applied Biosys-
tems, Darmstadt, Germany; see Table I). Each
real-time PCR was performed in duplicates, includ-
ing no-template controls. For normalization, several
endogenous controls were tested, and RNU48 was
selected after showing high stability and expression
in our model. Fold changes were determined using
Table I MiRNA Assays Used for qRT-PCR (Applied Biosystems)
Assay ID Assay name Target sequence
002282 hsa-let-7g UGAGGUAGUAGUUUGUACAGUU
000397 hsa-miR-21 UAGCUUAUCAGACUGAUGUUGA
001090 mmu-miR-93 CAAAGUGCUGUUCGUGCAGGUAG
000463 hsa-miR-141 UAACACUGUCUGGUAAAGAUGG
000583 hsa-miR-9 UCUUUGGUUAUCUAGCUGUAUGA
001006 RNU48 GAUGACCCCAGGUAACUCUGA
GUGUGUCGCUGAUGCCAUCAC
CGCAGCGCUCUGACC
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the ‘delta-delta Ct’ method relative to the expression
at the beginning (0 hr) before LIF stimulation was
initiated. The experiments were repeated indepen-
dently five times for miR-9, miR-141, and let-7g and
four times for miR-21 and miR-93. Differences in
the quantified gene expression were statistically
assessed using the non-parametric Wilcoxon test and
considered significant when P < 0.05.
Over-expression and Silencing of miR-141
Anti-miR miRNA inhibitors are single-stranded
nucleic acids specifically designed to bind and to
inhibit endogenous miRNA molecules. Conversely,
Pre-miR miRNA precursor molecules are double-
stranded RNA molecules, which mimic endogenous
mature miRNA. Owing to their small size, all these
molecules can be easily delivered into the cells using
transfection reagents similar to those used for small
interfering RNA transfection.
To determine the effect of miR-141 on cell prolif-
eration, JEG-3 cells were transfected with either
anti-miR inhibitors or pre-miR precursors specifically
designed for miR-141 or the respective non-genomic
negative controls (assays IDs: AM10860, AM17010,
PM10860, AM171010; Applied Biosystems). Trans-
fection was performed by applying Nanofectin (PAA,
Co¨lbe, Germany) as follows: 24 hr before transfec-
tion, cells were seeded in 12-well plates to obtain a
70–80% of confluence the day of transfection. The
following day, two solutions were prepared: (1)
Three microlitres of either anti- or pre-miR solution
(5 lm each) was diluted in 32 lL serum-free med-
ium. (2) Three microlitres of nanofectin was diluted
in 30 lL of serum-free medium. Solutions 1 and 2
were mixed and incubated for 30 min at room tem-
perature. Subsequently, the mix was added into the
wells containing the cells in 500 lL serum-free med-
ium and incubated at 37C for 4 hr. Transfection
was terminated by the addition of 250 lL of medium
supplemented with 30% FCS. The next morning,
cells were trypsinized and seeded into 96-well plates
(1 · 104 cells ⁄well).
Proliferation Assay
Cell proliferation was analyzed using a Cell Titer
AQeous MTS assay (Promega, Mannheim, Germany)
according to the manufacturer’s instructions. Assays
were commenced with 1 · 104 cells in 96-well
plates, and cells initiated spontaneous proliferation.
After 0- (basal value), 24-, and 48-hr incubation,
proliferation was measured by adding methyl tetra-
zolium salt (MTS) solution 20 lL ⁄well and measur-
ing the absorbance at 490 nm. Three independent
cultures have been performed for each time point.
Differences in the quantified proliferation rates of
JEG-3 cells were statistically assessed by Student’s
t-test and considered significant when P < 0.05.
Results
MiRNA Expression Kinetics After LIF Stimulation
JEG-3 cells were stimulated up to 24 hr with
10 ng ⁄mL LIF, and the expression of miRNAs was
assessed at five different time points by real-time
PCR. LIF stimulation significantly reduces the
expression of miR-141 after 4 and 6 hr compared
with the respective basal expression levels. MiR-93
increases at all time points (significantly after 2 and
24 hr of LIF stimulation up to 9.2-fold), and miR-21
increases significantly after 1, 6, and 24 hr with a
maximum of 19.8-fold. After 4 hr of LIF stimulation,
miR-21 expression is significantly reduced compared
with that at the aforementioned time points. This
strong reduction has been obvious in each individual
experiment. All other changes, including the 2.3-fold
increase in let-7g expression at 2 hr LIF stimulation,
were not significant (Fig. 1).
Effects of miR-141 Silencing and Over-expression
on Proliferation
Because we have observed the most stable LIF-
induced changes in miR-141, we decided to analyze
its impact on proliferation by silencing and over-
expression in JEG-3 cells. Transfection of JEG-3 cells
with control substances reduces proliferation at all
analyzed time points. Only silencing of miR-141
leads to a block of proliferation, when compared
with its respective control, and is, after 48 hr,
approximately 50% lower than in cells transfected
with a non-genomic control sequence. In all other
settings, proliferation is time-dependent. Over-
expression of miR-141 does not lead to a further
increase in proliferation (Fig. 2).
Discussion
We have observed a significant influence of LIF on
the expression of the miRNAs miR-21, miR-93
LIF-REDUCED MIR-141 INHIBITS CELL PROLIFERATION
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(upregulation), and miR-141 (downregulation). The
strongest effects were observable 4 and 6 hr after
stimulation with LIF when miR-141 was downregu-
lated by far more than 50%. A surprising result was
the downregulation of miR-21 after 4 hr of LIF stim-
ulation compared with the earlier and later analyses.
Silencing of miR-141 inhibits proliferation of JEG-3
cells, while over-expression does not further induce
proliferation. To the best of our knowledge, thus far,
no studies have been published on LIF-induced miR-
NA in any cell type, but several STAT3-induced miR-
NAs have been described. LIF is well known to
phosphorylate and activate STAT3 in a variety of
cells including trophoblastic cells, where it induces
invasiveness.3
In our experiments, LIF stimulation of JEG-3 cells
significantly increased miR-21 expression. This is
compatible with previous reports that in head and
neck carcinoma, osteosarcoma, ovarian carcinomas,
and others, miR-21 promotes proliferation, migra-
tion, and invasion.23–25 The significant downregula-
tion of miR-21 after 4 hr of stimulation may be
attributable to the initiation of negative intracellular
feedback mechanisms, such as induction of suppres-
sors of cytokine signaling 3, but which may then
again be overcome by the permanence of LIF stimu-
lation.26 Let-7g was slightly, but not significantly,
increased after LIF stimulation, which is in contrast
to previous descriptions on let-7g in cancer. In hepa-
tocellular carcinoma, ectopic expression of let-7g
inhibits cell migration and growth.27 In gastric can-
cer, low let-7g is associated with unfavorable out-
come in overall survival independent of clinical
covariates, including depth of invasion, lymph-node
metastasis, and stage.28 LIF-stimulated JEG-3 cells
expressed significantly higher levels of miR-93,
which is in line with previous observations on
tumors. In human glioblastoma, miR-93 suppresses
integrin-b8 expression, which promotes tumor
growth and angiogenesis.29 In human T-cell leuke-
mia virus 1, miR-93 targets the mRNA for tumor
protein 53–induced nuclear protein 1 (TP53INP1),
which is a tumor suppressor protein.30 In our experi-
ments, miR-9 did not change considerably. In
human embryonic stem cell-derived neural progeni-
tors, loss of miRNA-9 reduces proliferation and
increases migration.31 On the other hand, miR-9 tar-
gets E-cadherin, which is a suppressor of metastas-
ization and angiogenesis. Its high expression in
breast cancer is correlated with the malign proper-
ties.32
In JEG-3 cells, LIF significantly downregulated
miR-141. Repression of miR-141 induces invasive-
ness of breast cancer cells by targeting the endothe-
lial mesenchymal transition activators ZEB1 and
ZEB2, which downregulate E-cadherin expression.18
Also in colorectal cancer, miR-141 negatively corre-
lates with migration and invasion.9 A different func-
tion has been observed for miR-141 in gastric cancer
cells, where its over-expression by the application of
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Fig. 1 Normalized expression kinetics of miRNAs after leukemia inhib-
itory factor (LIF) induction. JEG-3 cells were stimulated with LIF
(10 ng ⁄mL), and miRNA gene expression was measured by real-time
PCR at several time points. Results were normalized to the basal (0 hr)
expression levels of the respective miRNAs and are expressed as
mean. Error bars show standard error of the mean. n = 5 independent
experiments for miR-9, miR-141, and let-7g, n = 4 for miR-21 and miR-
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its precursors inhibited the proliferation.33 In con-
trast, it is upregulated in nasopharyngeal carcinoma,
where it positively correlates with proliferation,
migration, and invasion.34 In our hands, silencing of
miR-141 inhibits proliferation of JEG-3 choriocarci-
noma cells, which goes in line with these results.
The observed strong impact of LIF on various miRNA
in JEG-3 choriocarcinoma cells underlines the
expected involvement of miRNAs in the regulation
of essential functions in trophoblastic cells and thus
in tuning placentation and other crucial processes in
reproduction and pregnancy.
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Background: MicroRNAs (miRNAs) are small single-stranded RNA molecules which 
are important post-transcriptional modulators of gene expression. Trophoblast cells 
are a heterogenous group a fetal cells in the placenta displaying a spectrum of 
functions. The regulation of their behavior may partly underly the control through 
miRNAs. Therefore, we aimed to compare the miRNA profile of primary third 
trimester trophoblast cells with that of different trophoblastic cell lines.  
Material and methods: Total RNA was isolated from cytotrophoblast cells from 3 
healthy term placentae and the cell lines HTR-8/SVneo (immortalized trophoblast 
cells), JEG-3 (choriocarcinoma), ACH-3P and AC1-M59, which are choriocarcinoma 
cells fused with first and third trimester trophoblast cells, respectively. The expression 
level of 762 different miRNAs was quantitatively analzed by using a TaqMan Human 
MicroRNA Array. The results for 10 important miRNA were confirmed by individual 
qPCR.  
Results: The analyzed cell types share many similar patterns of miRNAs, but are 
significantly distinct in the expression of two major miRNA clusters: chromosome 19 
miRNA cluster (C19MC; containing at least 54 different miRNAs) and C14MC (at 
least 34 miRNAs). Both clusters are expressed in primary term trophoblast cells, but 
C19MC is not expressed in HTR-8/SVneo and C14MC not in the choriocarcinoma-
derived cell lines (complete array data at NCBI Gene Expression Omnibus: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32346). Another minor 
cluster (miRNA-371 to miRNA-373 cluster), also located on chromosome 19 is also 
expressed in all cells except HTR-8/SVneo. Beside the miRNAs within the clusters, 
miR-24, miR-193b and miR-720 are the three highest expressed in all cell types, 
while miR-200c expression is >50fold higher in primary trophoblast than in all cell 
lines. 
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Conclusion: Primary term trophoblast cells and trophoblastic cell lines display major 
differences in their miRNA fingerprints which may be involved in their different 
behavior and characteristics. 
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Since the discovery of the first microRNA lin-4 in 1993 [1], the study of microRNAs 
(miRNAs) has generated great interest due to their vast potential in the regulation of 
protein-coding genes. MiRNAs are highly conserved sequences of single-stranded 
RNA (~19-22nt) which repress gene expression by a mechanism involving the RNA 
interference pathway [2]. Depending on the complementary grade between the 
miRNA and its mRNA target, the pathway results in inhibition of translation, or 
cleavage of the target mRNA, when partially or fully complimentary, respectively [3]. 
This characteristic allows targeting of several genes simultaneously and therefore, it 
can be expected that 30% of the human genome may be regulated by miRNAs [4].  
 
Remarkably, miRNA genes are frequently located at fragile sites and cancer-related 
genomic regions [5], and trend to be organized into clusters suggesting that miRNAs 
belonging to a same cluster are likely to have similar functions and be regulated by 
the same promoter and in the same transcriptional orientation [6, 7]. The analysis of 
the miRNA signature (miRNome) in normal human tissues revealed some universally 
expressed miRNAs but also several groups of miRNAs exclusively or preferentially 
expressed in a tissue-specific manner [8]. Likewise, the miRNA expression signature 
is frequently found altered in cancer [9, 10], and can be successfully used to 
distinguish between cancer and normal tissues [11, 12] or even to clarify poorly 
differentiated tumors [13].  
 
Recent reports have described two large miRNA clusters expressed in placenta: The 
chromosome 19 miRNA cluster (C19MC), which maps to chromosome 19q13.41 and 
comprises 54 predictive miRNAs, 43 of which have been already cloned an 
sequenced (reviewed in [3]); and the C14MC located in the 14q32 domain and which 
contains at least 34 miRNAs [
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14]. These clusters differ in some important features: 
C19MC is only found in primates while C14MC appears to be conserved among 
eutherian species [15]; and even when both of them are imprinted genes, C19MC is 
only expressed from the paternally inherited chromosome whilst C14MC is only 
expressed from the maternally inherited chromosome [15, 16]. Imprinting genes are 
known to be involved in human embryonic development and to play important roles in 
the regulation of cellular differentiation and fate [17]. Therefore, study of these 
clusters could provide information about the regulatory mechanisms involved in the 
embryonic development.  
 
The study of the miRNome of trophoblast cells, however, is restricted by the 
limitations associated with the work on primary cells such as relatively low number of 
isolated cells, short lifespan or lack of proliferation in vitro [18]. Several trophoblastic 
cell lines have been established during the last three decades attempting to resemble 
primary trophoblasts and avoiding the limitations of isolation. Two main 
methodologies have been used: Introduction of the gene encoding simian virus 40 
large T (sv40T) antigen [14] or establishment of human choriocarcinoma cell lines 
[19]. Therefore, the different genetic background and the methods used for 
immortalization should be taken into consideration for interpretation and discussion of 
results obtained from the respective cell line.  
 
To our knowledge, there are no publications yet on the miRNA expression profiles in 
trophoblastic cells, or their comparison with primary isolated trophoblast cells. To 
overcome this lack of knowledge, we assessed the miRNA expression patterns of 
four cell lines and isolated trophoblast cells. We included the immortalized human 
first trimester trophoblast cell line HTR-8/SVneo [20], the choriocarcinoma cell line 
JEG-3 and the two hybrids cell lines, ACH-3P and AC1-M59, which resulted of fusion 
of the AC-1 choriocarcinoma cell line with first and third trimester isolated trophoblast 
cells, respectively [
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By fingerprinting miRNA gene expression we aimed to contribute to better 
understanding of differences and resemblances of these frequently used cell lines 
and primary trophoblast cells. Concluding from our observations, the above 
mentioned cluster C14MC and C19MC may play key roles in regulating their 
phenotypical and functional diversity. 
 
 
Materials and Methods 1 
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Four cell lines were investigated in this study: the immortalized first-trimester 
trophoblast cell line HTR-8/SVneo (kind gift from CH Graham, Kingston Canada) 
[20], the choriocarcinoma cell line JEG-3 (DSMZ, Braunschweig, Germany), and two 
hybrids of JEG-3 with human first and third trimester trophoblast cells, ACH-3P and 
AC1-M59 cells, respectively (kind gift from G Desoye, Graz, Austria) [19, 21, 22].  
 
Cell culture 10 
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Cell cultures were performed at 106 cells/175 cm2 flask, and maintained under 
standard conditions (37ºC, 5% CO2, humid atmosphere) in Ham’s F-12 Nutrient 
Mixture with L-glutamine (GIBCO, Paisley, UK) or RPMI Medium (GIBCO) (HTR-
8/SVneo cells) supplemented with 10 % heat-inactivated fetal calf serum (FCS; 
GIBCO) and 1 % penicillin/streptomycin antibiotic solution (GIBCO). 
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Trophoblast isolation was performed using a modified Kliman method as described in 
detail by Stenqvist et al [23]. Briefly, 20g tissue from healthy term placentae was 
physically disaggregated and enzymatically digested for 30 min. After washing, 
isolated cells were applied on a density gradient (Percoll, Pharmacia, Sweden) and 
the fraction retained within the layer of 25% Percoll was collected and washed. For 
depletion of non-trophoblastic cells, Dynabeads coated with CD45 and CD82 
antibodies (Life Technologies, Darmstadt, Germany) were used.  
 
RNA isolation and array analysis  26 
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Cells were seeded in 12-well plates, allowed to attach overnight and serum deprived 
for at least two hours. Total RNA was isolated by using a mirVana isolation kit (Life 
Technologies, Darmstadt, Germany), according to the manufacturer's protocol. 
Thereafter, 100 ng of total RNA containing miRNAs was reverse transcribed using 
the specific Megaplex RT primers (Life Technologies) followed by a pre-amplification 
of the obtained cDNAs. Finally, the expression level of 762 different miRNAs was 
performed using the TaqMan® Array Human MicroRNA A+B Cards Set v3.0 (Life 
Technologies). Card A includes historically “older” miRNAs, which have been 
described early than those of card B. This correlates with their generally higher 
expression and frequency in many tissues. Experimental data were analyzed by 
DataAssist v3.0 (Life Technologies) using RNU48 and RNU44 as endogenous 
controls. Due to software settings, results from card A and card B had to be analyzed 
separately and are displayed as heatmaps from unsupervised hierarchical clustering 
of all miRNAs and all individual samples. The arrays were repeated independently 
twice for ACH-3P, AC1-M59 cells and HTR8/SVneo, and three times for JEG-3 and 
trophoblast cells. 
 
Real-time quantitative RT-PCR 19 
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The expression levels of five miRNAs (miR-518a-5p, miR-519e, miR-373, miR-411, 
miR-539) representing three different miRNA clusters (C19MC, cluster miR-371, 
C14MC) and with large differences between HTR-8/SVneo and the other cell lines 
were confirmed by applying individual TaqMan miRNA Assays (Applied Biosystems, 
Foster City, CA, USA) according to the protocol provided by the supplier. 
Additionally, the expression of another set of 5 miRNAs (miR-9, miR-21, miR-93, 
miR-141, let-7g), which are known to correlate with tumor-grade, to be implicated in 
pregnancy or to be related with members of the signaling intracellular cascade of LIF 
was confirmed by use of the same method (analyzed and summarized in [ ]).
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RNA was isolated by using a mirVana isolation kit (Life Technologies). RNA purity 
was assessed by the ratio of spectrophotometric absorbance at 260 and 280 nm 
(A260/280nm) on a NanoDrop ND-1000 (NanoDrop Inc, Wilmington, DE USA). 
Reverse transcription was performed with miRNA specific stem-loop RT primers and 
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems), followed by qRT-
PCR using specific TaqMan Assays and TaqMan Universal PCR Master Mix. All 
reactions were run in duplicates including no-template controls in 96-well plates on a 
7300 Real Time PCR System (Applied Biosystems). Fold changes were calculated 
by the formula 2-∆∆Ct relative to the expression in primary trophoblast cells. The 
experiments were repeated independently three times and differences in the 
quantified gene expression were statistically assessed by using a Student’s t-test and 
considered statistically significant when p<0.05.  
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Expression profiling of microRNAs in trophoblastic cells 
We assessed the complete (miRBase v13.0) microRNA expression profile of the four 
trophoblastic cell lines HTR-8/SVneo, JEG-3, AC1-M59 and ACH-3P as well as that 
of trophoblast cells isolated from third trimester placentae (complete array data at 
NCBI Gene Expression Omnibus: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32346). The detection of the 
total of 762 miRNAs was done on two different array cards A and B containing 381 
miRNAs each. Around 65% of the miRNAs on card were notably expressed (ct < 
35.0), but only approximately 35% on card B (Figure 1A, 1B and Supplement 1).  
Unsupervised cluster analysis of all ct values revealed that in both arrays (card A and 
B) choriocarcinoma-derived cell lines cluster together, whilst HTR-8/SVneo cells 
appear in a different branch of the dendrogram (Figure 1A and B).Isolated 
trophoblast cells clustered more closely to choriocarcinoma derived cell lines than to 
HTR-8/SVneo cells, except one sample of trophoblast cells on card B which had a 
generally very low miRNA expression.   
Similarly, the analysis of the microRNA signature allowed us to identify two major 
groups of microRNAs, both present in primary trophoblast cells, but one of which 
almost exclusively expressed in HTR-8/SVneo cells and the other in the 
choriocarcinoma-derived contra-parts (Figure 1C and 1D). A deeper analysis 
revealed that among the 43 miRNAs highly expressed (Ct+ ≤ 28.0) in HTR-8/SVneo 
cells, 25 map to the chromosome 14, and 24 of them belong to the C14MC (Table 1). 
Likewise, we found 45 miRNAs almost exclusively expressed in JEG-3 cells and its 
hybrid cell lines, but not in HTR-8/SVneo cells (Ct > 35 in HTR-8 and Ct ≤ 25.0 in 
JEG-3 cells). All these miRNAs are located in chromosome 19: 42 of these miRNAs 
belong to the placenta-specific cluster C19MC, and 3 miRNAs to the miR-371 cluster, 
which is also located on chromosome 19 (Table 1). Isolated trophoblast cells highly 
express miRNAs corresponding to C19MC but not those of the miR-371 cluster. They 
also express of some members of C14MC.  
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The mentioned clusters dominate the miRNA fingerprints and have high influence on 
the unsupervised clustering of analyzed samples. Due to the high expression levels 
of > more than 30 miRNAs within the C19MC cluster in all choriocarcinoma-derived 
cell lines and primary trophoblast cells, but their almost complete absence in HTR-
8/SVneo cells, the dendogram is mainly organized depending on the statiscal power 
of these strong components. In order to investigate the relevance of further miRNAs, 
which do not belong to C14MC or C19MC, the unsupervised hierarchical clustering 
was repeated after depleting their respective results. When only C14MC miRNAs 
were excluded, the resulting dendogram was very similar to the original with a close 
association between choriocarcinoma cell lines and trophoblast cells (Figure 2A). 
When C19MC miRNAs were excluded, trophoblast cells appear in a separate branch 
of the dendogram, which demonstrates that miRNAs belonging to the C19MC are the 
mostly responsible for the observed similarities between choriocarcinoma derived cell 
lines and isolated trophoblast cells (Figure 2B). After elimination of C19MC miRNAs, 
JEG-3 cells clustered in a different branch than their hybrids, which indicates major 
systematic differences in other miRNAs, which do not belong to C19MC. The 
depletion of the combination of both, C19MC and C14MC miRNAs data, did not 
result in additional changes (Figure 2C). These results highlight on the one hand the 
leading relevance of C19MC in distinction of the analyzed cell types, but on the other 
hand, that the fingerprints and differences between the different analyzed cell types 
do not depend exclusively on C19MC and C14MC miRNAs. 
 
Expression of miRNAs in isolated trophoblasts resembles choriocarcinoma 
cell lines more than immortalized first trimester trophoblast HTR-8/SVneo cells 
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For confirmation of array results, we analyzed individually by qPCR the expression of 
2 miRNAs representing C14MC (miR-411 and miR-539), 2 miRNAs representing 
C19MC (miR-519e and miR-518a-5p) and miR-373, a member of the small cluster of 
miR-371. As observed in the arrays, HTR-8/SVneo cells differ significantly in the 
expression of the miRNAs located on the chromosome 19. The levels of miR-518a-
5p, miR-519e and miR-373 were 89.9-, 5634.2-, and 286.0- fold, statistically 
significantly higher in trophoblast cells than in HTR-8/SVneo cells, respectively 
(Figure 3A-C). Conversely, only the expression of miR-539 was slightly, not 
significantly, higher in HTR-8/SVneo cells than in trophoblast cells (24.0-fold). 
Expression of miRNAs belonging to C14MC were between 1.3- and 7.2 higher in 
trophoblast cells than in JEG-3, ACH-3P and AC1-M59. (Figure 3 D-E). In 
comparison with the choriocarcinoma-derived cell lines, C14MC miRNAs expression 
in HTR-8/SVneo cells was higher but not always significantly. These results confirm 
the array data showing that microRNA expression of isolated trophoblast cells 
resembles more closely that of choriocarcinoma-derived cell lines than that of the 
immortalized trophoblast cell line HTR-8/SVneo. 
Additionally, we have done qPCR for the analysis of expression of 5 further miRNAs 
which may be related with malignant properties. These analyses have been 
performed exclusively to compare the 4 above-mentioned cell lines subsequently to a 
previously published manuscript on their kinetics in JEG-3 cellss after LIF stimulation 
[24]: The expression of miR-9 and miR-141 is significantly lower in HTR-8/SVneo 
cells than in JEG-3 cells, while the expression of miR-21, miR-93 and let-7g is 
significantly higher.
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Recent studies indicate that miRNA expression signatures may be useful for the 
characterization and prediction of cancer [13], but investigations on their role in 
pregnancy are still incipient. Pioneer reports have revealed a group of miRNAs, the 
cluster C19MC, exclusively expressed by the placenta. Serum levels of some of its 
members are altered in preeclampsia [8, 25, 26]. However, the cellular origin of these 
miRNAs or their role in the control of trophoblast invasion and other functions is still 
unknown.  
For the study of the molecular mechanisms involved in the regulation of trophoblast 
proliferation and invasion an increasing variety of cell lines are used as models due 
to the limitations of primary cultures. The here investigated cell lines include the most 
accepted models: HTR-8/SVneo, JEG-3,. AC1-M59 and ACH-3P). However, it is still 
controversially discussed to which extend they resemble trophoblast cells and how to 
extrapolate results from these models for generation of hypothesis for the different 
trophoblastic subtypes. On the one hand, HTR-8/SVneo cells have the advantage of 
being benign first trimester trophoblast cells, but vector transformation as used for  
their immortalization can be associated with uncontrolled amplification and splicing of 
viral DNA resulting in a heterogeneous genotype [21]. On the other hand, 
choriocarcinoma cells are not virus-treated, but have, due to their malign origin, 
different gene expression patterns when compared with normal trophoblasts [27].  
 
A recent study of mRNA patterns performed on several trophoblastic cell lines and 
isolated trophoblast cells demonstrates that mRNAs signatures allow differentiation 
between choriocarcinoma-derived cell lines, immortalized trophoblast cell lines and 
primary trophoblast cells [18]. Also several functional differences, mainly in regard of 
invasiveness and proliferation, in combination with different expression patterns of 
proteins have been described between HTR-8/SVneo cells and choriocarcinoma 
cells [
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18, 28]. Similar to these observations, in the current study, we demonstrate that 
miRNA profiles of the choriocarcinoma-derived cell lines JEG-3, ACH-3P and AC1-
M59 share large congruences with each other, but not with HTR-8/SVneo. In 
comparison with primary third trimester trophoblast cells by performing unsupervised 
hierarchical clustering,  miRNA profiles of choriocarcinoma-derived cell lines 
resemble more the primary trophoblast cells than profiles from HTR-8/SVneo do. We 
could also demonstrate that the placenta (and brain) specific miRNA cluster C19MC 
is highly expressed in trophoblast cells and choriocarcinoma-derived cells, but not in 
HTR-8/SVneo.  Due to its placenta specifity, it can be expected that alterations of 
C19MC may be involved in pregnancy pathologies by being their cause or their 
conseuqence. In other cells than trophoblast and brain, a distal CpG-rich region on 
chromosome 19 is hypermethylated, but can be demethylated in human cancers, 
which leads to expression of the respective miRNAs [17]. In can be argued if C19MC 
miRNA expression in choriocarcinoma cells derives from their trophoblastic origin or 
their cancerous properties or from both, which may explain the mostly higher C19MC 
expression than in primary trophoblast cells. In contrast to C19MC, another placenta 
(embryonic tissue and brain) specific miRNA cluster, C14MC [26], is highly 
expressed in HTR-8/SVneo, little in primary third trimester trophoblast cells, but it is 
almost absent in the here analyzed choriocarcinoma-derived cell lines. In a previous 
study, several members of both clusters have been detected in plasma, where they 
are elevated during pregnancy [29].  
 
Another major difference between choriocarcinoma and HTR-8/SVneo cells is, that 
JEG-3 cells and their hybrids express the human embryonic stem cell specific miRNA 
cluster miR-371 (containing miR-371, miR-372 and miR-373), while HTR-8/SVneo do 
not. HTR-8/SVneo expresses high levels of miRNAs of the Let-7 family, which is 
generally related with malignancies, and miR-21, which is secreted strongly by 
human embryonic stem cells derived mesenchymal stem cells [
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30]. We conclude that 
these miRNAs regulate specific characteristics of the different trophoblastic cell lines.  
 
Our study provides a comprehensive encyclopedia of the microRNA expression 
profile of four cell lines widely used as models of trophoblast cells, and their 
comparison with primary isolated term trophoblast cells. In regard of the current 
international discussion about the nature of HTR-8/SVneo cells, this study confirms 
their close relationship with primary trophoblast cells, but it also exhibits large 
inequalities. The obtained encyclopedia  may be useful for comparison with other cell 
types and tissues, for interpretation of any experimental results from the analyzed 
cell lines, for future analysis of function of major trophoblast-related miRNA clusters, 
or for selection of new miRNA targets.  
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Table1. Selected miRNAs belonging to C14MC, C19MC, C19 and the let-7 family 
with relatively high expression (ct < 28) either in HTR-8/SVneo or choriocarcinoma-
derived cell lines.  
 
Table 2. Heatmapped list and chromosome localization of the 30 (out of 754) highest 
expressed miRNAs in isolated term trophoblast cells. Mean ct-values of these 
miRNAs are listed for all analyzed cell types. The mark indicates their belonging to 
the C19MC miRNA cluster. None of the listed miRNAs belongs to C14MC. 
Background colors: white: ct-value <25; light grey: ct-value 25-30; dark grey: ct-value 
30-35; black: ct-value >35. EC: Endogenous control.    
 
Figure 1. Unsupervised hierarchical clustering analysis of miRNAs expression 
profiles of all individually analyzed samples and miRNAs.The level (ct-value) of 
miRNA expression is color-coded. Red: higher miRNA expression; blue: lower 
miRNA expression. A) and B) represent the 377-containing miRNA Assays A and B, 
respectively. C) and D) zoom into the boxes marked in A, which display expression of 
miRNAs belonging to the clusters C19MC (purple) and C14MC (green).   
 
Figure 2. Dendograms of the unsupervised hierarchical clustering as shown in figure 
1 after exclusion of data from the leading clusters A) C14MC, B) C19MC or C) both, 
C14MC and C19MC. 
 
Figure 3. Confirmation of array data by individual qRT-PCR. Mean relative 
expression of miRNAs belonging to either C19MC (miR-519e and miR-518a-5p), the 
miR-371 cluster (miR-373) or C14MC (miR-539 and miR-411) were analyzed in four 
cell lines and isolated trophoblast. Data is presented as fold change (Log2RQ) 
compared to mean expression in isolated trophoblast cells ± SE. *  p<0.05 when 
compared with isolated trophoblast cells; § p<0.05 when compared with any of the 
choriocarcinoma-derived cell lines (Student’s t-test).  
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Figure 4. Confirmation of array data by individual qRT-PCR. Mean relative 
expression of miRNAs which have been analyzed in previous studies. Data is 
presented as fold change (Log2RQ) compared to mean expression in isolated 
trophoblast cells ± SE. *  p<0.05 when compared with isolated trophoblast cells; § 
p<0.05 when compared with any of the choriocarcinoma-derived cell lines (Student’s 
t-test).  
 
   
 
Tables 1 
2 
3 
 
Table1.  
HIGH EXPRESSION IN HTR-8/SVneo cells HIGH EXPRESSION IN JEG-3, AC1-M59 and ACH-3P cells 
miRNA Sequence (5' to 3') Locus miRNA Sequence (5' to 3') Locus 
miR-127-3p UCGGAUCCGUCUGAGCUUGGCU C14MC miR-371-3p AAGUGCCGCCAUCUUUUGAGUGU C19
miR-134 UGUGACUGGUUGACCAGAGGGG C14MC miR-372 AAAGUGCUGCGACAUUUGAGCGU C19
miR-136* CAUCAUCGUCUCAAAUGAGUCU C14MC miR-373 GAAGUGCUUCGAUUUUGGGGUGU C19
miR-154 UAGGUUAUCCGUGUUGCCUUCG C14MC miR-512-3p AAGUGCUGUCAUAGCUGAGGUC C19MC
miR-299-5p UGGUUUACCGUCCCACAUACAU C14MC miR-512-5p CACUCAGCCUUGAGGGCACUUUC C19MC
miR-337-5p GAACGGCUUCAUACAGGAGUU C14MC miR-515-3p GAGUGCCUUCUUUUGGAGCGUU C19MC
miR-369-5p AGAUCGACCGUGUUAUAUUCGC C14MC miR-515-5p UUCUCCAAAAGAAAGCACUUUCUG C19MC
miR-370 GCCUGCUGGGGUGGAACCUGGU C14MC miR-516a-5p UUCUCGAGGAAAGAAGCACUUUC C19MC
miR-376a AUCAUAGAGGAAAAUCCACGU C14MC miR-516b AUCUGGAGGUAAGAAGCACUUU C19MC
miR-379 UGGUAGACUAUGGAACGUAGG C14MC miR-517a AUCGUGCAUCCCUUUAGAGUGU C19MC
miR-380 UAUGUAAUAUGGUCCACAUCUU C14MC miR-517* CCUCUAGAUGGAAGCACUGUCU C19MC
miR-382 GAAGUUGUUCGUGGUGGAUUCG C14MC miR-517b UCGUGCAUCCCUUUAGAGUGUU C19MC
miR-409-3p GAAUGUUGCUCGGUGAACCCCU C14MC miR-517c AUCGUGCAUCCUUUUAGAGUGU C19MC
miR-410 AAUAUAACACAGAUGGCCUGU C14MC miR-518b CAAAGCGCUCCCCUUUAGAGGU C19MC
miR-411 UAGUAGACCGUAUAGCGUACG C14MC miR-518c CAAAGCGCUUCUCUUUAGAGUGU C19MC
miR-431 UGUCUUGCAGGCCGUCAUGCA C14MC miR-518c* UCUCUGGAGGGAAGCACUUUCUG C19MC
miR-487b AAUCGUACAGGGUCAUCCACUU C14MC miR-518d-5p CUCUAGAGGGAAGCACUUUCUG C19MC
miR-539 GGAGAAAUUAUCCUUGGUGUGU C14MC miR-518e AAAGCGCUUCCCUUCAGAGUG C19MC
miR-541 UGGUGGGCACAGAAUCUGGACU C14MC miR-518e* CUCUAGAGGGAAGCGCUUUCUG C19MC
miR-543 AAACAUUCGCGGUGCACUUCUU C14MC miR-518f GAAAGCGCUUCUCUUUAGAGG C19MC
miR-654-5p UGGUGGGCCGCAGAACAUGUGC C14MC miR-518f* CUCUAGAGGGAAGCACUUUCUC C19MC
miR-758 UUUGUGACCUGGUCCACUAACC C14MC miR-519a AAAGUGCAUCCUUUUAGAGUGU C19MC
miR-889 UUAAUAUCGGACAACCAUUGU C14MC miR-519b-3p AAAGUGCAUCCUUUUAGAGGUU C19MC
miR-1247 ACCCGUCCCGUUCGUCCCCGGA C14 miR-519c-3p AAAGUGCAUCUUUUUAGAGGAU C19MC
let-7b UGAGGUAGUAGGUUGUGUGGUU C22 miR-519d CAAAGUGCCUCCCUUUAGAGUG C19MC
let-7d AGAGGUAGUAGGUUGCAUAGUU C9 miR-519e AAGUGCCUCCUUUUAGAGUGUU C19MC
let-7e UGAGGUAGGAGGUUGUAUAGUU C19 miR-519e* UUCUCCAAAAGGGAGCACUUUC C19MC
let-7g UGAGGUAGUAGUUUGUACAGUU C3 miR-520a-3p AAAGUGCUUCCCUUUGGACUGU C19MC
let-7c UGAGGUAGUAGGUUGUAUGGUU C21 miR-520a-5p CUCCAGAGGGAAGUACUUUCU C19MC
let-7f UGAGGUAGUAGAUUGUAUAGUU C9 miR-520b AAAGUGCUUCCUUUUAGAGGG C19MC
let-7i* CUGCGCAAGCUACUGCCUUGCU C12 miR-520c-3p AAAGUGCUUCCUUUUAGAGGGU C19MC
   miR-520d-3p AAAGUGCUUCUCUUUGGUGGGU C19MC
   miR-520d-5p CUACAAAGGGAAGCCCUUUC C19MC
   miR-520e AAAGUGCUUCCUUUUUGAGGG C19MC
   miR-520f AAGUGCUUCCUUUUAGAGGGUU C19MC
   miR-520g ACAAAGUGCUUCCCUUUAGAGUGU C19MC
   miR-520h ACAAAGUGCUUCCCUUUAGAGU C19MC
   miR-521 AACGCACUUCCCUUUAGAGUGU C19MC
   miR-522 AAAAUGGUUCCCUUUAGAGUGU C19MC
   miR-523 GAACGCGCUUCCCUAUAGAGGGU C19MC
   miR-524 GAAGGCGCUUCCCUUUGGAGU C19MC
   miR-524-5p CUACAAAGGGAAGCACUUUCUC C19MC
   miR-525-3p GAAGGCGCUUCCCUUUAGAGCG C19MC
   miR-525-5p CUCCAGAGGGAUGCACUUUCU C19MC
   miR-526b CUCUUGAGGGAAGCACUUUCUGU C19MC
 4 
Table 2. 1 
2  
MiRNA Troph JEG3 HTR-8 ACH-3P
AC1-
M59 
C19
MC Chr 
hsa-miR-512-3p 19.59 17.39 40.00 16.81 16.48 √  
hsa-miR-24 20.23 21.11 19.66 20.87 20.31  9 
hsa-miR-517c 20.46 18.58 36.64 17.86 17.74 √  
hsa-miR-517a 20.52 18.42 36.42 17.91 17.84 √  
hsa-miR-193b 21.24 19.71 23.77 19.96 19.29  16 
hsa-miR-519a 21.63 19.05 35.72 18.04 17.98 √  
hsa-miR-200c 21.73 27.36 29.02 28.03 28.36  12 
hsa-miR-720 21.80 18.13 21.92 26.23 20.58  3 
hsa-miR-519d 22.10 19.52 29.94 18.06 17.49 √  
hsa-miR-1274B 22.24 17.79 19.95 27.33 21.42  19 
hsa-miR-191 22.30 21.65 21.77 21.29 20.82  3 
hsa-miR-525-3p 22.39 22.00 40.00 21.79 21.32 √  
hsa-miR-30b 22.56 20.91 21.04 20.67 20.41  8 
hsa-miR-518e 22.63 19.25 29.61 17.94 17.72 √  
hsa-miR-484 22.68 20.99 23.05 21.12 20.91  16 
hsa-miR-483-5p 22.89 22.64 31.72 24.68 24.40  11 
hsa-miR-1274A 22.95 19.27 21.91 26.00 21.57  5 
hsa-miR-30c 22.99 20.31 21.01 20.34 19.99  1 
hsa-miR-342-3p 23.00 23.28 23.65 23.67 23.18  14 
hsa-miR-518f 23.20 21.47 33.43 19.64 19.09 √  
hsa-miR-19b 23.22 17.88 20.09 17.96 18.00  X 
hsa-let-7b 23.35 27.00 22.32 29.92 30.74  22 
hsa-let-7e 23.44 24.99 22.15 25.89 27.06  19 
hsa-miR-126 23.65 26.95 23.44 25.21 25.00  9 
hsa-miR-106a 23.68 19.26 20.90 19.16 19.01  X 
hsa-miR-574-3p 23.70 25.60 23.49 25.70 25.70  4 
hsa-miR-200b 23.73 31.56 34.62 28.28 27.60  1 
hsa-miR-518b 23.84 20.34 33.62 19.38 19.13 √  
hsa-miR-145 23.86 28.77 27.51 28.06 26.98  5 
hsa-miR-20a 23.87 19.90 22.49 19.06 18.88  13 
RNU48 18.98 17.71 20.09 19.50 17.57  EC 
RNU44 22.61 18.54 21.93 20.26 18.43  EC 
    
Definition of 
background color:   Ct <20.0 20-25 25-30 > 30   
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Background: MicroRNAs (miRNAs) are small single-stranded RNA molecules which 
are important post-transcriptional modulators of gene expression. The expression of 
miRNAs is distinct in primary trophoblast cells and among different trophoblastic cell 
lines. LIF is a pleitropic cytokine which induces a variety of effects on trophoblast 
cells, including proliferation and invasion, during implantation and placentation. It 
uses the Janus Kinase/Signal Transducer and Activator of Transcription 3 
(JAK/STAT3) intracellular signalling pathway, which is regulated by Protein Inhibitors 
of Activated STATs 3 (PIAS3). Aim of this study was to identify miRNAs which are 
regulated by LIF in different trophoblastic cell lines and to identify a possible function. 
Material and methods: After LIF stimulation, total RNA was isolated from the cell lines 
HTR-8/SVneo (immortalized trophoblast cells), JEG-3 (choriocarcinoma), ACH-3P 
and AC1-M59, which are choriocarcinoma cells fused with first and third trimester 
trophoblast cells, respectively. The expression level of 762 different miRNAs was 
quantitatively analzed by using a TaqMan Human MicroRNA Array. The results for 4 
interesting miRNA were confirmed by individual qPCR. Finally, we silenced and 
overexpressed one out of those 4 miRNAs: miR-141 and analyzed PIAS1/3 
expression by Western blotting.  
Results: Approximately 10-30 % of miRNAs were affected by LIF stimulation of the 
different cell line. Three out of 762 miRNAs were significantly down-regulated in all 
cell lines after LIF treatment: miR-511, miR-550 and miR-885-5p, but only miR-641 
was up-regulated in all tested cell lines. MiR-141 was differently affected by LIF in the 
different cell lines. Its silencing induced a decrease and its over-expression an 
increase of PIAS3 in HTR-8/SVneo cells, but not in JEG-3 cells, in which PIAS3 was 
not detectable. 
Conclusion: LIF strongly affects miRNA expression in trophoblastic cell lines, but only 
a few miRNAs behave in a similar manner and, thus, may have crucial functions in 
the regulation of different subtypes of trophoblastic cells. 
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The study of gene regulation beyond the DNA transcription has provided important 
insights into the field of genetics and has generated great interest in the field of 
human reproduction. Epigenetics is defined as the study of changes in gene 
expression that are not caused by changes in the DNA sequence [1, 2]. Epigenetic 
changes control differentiation in many tissues and are involved in the ability of a 
specie to response to environmental variations [2]. Remarkably, during 
embryogenesis, two critical time periods are controlled by epigenetic modification of 
genes: gamete development and preimplantation and trophoblastic growth [2]. 
Epigenetic regulation seems to be a key factor in the functional specificity of 
cytotrophoblast [3] thus, it to expect that alteration in the epigenetic regulation may 
be associated with a variety of pregnancy diseases. To date, four main mechanisms 
of epigenetic regulation have been described: DNA methylation, imprinting, histone 
modification, and small RNA-mediated control, specifically microRNAs (miRNAs) [1].  
 
 
MicroRNAs are endogenous single-stranded RNA (~19-22nt) which repress gene 
expression transcriptionally [4]. Expressed in the nucleus as langer transcripts, 
miRNAs are sequentially processed by the RNAseIII enzymes Drosha and Dicer into 
a mature mRNA sequence, which by association with the RISC complex, has the 
ability to inhibit translation or cleavage target mRNAs, if partially or fully sequence 
complimentary occurs [5]. MiRNAs act as translational repressors controlling 
numerous cell procceses including fat metabolism, cell proliferation, apoptosis, and 
differentiation in several cell types [6-9].  
 
Some microRNAs are universally expressed in normal human tissues, while some 
others are exclusively or preferentially expressed in a tissue-specific manner [10]. 
Interestingly, these last miRNAs tend to be organized into clusters [11, 12], 
commonly located in fragile sites of the chromosomes and also found frequently 
altered in cancer [13, 14]. Recent reports described two large microRNA clusters 
expressed almost exclusively in placenta: C19MC and C14MC [5, 9, 15]. 
Interestingly, C19MC is a primates’ specific cluster and C14MC is found only within 
eutherian species [15], which suggests a pivotal role in the evolution and placenta 
development.  
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Leukemia inhibitory factor (LIF) is a pleiotropic cytokine known to be indispensable 
for human reproduction. LIF controls uterine receptivity and influences trophoblast 
behavior by promoting proliferation, invasion and differentiation, and its aberrant 
expression is related with infertility and poor pregnancy outcome (Reviewed in [16]). 
Previously, we demonstrated that LIF stimulation is able to alter the expression of 
some microRNAs in JEG-3 choriocarcinoma cells [17], which suggested a role of 
miRNAs in the regulation of trophoblast behavior during pregnancy. In order to gain 
more insights into the regulation of miRNAs mediated by LIF, we used microarray 
analysis to elucidate the miRNome (768 genes miRBase version 13.0) of four 
trophoblastic cell lines (HTR-8/SV-neo, JEG-3, ACH-3P and AC1-M59), before and 
after LIF-induction. Thereafter, we decided to investigate the mRNA targets of some 
selected miRNAs and their association with proliferation and invasion of trophoblastic 
cells.   
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Cell lines 
Four cell lines were used in this work: JEG-3 (DSMZ, Braunschweig, Germany), 
which is a human choriocarcinoma cell line preserving several trophoblast-like 
capacities including production of pregnancy related hormones and cytokines; two 
hybrids of JEG-3 with human first and third trimester trophoblast cells, ACH-3P and 
AC1-M59 cells [18-20], respectively (kind gift from G Desoye, Graz, Austria) and the 
immortalized human first-trimester trophoblast cell line HTR-8/SV40 [21]. 
 
Cell culture 
Cells cultures were performed at 106 cells/175 cm2 flask, and maintained under 
standard conditions (37ºC, 5% CO2, humid atmosphere) in Ham’s F-12 Nutrient 
Mixture with L-glutamine (GIBCO, Paisley, UK) or RPMI Medium (GIBCO) (HTR-8 
cells) supplemented with 10 % heat-inactivated fetal calf serum (FCS; GIBCO) and 1 
% penicillin/streptomycin antibiotic solution (GIBCO). 
 
RNA isolation and array analysis  
 
Cells were cultivated in 12-well plates and allowed to attach overnight. Afterwards, 
cells were deprived of serum for at least 2 hours and then challenged 4 hours with 10 
ng/ml LIF (Millipore, Schwalbach, Germany). Total RNA was isolated with mirVana 
isolation kit (Life Technologies), according to the manufacturer's protocol. Thereafter, 
100 ng of total RNA containing small RNAs was reverse transcribed using the 
specific Megaplex RT primers (Life Technologies) followed by a pre-amplification of 
the obtained cDNAs. Finally, the expression level of 768 miRNAs was performed 
using the TaqMan® Array Human MicroRNA A+B Cards Set v3.0 (Life 
Technologies). Experimental data were analyzed by DataAssist v3.0 (Life 
Technologies) using RNU48 and RNU44 as endogenous controls.  
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Real-time quantitative RT-PCR 
 
Arrays data was validated using individual TaqMan miRNA Assay (Applied 
Biosystems, Foster City, CA, USA) according to the protocol provided by the 
supplier. Briefly, cells were challenged as described above and total RNA was 
isolated by using miRVana kit (Applied Biosystems). RNA purity was assessed by the 
ratio of spectrophotometric absorbance at 260 and 280 nm (A260/280nm) using 
NanoDrop ND-1000 (NanoDrop Inc, Wilmington, DE USA). Reverse transcription 
were performed with miRNA specific stem-loop RT primer using TaqMan MicroRNA 
Reverse Transcription Kit (Applied Biosystems) followed by qRT-PCR using specific 
TaqMan Assays and TaqMAn Universal PCR Master Mix. All reactions were run in 
duplicates including no-template controls in 96-well plates on a 7300 Real Time PCR 
System (Applied Biosystems). Fold changes were determined using the formula 2-∆∆Ct 
relative to the expression of non-stimulated cells. Experiments were repeated 
independently three times and differences in the quantified gene expression were 
statistically assessed by using ttest and consider statistically significant if p<0.05.  
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Trophoblast cells present distinct miRNome signatures after LIF  
 
In order to investigate the miRNome of trophoblastic cells upon LIF-treatment, cells 
were serum-starved and then treated 4 hour with LIF (10ng/ml). MicroRNA 
expression was normalized to the one in non-treated cells and using RNU48 and 
RNU44 as endogenous controls.  
Our results confirmed that LIF is able to induce changes in the miRNome of 
trophoblastic cells, however, this response seems to be cell-type dependent. ACH-3P 
cells present the highest change with a total of 237 miRNAs displaying more than 
1.5-fold change (160 up-regulated and 77 down-regulated), followed by HTR-8 cells 
with 145 (66 up- and 79 down-regulated), AC1-M59 with 124 (68 up- and 56 down-
regulated), and JEG-3 with 115 (60 up- and 55 down-regulated) (Figure 1 and 
Annexes).  
 
A deeper analysis of the miRNAs found altered in 2 or more cell lines revealed that 
ACH-3P and HTR-8 had the most similar response to LIF with 35 miRs in common 
(18 up- and 17- down regulated) followed by ACH-3P and AC1-M59 which share 33 
miRs: 9 up- and 24 down-regulated (Figure 1). Table 1 contains the complete list of 
miRNAs up- or down- regulated in two or more cell lines and the relative expression 
of these miRs before LIF treatment. Surprisingly, only 3 miRs were down-regulated in 
all cell lines after LIF treatment: miR-511, miR-550 and miR-885-5p, but only miR-
641 appeared to be up-regulated in all tested cell lines (Figure 1 and Table 1).  
 
Validation of miRNAs arrays data 
In order to confirm our results, four miRNAs were selected and the expression was 
measured by qRT-PCR. We confirmed the up-regulation of miR-21 and miR-21# in 
all cell lines, as well as the down-regulation of miR-511 (Figure2). However, our 
results of miR-141 do not agree with the observed in the cards suggesting a problem 
during the measurement. In addition, the number of assays should be increased in 
order to minimize the error. 
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Knock-down of miR-141 correlates with decrease of PIAS3 in HTR-8 cells 
MiR-141 was found to be altered simultaneously in most of the cell lines (Table 1). 
However, we observed a down-regulation of JEG-3 whilst in HTR-8SV Neo, AC1-
M59 and ACH-3P it was up-regulated. Based on our previous report demonstrating 
an involvement of miR-141 in the regulation of JEG-3 proliferation [17], and also the 
fact that miR-141 in maternal plasma increases during pregnancy [22], we decided to 
investigate the possible targets of miR-141. Interestingly, PIAS3, a negative regulator 
of the LIF pathway, was found to be a putative target of miR-141 our results 
demonstrate that it is reduced after knock-down of miR-141 (Figure 3). This results in 
conjunction with our previous observations of changes in the JEG-3 proliferation after 
miR-141 inhibition, demonstrated that miR-141 is related with the JAK/STAT pathway 
and the changes in its levels may be a direct result of LIF stimulation.  
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MicroRNA regulation of gene expression is one of the four main mechanisms of 
epigenetic regulation [1] and thus, alteration in the miRNAs expression levels may be 
associated with a variety of pregnancy diseases. Despite being demonstrated to be 
useful in the diagnosis and prediction of cancer [23], the study of miRNAs signatures 
during pregnancy remains incipient. Even though some miRNAs were found to be 
altered in preeclampsia [24], the biological functions and expression in placental cells 
remain unclear.  
 
Several cell lines are used as a model for trophoblast invasion and proliferation, 
some of them derived from choriocarcinoma (e.g. JEG-3, ACH-3P and AC1-M59) or 
immortalized from isolated trophoblast (e.g. HTR-8) [18-21]. However the differences 
in their origin are also related with changes in the expression patterns of proteins and 
mRNA [25, 26], and recently, we have also reported several differences in the 
miRNome of those cell lines. These alterations correlate also with the invasiveness, 
proliferative rates and their response to external stimuli, for instance, cytokines 
stimulation [27]. Previously we demonstrated that LIF was able to induce proliferation 
and invasion in JEG-3 and HTR-8 cells and the mechanism involved changes in the 
activation of STAT3 and in the expression of several mRNAs including 
metalloproteinase 9 (MMP-9) and caspase 4(CASP4) [27, 28]. In addition, in JEG-3 
cells we demonstrated that LIF reduces the levels of miR-141 that, in turn, is involved 
in the regulation of JEG-3 proliferation [17].  
 
Here we analyzed the complete miRNome of four trophoblastic cells after LIF 
stimulation. Our results shown several differences in the cell-response to LIF, as only 
three miRNAs were found down-regulated (miR-511, miR-550 and miR-885-5p), and 
one up-regulated (miR-641) in all cell lines after LIF treatment. Among them, miR-
511 has been more studied due to its significantly lower expression in 
adenocarcinomas compared with normal tissues [29] and its potential role as 
modulator of human immune response [30]. On the other hand, miR-885-5p was also 
found down-regulated in primary neuroblastoma and seems to have a tumor 
suppressive role interfering with cell cycle progression and cell survival [31]. These 
associations allow us to hypothesize that these miRNAs may play an important role 
in the trophoblast response to external agents and thus, seek of their targets may be 
of great importance to understand the LIF-mediated invasion and proliferation and 
generate new approaches for future therapies.  
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Among the thousands of putative target genes of miR-511, miR-550 and miR-885-5p, 
and by using the microrna.org software, MAX interactor 1 (MXI1) and Wilms tumor 1 
associated protein (WTAP) genes were predicted to be targets of all three miRNAs 
and were found to display the highest mirSVR score. Interestingly, both MXI1 and 
WTAP codify for proteins known to be tumor suppressors, however, to our 
knowledge, none of them have been associated with LIF. Based on the knowledge 
that LIF induces invasion in trophoblast cells, one may hypothesize that the reduction 
of miR-511, miR-550 and miR-885-5p may result in increased invasiveness of 
trophoblast cells, but this relation should be confirmed.  
 
Knock-down of miR-141 correlates with decrease of PIAS3 in HTR-8 cells 
 
We have recently reported that HTR-8 and JEG-3 cells differ in the expression of 
several proteins of the LIF intracellular cascade, including the basal levels of p-
STAT3 (Ser727), p-ERK [27] and PIAS1/3. PIAS are negative regulatory molecules 
of the JAK/STAT cascade, which in turn controls proliferation and invasion of 
trophoblast cells. PIAS shut down STATs effects by binding to STAT dimers 
preventing them from binding DNA [32, 33] and therefore they play an important role 
in the invasion capability of trophoblast cells. Interestingly, we found that HTR-8 cells 
expressed both PIAS1 and PIAS3, while in JEG-3 cells only the expression of PIAS1 
was detected (Figure 3). However, we also demonstrated that both cell lines 
expressed mRNA for PIAS1 and PIAS3 and in similar levels (Grosse, et al In 
preparation). Since miRNAs regulation occurs postranscriptionally, we decided to 
investigate miRNAs that may potentially target PIAS3. Among them, miR-141 was 
found to be highly expressed in JEG-3 cells but almost absent in HTR-8 (Morales-
Prieto, et al submitted), and here we demonstrated a deregulation in the levels in 
presence of LIF thus, suggesting a direct association with the PIAS3 protein levels.  
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The inhibition of miR-141 by knock-down in JEG-3 cells showed no alterations in the 
PIAS3 protein levels. Surprisingly, in HTR-8 cells, inhibition of miR-141 decreases 
significantly the expression of PIAS3 protein. As no changes in the PIAS1 protein 
expression were found, this result demonstrates that PIAS3 is indeed a target of miR-
141. A recent study has demonstrated that miRNAs can switch to translation 
activation under growth-arrest conditions [34], since we have performed the protein 
expression experiments in serum-deprived medium we hypothesize that this may be 
the molecular mechanism responsible for our observations.  
 
The molecular mechanisms underlying the regulation of gene expression by miRNAs 
are still unclear. This work correlates with recent publications demonstrating that 
miRNA alterations mediated by external factors seem to be cell-type depended [5, 
14], but also that the microRNAs oscillate between repression and activation in 
coordination with the cell cycle [34]. We also highlight some miRNAs as potential 
regulators of the LIF-mediated cell response in trophoblastic cells including a direct 
implication in the control of trophoblast proliferation and invasion. These observations 
should be confirmed also in in vivo models, but our results open the possibility to use 
them as potential diagnosis markets.   
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Table1. List of microRNA found up- or down-regulated after LIF-induction in more 
than two cell lines simultaneously. Expression levels are color-coded. Dark blue: Low 
expression, Light blue: High expression. Numbers within cells are the fold-change 
relative to non-stimulated cells. Boxes containing numbers but no colored display 
miRNAs also found deregulated but with fold-change < 1.5. 
 
Figure 1. Venn Diagramas summarizing miRNAs altered after LIF treatment. Left: 
MicroRNAs up-regulated Right: MicroRNAs down-regulated after LIF, respectively. 
 
Figure 2. Validation of microarray data by qRT-PCR. Expression levels of A) mir-511, 
B) miR-141, C) miR-21, D) miR-21# in all four tested cell lines n=3. Statistical 
analysis were performed in comparison with JEG-3 cells, calculated by Student-ttest 
and considered statistical significant when p<0.05. 
 
Figure 3. Knock down of miR-141 decreases PIAS3 in HTR-8 cells. Cells were 
transfected either with pre- or anti- miRNAs and PIAS 1/3 protein levels were 
assessed by Western blot.  
Tables 1 
2 Table1.  
miRNAs up-regulated miRNAs down-regulated 
miRNA  JEG-3 AC1-
M59 
ACH-
3P 
HTR8 miRNA  JEG-3 AC1-
M59 
ACH-
3P 
HTR8 
hsa- let-7c 2.86   18.25   hsa-miR- dme-miR-7     2.42 2.66
hsa- let-7e#   23743.00   1.85 hsa-miR- 1305 19.38 3.19 0.05 2.57
hsa-miR- 100#   1.66   1.58 hsa-miR- 155 35.21 2.88   2.03
hsa-miR- 1201 1.14 1.50 5.52   hsa-miR- 10a 20.28 35.97     
hsa-miR- 1243   3.57   9.28 hsa-miR- 10b# 62.50 1.06 4.47   
hsa-miR- 1256 1.12 50.73 1.86   hsa-miR- 1226#     10.00 2.08
hsa-miR- 1262   2.19 1.61   hsa-miR- 1255B     4.67 3.36
hsa-miR- 1276   1.90 2.90   hsa-miR- 1276 2.15     7.57
hsa-miR- 1282 2.21 1.04 28.06   hsa-miR- 136     7.67 8.31
hsa-miR- 1291   1.59 1.63   hsa-miR- 148a#   714.29 196.08   
hsa-miR- 130a# 1.12 72.80 1.99   hsa-miR- 192# 2.37   4.31   
hsa-miR- 141 1.27 3.09 3.55 11.36 hsa-miR- 206     5.35 4.07
hsa-miR- 142-5p 28.67   520.74 22.80 hsa-miR- 221#   2.79   3.26
hsa-miR- 148a# 1.72     72.70 hsa-miR- 23a#   243.90   39.84
hsa-miR- 152 2.24 31.27     hsa-miR- 23b#   625.00 9.81   
hsa-miR- 196b 2.02   7.52   hsa-miR- 302c# 71.43 5.34 0.02   
hsa-miR- 199a-3p 6.49 7.97     hsa-miR- 330-3p 2.00     2.35
hsa-miR- 206 1.91 3.00     hsa-miR- 33a     192.31 135.14
hsa-miR- 21# 3.19 2.91 23.47   hsa-miR- 378     3.50 2.07
hsa-miR- 217 1.02   35.95 5.96 hsa-miR- 429 3.89   6.48 6.40
hsa-miR- 221# 83.63   3.52   hsa-miR- 449b 2.18 1.99     
hsa-miR- 23a# 1.78   4.16   hsa-miR- 486-5p 42.19     4.63
hsa-miR- 23b 1.12 1.77 2.15   hsa-miR- 500   312.50   833.33
hsa-miR- 23a-2#   1.87 10.44   hsa-miR- 501-5p   2000.00   3.32
hsa-miR- 29a# 2.21 6.89 16.43   hsa-miR- 511 13.05 18.05 10.98 28.49
hsa-miR- 29b-1#  3.65 12.59   hsa-miR- 516-3p     2.79 3.10
hsa-miR- 30d#   1.77 8.32   hsa-miR- 548E   2.28 4.34   
hsa-miR- 31#   1.61 4.13   hsa-miR- 548I 15.43 1.08 4.32   
hsa-miR- 374b# 3.42 4.53 43.71   hsa-miR- 548J   20.08   10.88
hsa-miR- 450a   2.38 3.15   hsa-miR- 550 1.49 2.99 36.36 2.04
hsa-miR- 488 1.67 1.58     hsa-miR- 550     3.86 3.25
hsa-miR- 489 2.41     5.99 hsa-miR- 561   2.89 21.37   
hsa-miR- 505 958.80 1.68 2.36   hsa-miR- 570     4.53 10.17
hsa-miR- 518a-5p 1.62 1.32 2.23   hsa-miR- 580     2.72 2.50
hsa-miR- 519e 1.03   2.25 1.62 hsa-miR- 581     54.95 11.45
hsa-miR- 539 63.42 2.63 1.58   hsa-miR- 592     75.76 51.28
hsa-miR- 545#   6.19   3.73 hsa-miR- 606     114.94 24.75
hsa-miR- 545   3.58 4.70 1.93 hsa-miR- 654-3p   68.97 21.14   
hsa-miR- 548c-5p 1.92 2.87     hsa-miR- 672 20.16 1.06 80.00   
hsa-miR- 548E 41.70     4.74 hsa-miR- 708 50.25 2.87 42.74   
hsa-miR- 548K   25.73   2.81 hsa-miR- 885-5p 7.42 588.24 1.69 92.59
hsa-miR- 590-3P   1.73 5.89   hsa-miR- 922 7.39 8.35 0.02   
hsa-miR- 601 4.27     1.54 hsa-miR- 99b# 2.22 1.20 2.56   
hsa-miR- 618   6.76   19.28       
hsa-miR- 624     1.89 1.69       
hsa-miR- 628-5p 1.62 1.57 1.91         
hsa-miR- 635   3.28   9.10       
hsa-miR- 638     82.56 34.15       
hsa-miR- 641 1.82 1.05 5.06 1.60       
hsa-miR- 643 250.53 279.64           
hsa-miR- 645 2.09 3.71   1.67       
hsa-miR- 663B 8289.25 1.76           
hsa-miR- 744#     2.50 1.51       
hsa-miR- 767-3p 41.18 71.43           
hsa-miR- 892b 129.70     69.06       
hsa-miR- 938 4.84     9.19       
hsa-miR- 99a# 1.70 18.72   8.64       
hsa- U6 snRNA   1.74 7.12         
hsa-miR- 130b     1.70 2.59       
hsa-miR- 146b-5p 1.18 1.52 1.81         
hsa-miR- 202     1.73 2.18       
hsa-miR- 204     1.53 1.76       
hsa-miR- 24-2# 1.92 1.34 1.72         
hsa-miR- 34b 2.96 1.30 1.80         
hsa-miR- 373     1.66 5.97  <25 25-30 30-35 >35  
hsa-miR- 449a     1.81 1.52       
hsa-miR- 451 20.32 1.48 1.52         
hsa-miR- 627   1.59 1.94         
hsa-miR- 664     1.95 3.31       
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Abstract
This study examines the IL-11 mediated activation of downstream signaling and expression of effector molecules to resolve
the controversies associated with the IL-11 mediated regulation of the invasiveness of two commonly used trophoblastic
cell models viz. JEG-3 and HTR-8/SVneo cells. It has been reported that IL-11 increases the invasiveness of JEG-3 cells while,
reduces the invasiveness of HTR-8/SVneo cells. Invasion assay performed simultaneously for both the cell lines confirmed
the above findings. In addition, HTR-8/SVneo cells showed a higher basal invasiveness than JEG-3 cells. Western blot
showed the IL-11 mediated activation of STAT3(tyr705) and STAT1(tyr701) in both the cell lines. However, IL-11 activated the
ERK1/2 phosphorylation in JEG-3 cells but, inhibited it in HTR-8/SVneo cells. Within 10 min of IL-11 treatment, p-
STAT3(tyr705) was localized inside the nucleus of both the cell lines but, there was enhanced co-localization of protein
inhibitor of activated STAT1/3 (PIAS1/3) and p-STAT3(tyr705) in HTR-8/SVneo cells and not in JEG-3 cells. This could be
reason for the poor responsiveness of STAT3 responsive genes like mucin 1 (MUC1) in HTR-8/SVneo cells and not in JEG-3
cells. Further, microarray analysis of the IL-11 treated cells revealed differential responsiveness of JEG-3 as compared to HTR-
8/SVneo cells. Several family of genes like activator protein-1 (AP-1) transcription factors (Jun and Fos), mucin-type
molecules, MMP23B etc showed enhanced expression in IL-11 treated JEG-3 cells while, there was no response or decrease
in their expression in IL-11 treated HTR-8/SVneo cells. Expression of these molecules was confirmed by quantitative RT-PCR.
In addition, HTR-8/SVneo cells also showed a significant decrease in the expression of MMP2, MMP3 and MMP9 upon IL-11
treatment. Hence, IL-11 mediated differential activation of signaling and expression of effector molecules is responsible for
the differential invasive response of JEG-3 and HTR-8/SVneo cells.
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Introduction
Invasion of trophoblast cells is one of the critical events
associated with the embryo implantation as it helps in establishing
the exquisite contact between the fetus and the maternal
circulation. Aberration in invasive behavior of the trophoblast
cells may lead to several pathological conditions which may range
from pre-eclampsia (due to shallow implantation) to placental bed
tumors (due to excessive invasion) [1,2]. Several cytokines and
growth factors present at the implantation site regulate the spatial
and temporal invasion of the trophoblast cells either by acting in
autocrine or paracrine manner to achieve successful conception
[3].
IL-11, a member of the IL-6 family, is present at the site of
implantation and has been observed to be indispensable for the
embryonic development [4]. The IL-11 receptor a (IL-11Ra)
knockout female mice, are infertile because of defective decid-
ualization of the endometrial stromal cells [5,6]. In humans, IL-
11Ra is consistently expressed in the endometrium from
proliferative and secretory phase to 7–9 weeks of gestation [7].
In contrast to this, IL-11 expression is barely detectable in the
proliferative and secretory phase of endometrium but, its
expression is significantly higher in the chorionic villi as well as
in the decidua [5]. Further, defective production of IL-11 is
associated with reduced fertility rate in human pregnancy [5].
Additionally, plasma level of IL-11 was low in women with
spontaneous abortion [8].
Though, IL-11 plays a defined role in endometrial decidualiza-
tion, its role in trophoblastic cell invasion has been held in
controversy. Exogenous treatment of JEG-3 choriocarcinoma cells
with IL-11 led to an increase in invasion [9]. The increase in the
invasiveness of JEG-3 choriocarcinoma cells was associated with
the activation of signal transducer and activator of transcription 3
(STAT3) as well as of STAT1 and extracellular signal regulated
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kinases1/2 (ERK1/2) [9]. Further, silencing of STAT3 and gp130
(co-receptor for the IL-11 mediated signaling) expression in JEG-3
cells inhibits the IL-11 mediated increase in JEG-3 cells invasion
[9]. However, using extra villous trophoblast (EVT) cells and
HTR-8/SVneo cells (derived from human first trimester placenta
explant cultures immortalized by SV40 large T antigen) as a
trophoblast cell model, it was shown that, IL -11 reduces their
invasiveness in spite of the activation of STAT3 dependent
signaling pathway [10]. This decrease in invasiveness of HTR-8/
SVneo cells was not associated with any significant changes in the
expression of classical invasion associated molecules like matrix
metalloproteinase 2 (MMP2), MMP9, tissue inhibitor of metallo-
proteinase 1 (TIMP1), TIMP2, TIMP3, plasminogen activator
urokinase (PLAU), plasminogen activator urokinase receptor
(PLAUR), and serpin peptidase inhibitors 1 and 2 (SERPINE1
and SERPINE2) [10]. Thus, the reason for inhibition of invasion
of HTR-8/SVneo cells in response to IL-11 is not known.
The existing studies leaves behind several key questions which
need to be addressed to resolve the ambiguities associated with the
differential responsiveness of JEG-3 and HTR-8/SVneo cells
towards the IL-11 treatment. 1) Are there differences in the IL-11
mediated activation of the downstream signaling in JEG-3 and
HTR-8/SVneo cells? 2) What are the effector molecules whose
alterations in response to IL-11 can explain the respective increase
and decrease in the invasiveness of JEG-3 and HTR-8/SVneo
cells? Keeping these key questions in mind, present study has been
designed to provide evidences for the differential regulation of IL-
11 mediated invasiveness of JEG-3 and HTR-8/SVneo cells.
Materials and Methods
Cell culture
JEG-3 (German collection of cell lines and microorganisms;
DZMO, Braunschweig, Germany) and HTR-8/SVneo (kindly
provided by Dr. Charles Graham, Queen’s University, Kingston,
ON, Canada) cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM; Sigma-Aldrich Inc., St. Louis, MO,
USA) or RPMI-1640 (Sigma-Aldrich Inc.) medium respectively,
supplemented with 10% Fetal Bovine Serum (FBS; Biological
Industries, Kibbutz beit Haemek, Israel) and an antibiotic-
antimycotic cocktail [Penicillin (100 units/ml), Streptomycin
(100 mg/ml) and Amphotericin B (0.25 mg/ml); Pen-Strep-Ampho
sol, Biological Industries] under 5% CO2 humidified atmosphere
at 37uC [11].
Invasion assay
Invasion assay was performed as described before [9]. Briefly,
,105 cells were seeded onto the Matrigel matrix and incubated
with or without an optimized concentration of IL-11 (200 ng/ml;
Peprotech, Rocky Hill, NJ, USA) [9]. After 24 h of incubation,
Table 1. Primer sequences used for the real-time PCR.
Gene Primers Annealing temperature Product size (bps)
Integrin aV F: 59 GCTCCATCTTCAGTGCCCTTA 39
R: 59 TTGGCAGACAATCTTCAAGCA 39
60uC 274
Integrin a5 F: 59 CGCAGCTCTGCTTCCTCGGG 39
R: 59 GCTGTGGCCACCTGACGCTC 39
60uC 260
Integrin a6 F: 59 TGCAGGCACTCAGGTTCGAGTGA 39
R: 59 AGCATGGTATCGGGGAACACTGTCA 39
60uC 193
MMP2 F: 59 ACCGCAAGTGGGGCTTCTGC 39
R: 59 CGTGGCCAAACTCGTGGGCT 39
60uC 72
MMP3 F: 59 TTGGCCCATGCCTATGCCCC 39
R: 59 ACAGGCGGAACCGAGTCAGG 39
57uC 214
MMP9 F: 59 CCGGCATTCAGGGAGACGCC 39
R: 59 TGGAACCACGACGCCCTTGC 39
61uC 71
MMP23B F: 59 GCTGGTCGCCCTGTGCCTC 39
R: 59 GGAGTCAGCGTGTAGCGGCG 39
60uC 177
TIMP1 F: 59 TGACATCCGGTTCGTCTACA 39
R: 59 GTTTGCAGGGGATGGATAAA 39
62uC 248
TIMP2 F: 59 GATGCACATCACCCTCTGTG 39
R: 59 GTGCCCGTTGATGTTCTTCT 39
62uC 196
TIMP3 F: 59 CTGACAGGTCGCGTCTATGA 39
R: 59 AGTCACAAAGCAAGGCAGGT 39
60uC 165
18S F 59 GGAGAGGGAGCCTGAGAAAC 39
R 59 CCTCCAATGGATCCTCGTTA 39
60uC 171
Jun F 59 AGAGCGGTGCCTACGGCTACAGTAA 39
R 59 CGACGTGAGAAGGTCCGAGTTCTTG 39
60uC 125
Fos F: 59 ATGGGCTCGCCTGTCAACGC 39
R: 39 GGAGATAACTGTTCCACCTTGCCCC 39
60uC 284
MUC1 F: 59 GTG CCC CCT AGC AGT ACC GA 39
R: 59 GAC GTG CCC CTA CAA GTT GG 39
60uC 123
PDPN 1/3 F: 59 AGCACAGTCCACGCGCAAGA 39
R: 59 CTTTAGGGCGAGTACCTTCCCGACA 39
58uC 168
PDPN 2/4 F: 59 GCCACCAGTCACTCCACGGAGAA 39
R: 59 GGGCCTTCCCGACATTTTTCGC 39
58uC 230
doi:10.1371/journal.pone.0029745.t001
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medium from lower chamber was aspirated and the excess of cells
and Matrigel on the top of membrane of the transwell inserts were
removed using moist cotton swab. Cells from the lower side of the
membrane were fixed by chilled methanol for 7–10 min at 4uC,
followed by staining with 0.2 mM Hoechst 33342 nuclear dye
(Biotium Inc., Hayward, CA, USA) for 5 min at 37uC, washed
with 50 mM PBS; pH 7.4 and visualized for counting using the
fluorescent phase contrast microscope (Eclipse 80i, Nikon,
Chiyoda Ku, Japan) under oil immersion.
Preparation of whole cell extract
Cells (105) were cultured in six well culture plates for 24 h and
starved of FBS for at least 4 h before treatment with IL-11
(200 ng/ml) for 10, 30 and 60 min or for 24 h in the serum free
medium. After each time point, the medium was aspirated and
cells were lysed in 100 ml of lysis buffer (20 mM Tris-HCl, 10%
glycerol, 0.2 mM EDTA, 0.137 M NaCl, 1% NP-40) supple-
mented with Complete protease and phosphatase inhibitor
cocktail (Roche Diagnostics GmbH, Mannheim, Germany). This
was followed by 3 rapid freeze and thaw cycles to ensure the
complete lysis of the cells. Cell lysates were centrifuged at 12,0006
g for 10 min at 4uC and the supernatant was collected. The
amount of protein in each sample was quantitated by BCA
colorimetric assay using bovine serum albumin (BSA) as standard.
Western blot
About 40 mg of cell extract was electrophoressed and transferred
onto the nitrocellulose membrane as described before [9].
Individual blots were incubated at 4uC overnight with 1:1000
dilution of rabbit polyclonal antibodies against phospho-STAT1
(p-STAT1)(tyr701), p-STAT3(tyr705), p-STAT3(ser727), p-
ERK1/2(thr202/204), STAT1, STAT3 (All from Cell Signaling
Technology Inc., Danvers, MA, USA) and mouse monoclonal
antibody against ERK1/2 (Abcam, Cambridge, MA, USA)
followed by incubation with 1:2000 dilution of HRP conjugated
goat anti-rabbit/mouse IgG antibody (Pierce, Rockford, IL, USA)
for 1 h at room temperature (RT). Intensity of bands on Western
blots were quantified by LabWorks Software Version 4.5 (Ultra-
Violet Products Ltd., Cambridge, UK).
In another set of experiment, cell lysates (,40 mg) prepared
after 24 h of IL-11 (200 ng/ml) treatment to either JEG-3 or
HTR-8/SVneo cells were resolved by SDS-PAGE and transferred
onto the nitrocellulose membrane as described above. Blots were
probed overnight at 4uC with goat polyclonal antibody against
protein inhibitor of activated STAT 1/3 (PIAS1/3; 1:1000
dilution; Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA)
followed by HRP conjugated donkey anti-goat IgG antibodies
(1:2000 dilution) for 1 h at RT. Blots were developed by
chemiluminescent substrate and further re-probed for actin as
described before [9].
Quantitative real-time reverse transcription-polymerase
chain reaction (qRT-PCR)
Cells (,105) were seeded onto the 6 well culture plate and
cultured for 24 h. Cell were serum starved for 4 h before addition
of IL-11 (200 ng/ml) for 24 h, keeping appropriate vehicle
control. Total RNA was isolated from cells using Tri reagent
(Sigma-Aldrich Inc.) following the standard protocol employing
chloroform-isopropanol-ethanol steps for its purification. Isolated
RNA samples were quantitated by NanoDrop 3300 spectropho-
tometer (Thermo Scientific, NanoDrop Products, Wilmington,
DE, USA) and were subjected to DNase I (Ferments International
Inc., Ontario, Canada) treatment at 37uC for 15 min as per the
manufacturer’s instruction. The isolated RNA (1 mg) was used to
prepare the cDNA using random hexamers, dNTP mixture, RT
buffer and Superscript III reverse transcriptase following the
manufacturer’s protocol (Superscript III RT PCR System;
Invitrogen, Carlsbad, CA, USA). qRT-PCR reactions were
carried out in triplicates in 20 ml reaction mixture containing
MaximaTM SYBR green qPCR master mix (26) (Ferments
International Inc.), synthesized cDNA and gene specific primers
(1 nm) on an ABI 7500 machine (Life Technologies Corp.,
Carlsbad, CA, USA). The primers used for real-time PCR and
their respective annealing temperatures are listed in Table 1. The
temperature profiles used for the amplification of target sequences
were: initial denaturation for 95uC for 10 min, followed by 40
cycles of 95uC for 15 sec, amplification for 1 min at primer
specific annealing temperature value (Table 1) and then a final
melting curve analysis with a range from 60 to 95uC over 20 min.
Gene-specific amplification was confirmed by a single peak in the
ABI Dissociation Curve software. Average threshold cycle (Ct)
values for 18S rRNA (run in parallel reactions to the genes of
interest) were used to normalize average Ct values of the gene of
interest. These values were used to calculate the average for each
group, and the relative DCt was used to determine the change in
expression between the groups.
Microarray
Total RNA was extracted using Tri reagent (Sigma Aldrich Inc.)
and purified on RNeasy columns (Qiagen, Crawley, UK)
according to the manufacturers recommendations. RNA quality
was checked using an Agilant 2100 Bioanalyser (Agilent
Technologies, Palo Alto, USA). Sense strand cDNA was prepared
using the Ambion WT expression kit (Ambion Inc., Austin, Texas,
USA) which was fragmented and biotin-labeled using the
Figure 1. Effect of IL-11 on invasion of JEG-3 and HTR-8/SVneo
cells. Invasion assay was performed as mentioned in Materials and
Methods. Data is expressed as fold change in invasion following IL-11
(200 ng/ml) treatment as compared to untreated JEG-3 cells as control.
Values are expressed as mean 6 SEM of at least 6 experiments
performed in duplicates. *p,0.05; **p,0.001.
doi:10.1371/journal.pone.0029745.g001
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Affymetrix GeneChip WT terminal labeling kit (Affymetrix, High
Wycombe, UK) according to manufacturers’ recommendations.
Fragmented and labeled cDNAs were hybridized to Affymetrix
Exon 1 ST GeneChips (Affymetrix) at 45uC for 17 h in
hybridization oven at 60 rpm according to Affymetrix protocols
(Affymetrix). The washing and staining were performed using the
Affymetrix Fluidics Station 450. The chips were read using a
GeneChip Scanner 3000, and the resulting raw image was
converted to signal intensities, detection calls, comparison files,
signal log ratios, and change calls (Center for Genomic
Application, New Delhi, India). Each of these pieces of data was
generated independent of each other using algorithms from the
Affymetrix GenChip Operating Software. For normalizing and
summarizing probe-level intensity measurements from Gene-
Chips, GCRMA was used which converts .CEL files into
expression set using the Robust Multi-array Average (RMA) with
the help of probe sequence and with GC-content background
correction. Statistical (Student’s t test) analysis was performed with
Affymetrix Data Mining Tool software. The data were filtered on
the criteria of 1.5 fold up- or 0.5 fold down-regulation taking into
account the genes whose p,0.05. Basic information related to the
microarray data has been submitted to the GEO database
following the MIAME guidelines (Accession no. GSE31608).
Silencing of matrix metalloproteinase 23B (MMP23B)
expression by siRNA
MMP23B siRNA contains the smart pool of 3 different siRNAs
(Thermo Scientific Dharmacon, Lafayette, CO, USA). Cells were
cultured in 6 well plates under standard conditions (37uC, 5%
CO2 humidified atmosphere). At 50% confluency, cells were
washed twice with OPTI-MEM I medium and 800 ml of fresh
OPTI-MEM I medium was added into each well. Annealed
oligonucleotides (final concentration 100 nm) were mixed with
OPTI-MEM I to make a total volume of 185 ml. In a separate
tube, 4 ml lipofectamine 2000 was mixed with 11 ml OPTI-MEM
I medium. Both the solutions were mixed and incubated for
20 min at RT. The mixed solutions were added carefully drop by
drop in respective wells and after 4 h of incubation, complete
medium was added to the cells in each well. Silencing
experiments were performed by keeping transfection (transfected
with non-genomic siRNA) controls. The extent of silencing
following transfection with siRNA was accessed by RT-PCR after
72 h of silencing.
Immunofluorescence
Cells (,26104) were grown on the cover slips in 24 well cell
culture plates for 24 h. After 4 h of serum starvation, cells were
Figure 2. Activation of STAT and ERK1/2 dependent signaling pathway following IL-11 treatment. JEG-3 and HTR-8/SVneo cells were
treated with IL-11 (200 ng/ml) for varying period of time and Western blots were done as mentioned in Materials and Methods. Panels A, B, C and D
represent the densitometric plots of p-STAT3(tyr705), p-STAT3(ser727), p-STAT1(tyr705) and p-ERK1/2 respectively. Band intensities were normalized
with respect to respective unphosphorylated proteins and the data is expressed as fold change with respect to JEG-3 control. The data is shown as
mean 6 SEM of at least 3 experiments. #p,0.001 between un-treated JEG-3 and HTR-8/SVneo cells; *p,0.05 with respect to respective un-treated
control cells.
doi:10.1371/journal.pone.0029745.g002
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treated with IL-11 (200 ng/ml) for 10 min in serum free medium
and fixed with chilled methanol for 5 min at 4uC. Cells were
washed with 50 mM PBS; pH 7.4 and blocking was done for 1 h
at RT using PBS containing 2% BSA. Cells were washed and
incubated overnight at 4uC with rabbit polyclonal antibody
against p-STAT3(tyr705) (1:100 dilution) and goat polyclonal
antibody against PIAS1/3 (1:100 dilution). This was followed by
washing of the cells with PBS for 3 times and incubation with
1:400 dilutions of Alexa Fluor 488 goat anti-rabbit IgG (H+L) and
donkey anti-goat IgG-rhodamine for 1 h at RT to perform the
double labeling. Cells were again washed with PBS (4 times) and
mounted in dark onto the glass slide using Vectashield hard set
mounting medium containing DAPI (1.5 mg/ml) (Vector Labora-
tories Inc., Burlingame, CA, USA). Slides were screened for
immunofluorescence under a fluorescent phase contrast micro-
scope (Nikon) and images were captured by using the Image
Proplus software (Nikon).
Statistical analysis
All the experiments were performed at least three times and the
results are expressed as mean 6 SEM. For different sets of
experiments like invasion assay and Western blot (densitometric
analysis), the statistical analysis was done by comparing the means
of the control and experimental sets by one-way ANOVA. A value
of p,0.05 was considered to be statistically significant.
Results
Invasion of JEG-3 and HTR-8/SVneo cells under the
influence of IL-11
At the basal level, a significantly higher (,12 fold; p,0.001)
invasiveness of HTR-8/SVneo cells as compared to JEG-3 cells
was observed (Fig. 1). As compared to untreated cells, almost five
fold increase in invasion was observed in response to optimized
concentration of IL-11 (200 ng/ml) in JEG-3 cells while, at the
same concentration, IL-11 inhibited invasion of HTR-8/SVneo
cells to almost half (p,0.05; Fig. 1).
Activation of downstream signaling molecules by IL-11 in
JEG-3 and HTR-8/SVneo cells
JEG-3 and HTR-8/SVneo cells were treated with IL-11
(200 ng/ml) for varying time periods (0, 10, 30 and 60 min) and
cell lysates collected at specific time points were subjected for
Western blot. There was a significantly higher (p,0.05) basal
levels of p-STAT3(tyr705) (Fig. 2A), p-STAT3(ser727) (Fig. 2B)
and p-ERK1/2 (Fig. 2C) in HTR-8/SVneo cells as compared to
JEG-3 cells but, no differences were observed in the levels of p-
STAT1(tyr701) in both the cell lines (Fig. 2D).
As compared to untreated controls, following IL-11 treatment
there was an increase in the activation of STAT3(tyr705) in both
JEG-3 and HTR-8/SVneo cells, which was evident as early as
10 min and continued until 60 min of IL-11 challenge (Fig. 2A).
However, no significant changes in the phosphorylation of
STAT3(ser727) was observed in both the cells at all the time
points studied (Fig. 2B). IL-11 treatment to JEG-3 and HTR-8/
SVneo cells led to a significantly higher (p,0.05) phosphorylation
of STAT1(tyr701) (Fig. 2C).
In JEG-3 cells, following IL-11 treatment, there was a
significant increase (p,0.05) in activation of ERK1 by 10 and
30 min which was still far less than the basal level of activated
ERK1 in HTR-8/SVneo cells (Fig. 2D). However, IL-11
treatment to HTR-8/SVneo cells led to a significant decrease
(p,0.05) in the activated ERK1 and ERK2 from the basal level by
10 and 30 min (Fig. 2D).
Microarray analyses of the IL-11 treated JEG-3 and HTR-8/
SVneo cells
JEG-3 and HTR-8/SVneo cells were treated with IL-11
(200 ng/ml) for 24 h and microarray analysis was carried out as
Figure 3. IL-11 mediated expression of Jun and Fos in JEG-3 and HTR-8/SVneo cells. Quantitative RT-PCR was done for the expression of
Jun (Panel A) and Fos (Panel B) as mentioned in Materials and Methods. Each bar represents the DCt values after normalization with the 18S rRNA. The
data is expressed as mean 6 SEM of 3 experiments performed in triplicates. *p,0.05; **p,0.001.
doi:10.1371/journal.pone.0029745.g003
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mentioned in Materials and Methods. We used the GeneChipH
Human Exon 1.0 ST (Affymetrix, Santa Clara, CA) for these
experiments. The array contains over 1.4 million probe sets and
over 5 million probes. The probe sets are grouped into over
300,000 transcript clusters with over 90,000 transcript clusters
containing more than one probe set. As compared to untreated
controls, following IL-11 treatment to JEG-3 and HTR-8/SVneo
cells, some distinct set of genes got up- and down- regulated. In
JEG-3 cells, upon IL-11 treatment, 314 genes got upregulated by
at least 1.5 fold while, 313 got downregulated by 0.5 fold. In
contrast to this, in HTR-8/SVneo cells, 75 genes showed
upregulation by at least 1.5 fold while, 54 showed downregulation
by at least 0.5 fold following IL-11 treatment. Out of these, there
were genes like MMP23B, Jun, secretogranin II, dual specificity
phosphatase 6, Wnt5A, homeobox A6, IL-1f and syntaxin 11, which
showed an increase in their expression in IL-11 treated JEG-3 cells
while, a decrease in their expression was observed in IL-11 treated
HTR-8/SVneo cells. Treatment of JEG-3 cells with IL-11 also led
to an increase in the expression of genes like mucin 1, cadherin 13
(CDH13), defensin b1, insulin like growth factor binding protein 2 (IGFBP2)
and IGFBP5, whose expression were not significantly altered in
HTR-8/SVneo cells. Validation of some of the leads gained after
microarray analysis have been carried out by performing qRT-
PCR analysis on the RNA samples isolated from IL-11 treated
JEG-3 and HTR-8/SVneo cells.
After this, we performed a comparative analysis of the gene
expression in JEG-3 and HTR-8/SVneo cells. As compared to
JEG-3 cells, in HTR-8/SVneo cells, there were about 1176 genes,
which showed at least 2 fold increase while, about 1334 genes
showed about 2 fold decrease in their expression. Amongst the
differentially expressed genes, there were several molecules whose
expression might influence the invasive capabilities of a given cell
type. As compared to JEG-3 cells, HTR-8/SVneo cells showed
over-expression of proteases [MMP1, MMP2, MMP9, MMP23B,
tissue palsminogen activator (TPA), PLAUR], protease inhibitor like
TIMP1, adhesion molecules [CDH13, CDH2, integrin A2 (ITGA2),
ITGA3, ITGA4, ITGA11, MUC1, syndecan 2 (SDC2)], cytokines or
their receptors (IL-11, IL-32, IL-27A, MCSF1, IL-8, IL-1b, LIFR,
NOTCH2) and signaling intermediates [Janus kinase 2 (JAK2),
STAT3, suppressor of cytokine signaling 3 (SOCS3), SOCS5, human
homologue of mothers against decapentaplegic 9 (SMAD9)]. However, there
were several molecules like MMP14, MMP19, TIMP4, CDH1(E-
cadherin), CDH3 (placental cadherin), CDH5, CDH8, protocadherin beta 13,
ITGB4, MUC15, CDH18, insulin like growth factor 2 (IGF2), STAT1,
FOS, SP6 transcription factor (SP6) etc that showed a higher expression
in JEG-3 cells as compared to HTR-8/SVneo cells.
Further, on the basis of the observed differences at the level of
gene expression, we carried out pathway analysis by using DAVID
functional annotation tool (DAVID Bioinformatics Resources 6.7,
NIAID/NIH, USA) [12,13]. HTR-8/SVneo cells showed an
over-expression of molecules associated with signaling pathways
which promote the invasiveness of cells. These were MAPK
signaling pathway, pathways in cancer, cytokine-cytokine receptor
interaction, focal adhesion, chemokine signaling, ECM-receptor
interaction, transforming growth factor b (TGF b) signaling
pathway etc. As compared to HTR-8/SVneo cells, JEG-3 cells
showed an increase in the expression of molecules associated with
signaling pathways like renal cell carcinoma, thyroid cancer,
insulin signaling, P53 signaling, tight junction etc.
Effect of IL-11 on the expression of activator protein-1
(AP-1) transcription factors
Jun and Fos are two main members of the AP-1 transcription
factor. Microarray of IL-11 treated JEG-3 and HTR-8/SVneo
cells suggested the upregulation of Jun expression in JEG-3 cells
while, downregulation in HTR-8/SVneo cells. To further validate
this observation, qRT-PCR was performed in IL-11 treated JEG-3
and HTR-8/SVneo cells. At the basal level, HTR-8/SVneo cells
showed a significantly higher (p,0.001) level of Jun expression
than that of the JEG-3 cells (Fig. 3A). Further, IL-11 treatment
significantly increased the expression of Jun in JEG-3 cells while,
the increase in its expression in HTR-8/SVneo cells was not
significant (Fig. 3A). Analysis of the expression of Fos (one of the
closely associated partners of Jun) was also carried out by qRT-
PCR. Unlike Jun, at the basal level, there was a significantly higher
(P,0.001) expression of Fos in JEG-3 cells as compared to HTR-
8/SVneo cells (Fig. 3B). Treatment of JEG-3 cells with IL-11 led
to a significantly higher (p,0.05) level of Fos expression while,
there was a significant decrease (p,0.05) in the expression of Fos
in HTR-8/SVneo cells (Fig. 3B).
Figure 4. IL-11 mediated expression of MUC1 and PDPN in JEG-
3 and HTR-8/SVneo cells. Quantitative RT-PCR was done for the
expression of MUC1 (Panel A) and PDPN (Panel B) as mentioned in
Materials and Methods. Each bar represents the DCt values after
normalization with the 18S rRNA. The data is expressed as mean 6 SEM
of 3 experiments performed in triplicates. *p,0.05; **p,0.001.
doi:10.1371/journal.pone.0029745.g004
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Effect of IL-11 on the expression of mucin-type
glycoproteins (mucin 1 and podoplanin) in JEG-3 and
HTR-8/SVneo cells
Microarray analysis suggested an upregulation in the expres-
sion of MUC1 in IL-11 treated JEG-3 cells while, its downreg-
ulation in IL-11 treated HTR-8/SVneo cells. This observation
was confirmed by performing the qRT-PCR on the RNA
samples isolated from JEG-3 and HTR-8/SVneo cells treated
with IL-11 for 24 h. We observed an increase (p,0.05) in the
expression of MUC1 in IL-11 treated JEG-3 cells (Fig. 4A).
However, decrease in the expression of MUC1 in IL-11 treated
HTR-8/SVneo cells was not statistically significant (Fig. 4A).
Podoplanin (PDPN) is another mucin-like protein which is
expressed as four splice variants. Though, its expression was
not significantly altered in the microarray data but, considering
its significance in the LIF mediated increase in invasion of
trophoblast cells (unpublished data), qRT-PCR was performed to
analyze the changes in its expression in IL-11 treated JEG-3 and
HTR-8/SVneo cells. To analyze the expression of all the four
splice variants, two sets of PCR primers were made for qRT-PCR
(Table 1). As observed for MUC1, HTR-8/SVneo cells had a
significantly higher (p,0.001) level of basal expression of PDPN
than that of JEG-3 cells (Fig. 4B). Further, IL-11 treatment
increased (p,0.05) the expression of PDPN in JEG-3 cells while;
there was no significant change in the expression of PDPN in IL-
11 treated HTR-8/SVneo cells (Fig. 4B).
Figure 5. Role of MMP23B in IL-11 mediated invasion of JEG-3 and HTR-8/SVneo cells. Quantitative RT-PCR was done for the expression of
MMP23B (Panel A) as mentioned in Materials and Methods. Each bar represents the DCt values after normalization with the 18S rRNA. The data is
expressed as mean 6 SEM of 3 experiments performed in triplicates. In another experiment, JEG-3 cells were transfected with either MMP23B siRNA
or non-genomic siRNA for 72 h and end point RT-PCR was done to check the level of silencing in them, keeping 18S rRNA as internal control (Panel B).
The transfected cells were used to study their invasive behavior in the presence or absence of IL-11 (200 ng/ml) as described in Materials and
Methods. The results are expressed as mean6 SEM of fold change in invasion as compared to non-genomic siRNA transfected cells in the absence of
IL-11, observed in 3 independent experiments. *p,0.05; **p,0.001; #p,0.01 between JEG-3 cells transfected with non-genomic and MMP23B
siRNA; $p,0.001 between IL-11 treated non-genomic siRNA transfected and MMP23B siRNA transfected JEG-3 cells.
doi:10.1371/journal.pone.0029745.g005
Table 2. Effect of IL-11 on the expression of MMPs, TIMPs and
integrins.
Gene JEG-3 HTR-8/SVneo
Control IL-11 Control IL-11
MMP2 160.23 1.360.29 39.4614.4# 14.466.2*
MMP3 160.34 0.860.56 19.367.18# 1.660.17*
MMP9 160.3 1.2160.44 217.3642.6# 83.5619.6*
TIMP1 160.12 1.460.59 13967.00# 111625.00
TIMP2 160.38 0.960.03 3.560.30# 2.261.00
TIMP3 160.39 0.960.03 0.960.07 0.660.35
Integrin a5 160.45 1.160.10 2.961.55# 2.961.25
Integrin a6 160.24 0.760.15 0.960.05 0.660.04
Integrin aV 160.32 1.260.19 0.660.01 0.460.01
For each sample, DCt values were obtained after normalization with the Ct
values for 18S rRNA. After that fold change in expression (DCt values) between
the groups was calculated with respect to the untreated JEG-3 cells.
#p,0.001 between untreated JEG-3 and HTR-8/SVneo cells;
*p,0.05 between un-stimulated and IL-11 treated HTR-8/SVneo cells.
doi:10.1371/journal.pone.0029745.t002
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IL-11 increases the expression of MMP23B in JEG-3 cells
while, decreases its expression in HTR-8/SVneo cells
Microarray analysis of the IL-11 treated JEG-3 and HTR-8/
SVneo cells showed an increase in the expression of MMP23B in
JEG-3 cells while, a decrease in its expression in HTR-8/SVneo
cells. To validate this observation, expression of MMP23B was
analysed by qRT-PCR in RNA samples isolated from IL-11
treated JEG-3 and HTR-8/SVneo cells. In HTR-8/SVneo cells,
there was a significantly higher basal expression (p,0.001) of
MMP23B as compared to JEG-3 cells (Fig. 5A). Upon IL-11
treatment to JEG-3 cells, there was a significant increase in the
MMP23B expression while, in HTR-8/SVneo cells, IL-11
significantly reduced (P,0.05) its expression (Fig. 5A).
Silencing of MMP23B expression abrogates the IL-11
mediated increase in JEG-3 cell invasion
To determine the significance of the increase in MMP23B
expression in IL-11 mediated increase in invasive behavior of JEG-
3 cells, its expression was silenced using siRNA. There was more
than 70% silencing of the expression of MMP23B after 72 h of
transfection with siRNA (Fig. 5B). Upon IL-11 treatment, there
was a significant increase (p,0.05) in the invasiveness of non-
genomic siRNA transfected cells (Fig. 5C). However, silencing of
MMP23B expression by siRNA led to a significant decrease in the
invasiveness of JEG-3 cells as compared to non-genomic siRNA
transfected cells. Treatment of MMP23B silenced JEG-3 cells with
IL-11 did not lead to a significant change in the invasion as
compared to the control cells (Fig. 5C).
Expression of MMPs and TIMPs in JEG-3 and HTR-8/
SVneo cells following IL-11 treatment
Expression of MMP2, 3, 9 and TIMP1, 2 and 3 was analysed in
JEG-3 and HTR/SVneo cells after 24 h of IL-11 treatment. In
JEG-3 cells, there were no significant changes in the expression of
these MMPs upon IL-11 treatment while, in HTR-8/SVneo
cells, IL-11 treatment brought a significant decrease (p,0.05) in
the expression of MMP2, 3 and 9 (Table 2). There were no
significant changes in the expression of TIMPs in IL-11 treated
JEG-3 and HTR-8/SVneo cells. At the basal level, HTR-8/
SVneo cells had a significantly higher expression of MMP2,
MMP3, MMP9, TIMP1 and TIMP2 than that of the JEG-3 cells
(Table 2).
IL-11 mediated expression of integrins and other
adhesion molecules in JEG-3 and HTR-8/SVneo cells
Switching in the expression of integrins like integrin a5, aV and
a6 have been observed during the invasive differentiation of
trophoblast cells. At the basal level, the expression of integrin a5
was significantly higher (p,0.01) in HTR-8/SVneo cells as
compared to JEG-3 cells (Table 2). However, following IL-11
treatment no significant change in the expression of integrin a5, aV
and a6 were observed in both the cell lines as compared to
respective controls (Table 2).
IL-11 decreases the expression of PIAS1 but, not of PIAS3
in HTR-8/SVneo cells
Western blots were performed for the analysis of PIAS1/3
expression in the cell lysates prepared after treatment of JEG-3
and HTR-8/SVneo cells with IL-11 for 24 h. At the basal level,
both the cell lines expressed the PIAS1 while, PIAS3 was
expressed only by HTR-8/SVneo cells. The level of expression
of PIAS3 in JEG-3 cells was almost negligible as compared to
HTR-8/SVneo cells. Upon IL-11 treatment, there was a
significant decrease (p,0.05) in the expression of PIAS1 in
HTR-8/SVneo cells while, there was no significant change in the
expression of PIAS3 as compared to the control (Fig. 6). However,
no significant changes in their expression were observed in JEG-3
cells after IL-11 treatment (Fig. 6).
IL-11 treatment to HTR-8/SVneo cells leads to nuclear
co-localization of PIAS1/3 and p-STAT3(tyr705)
PAIS3 is a potential negative regulator of STAT3 signaling. If
bound with the activated STAT3 molecules, PIAS3 can interfere
with its transcriptional activity. To observe the IL-11 mediated
nuclear localization of p-STAT3(tyr705) and its transcriptional
activity which might get interfered by PIAS3, JEG-3 and HTR-
8/SVneo cells were treated with IL-11 for 10 min and
immunostained for p-STAT3(tyr705) and PIAS1/3. In untreated
JEG-3 cells, fluorescence signal for PIAS1/3 was distributed
throughout the cytoplasm and nucleus along with a typical
punctate staining of PIAS1/3 at the cell boundary which would
correspond to PIAS1 as JEG-3 cells have feeble expression of
PIAS3 (Fig. 7). In untreated JEG-3 cells, there was no
fluorescence signal for p-STAT3(tyr705) (Fig. 7). Upon treatment
with IL-11, there was intense fluorescence signal for p-
STAT3(tyr705) that was present well inside the nucleus. Though
both activated STAT3 and PIAS1/3 were present in the nucleus
of cells treated with IL-11; there were very few co-localization
Figure 6. Expression of PIAS1/3 in JEG-3 and HTR-8/SVneo cells
following IL-11 treatment. Cell lysates were prepared after
treatment of JEG-3 and HTR-8/SVneo cells with IL-11 (200 ng/ml) for
24 h and Western blot was done for the expression of PIAS1/3 as
mentioned in Materials and Methods. Band intensities were normalized
with respect to actin and data is expressed as mean fold change in the
expression6 SEM of PIAS1 and PIAS3 as compared to the JEG-3 control.
*p,0.05 between untreated and IL-11 treated HTR-8/SVneo cells;
#p,0.001 between untreated JEG-3 and HTR-8/SVneo cells.
doi:10.1371/journal.pone.0029745.g006
Regulation of Trophoblastic Cell Invasion by IL-11
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e29745
points predicted by the software (Fig. 7). In un-treated HTR-8/
SVneo cells, fluorescence signals for both PIAS1/3 and p-
STAT3(tyr705) were distributed into the cytoplasm as well as
inside the nucleus (Fig. 7). Upon IL-11 treatment, an increase in
the nuclear localization of p-STAT3(tyr705) as well as of PIAS1/
3 was observed (Fig. 7). The overlay of p-STAT3(tyr705), PIAS1/
3 and DAPI showed co-localization into the nucleus (Fig. 7). In
untreated cells, the co-localization of PIAS1/3 and p-STAT3(-
tyr705) was relatively less as compared to that observed after IL-
11 treatment (Fig. 7).
Discussion
Amongst several trophoblastic cell models, JEG-3 choriocarci-
noma and transformed EVT cells (HTR-8/SVneo) are the two cell
lines, which have been widely employed to investigate the invasion
and proliferation of trophoblastic cells [14]. However, as
compared to EVTs, the JEG-3 cells show major differences in
their responses to physiological ligands [15–17]. For example,
TGF b decreases the invasiveness of EVT cells in Smad3
dependent manner while, JGE-3 cells could resist that effect due
to the absence of Smad3 expression [15]. Decorin is a decidual
product that acts in a TGF b independent manner to reduce the
invasiveness of EVT but not JEG-3 cells [18–20]. Similarly, IL-11
(a decidua derived product) inhibits the invasiveness of EVTs and
HTR-8/SVneo cells but, stimulates of invasion of JEG-3 cells
[9,10]. However, the molecular basis of this differential effect is
unknown. Under such situation, it is important to understand the
mechanistic basis of the differential effects of IL-11 in these two
cells lines, as it may give cues to understand the molecular basis of
trophoblast invasion and an idea of how different extrinsic factors
control the cellular invasion.
First trimester trophoblast cells, due to intrinsic mechanism
have the invasive ability comparable to their malignant counter-
part [21]. A comparative microarray analysis of JEG-3 and HTR-
8/SVneo cells suggest that due to higher basal expression of pro-
invasive molecules as well as the signaling pathways in HTR-8/
SVneo cells, it has the higher invasive ability than that of the JEG-
3 cells. At the molecular level, the increased expression of invasion
related molecules require activation of transcription factors
through activation of diverse signaling pathways. Of several
pathways which can contribute to an increase in the invasion of
cells, HTR-8/SVneo cells have a higher basal level of activation of
STAT3 as well as ERK1/2 (Fig. 2). Activation of ERK1/2 and
STAT3 may result into the higher level of basal expression of
proteases as well as the cytokines/their receptors like IL-11, IL-32,
IL-8, IL-1, CSF1, LIFR, IGF1R and IL-4R in HTR-8/SVneo cells
as compared to JEG-3 cells.
Regulation of invasiveness of JEG-3 and HTR-8/SVneo cells
by IL-11 has remained ambiguous, as it increases the invasiveness
of JEG-3 cells while, decreases the invasiveness of HTR-8/SVneo
cells [9,10]. In the present study also, IL-11 increased the
invasiveness of JEG-3 cells while, reduced the invasiveness of
HTR-8/SVneo cells. The active expression of invasion related
Figure 7. Immunolocalization of p-STAT3 (tyr705) and PIAS1/3 in JEG-3 and HTR-8/SVneo cells following IL-11 treatment. JEG-3 and
HTR-8/SVneo cells were treated with IL-11 (200 ng/ml) for 10 min and then checked for the immunolocalization of p-STAT3 and PIAS1/3 followed by
counter staining with DAPI. In the figure sub-panels are: A; phase contrast image, B; DAPI stained cells, C; staining for PIAS1/3, D; staining for p-
STAT3(tyr705), E; co-localization of p-STAT3(tyr705) and PIAS1/3, F; merge image of the PIAS1/3, p-STAT3(tyr705) and DAPI images. Co-localization
performed for PIAS1/3 and p-STAT3(tyr705) signals using ‘‘co-localization tool’’ of the ImageJ software. Two points are considered as co-localized, if
their respective intensities are strictly higher than the threshold of their channels. Each co-localization point appears as white dot. Scale bar
represents 20 mm size.
doi:10.1371/journal.pone.0029745.g007
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molecules is via activation of several signaling pathways including
the mitogen activated protein kinase (MAPK) and STAT
dependent signaling pathways [22]. Analysis of the IL-11 mediated
activation of STAT and ERK1/2 dependent signaling pathways in
both the cell lines was performed together on one blot to avoid
the experimental variations in band intensities during Western
blotting. IL-11 increased the activation of STAT3(tyr705) in both
the cell lines, which is in agreement with the published report
[9,10]. In addition to STAT3(tyr705), IL-11 also increased the
phosphorylation of STAT1(tyr701) in both the cells lines without
influencing the STAT3(ser727) phosphorylation. The major
difference in the IL-11 mediated downstream signaling in the
two cell lines was an increase in the ERK1 activation in JEG-3
cells while, a decrease in p-ERK1/2 in HTR-8/SVneo cells,
which is consistent with the observed increase and decrease in IL-
11 mediated invasiveness of JEG-3 and HTR-8/SVneo cells
respectively. The observed decrease in ERK1/2 activation in
HTR-8/SVneo cells could be due to the activation of phospha-
tases which dephosphorylate the activated ERK1/2 [23]. But, it
needs further validation to specifically pin point the molecule
which help in IL-11 mediated decrease in phosphorylation of
ERK1/2 in HTR-8/SVneo cells.
AP-1 family of transcription factors is a family of proteins which
controls the diverse biological processes like cellular proliferation,
invasion and apoptosis. Jun and Fos are the transcription factors of
AP-1 family which act as interacting partners for the activated
STAT3 and cooperate in enhancing the STAT3 mediated
transcriptional activity [24]. Upregulation of the expression of
both Jun and Fos in IL-11 treated JEG-3 cells would be of
paramount importance as they can enhance the transcriptional
activity by cooperating with STAT3 as well as by forming Jun-Jun
and Jun-Fos dimers and thereby facilitating the cellular invasion.
Reduction in the expression of Fos in HTR-8/SVneo cells treated
by IL-11 might be one of the factors associated with their reduced
invasiveness.
After analyzing the expression of transcription factors, analyses
of the IL-11 mediated expression of effector molecules (mucin-type
molecules, MMPs, inhibitors of MMPs and integrins) were carried
out in both the cell lines. Amongst mucin-type molecules, MUC1
and podoplanin (PDPN) gets upregulated in several tumors [25–
27]. IL-11 upregulated the expression ofMUC1 as well as PDPN in
JEG-3 cells while; there was no significant change in their
expression in IL-11 treated HTR-8/SVneo cells. It was surprising
to note that even after STAT3 activation in HTR-8/SVneo cells,
there was no significant change in the expression of STAT3-
responsive MUC1. Under such situation, it was plausible to
analyze the expression and localization of PIAS1/3 in these cell
lines as PIAS1/3 can inhibit the transcription activity of activated
STAT3. In that direction, change in the expression of PIAS1 and
PIAS3 was analysed after treatment of both JEG-3 and HTR-8/
SVneo cells with IL-11 for 24 h. At a basal level, JEG-3 cells did
not express PIAS3 while, HTR-8/SVneo cells expressed both
PIAS1 and PIAS3 as previously observed [28]. IL-11 treatment
reduced the expression of PIAS1 in HTR-8/SVneo cells while, it
Figure 8. Schematic representation of the IL-11 mediated signaling and gene expression in JEG-3 and HTR-8/SVneo cells. IL-11
treatment to JEG-3 cells led to the activation of STAT1/3, which after dimerization moves into the nucleus. The activation of STAT3 was associated
with a transient activation of ERK1/2. Activation of STAT3(tyr705) is associated with its nuclear localization. In effect to these, an increase in the
expression of pro-invasive molecules like Jun, Fos, MUC1, PDPN, MMP23B etc have been observed. In HTR-8/SVneo cells, IL-11 treatment increases the
activation of STAT1(tyr701) and STAT3(tyr705) while, decreases the activation of ERK1/2. The increase in p-STAT3(tyr705) was associated with its
nuclear localization within 10 min of IL-11 treatment. However, upon IL-11 treatment, there was nuclear co-localization of p-STAT3(tyr705) with its
inhibitory factor PIAS1/3. This could be the reason for the decrease in the expression of Fos,MMP2,MMP3,MMP9 and MMP23B. (Solid arrows show the
confirmed findings while, dotted arrows show the hypothetical links, which needs to be validated. Name of genes written in italics have been
confirmed at the RNA level while, other have been confirmed at the protein level.).
doi:10.1371/journal.pone.0029745.g008
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had no influence on the PIAS1 expression in JEG-3 cells. A
decrease in the PIAS1 expression in IL-11 treated HTR-8/SVneo
cells would pose less hindrance to the p-STAT1(tyr701) directed
anti-invasive transcriptional activity. So, this might be a contrib-
utory factor for the observed IL-11 mediated reduction in the
invasiveness of HTR-8/SVneo cells. Further, extensive co-
localization points for p-STAT3(tyr705) and PIAS1/3 in IL-11
treated HTR-8/SVneo cells as compared to JEG-3 cells would
pose hindrance to the normal DNA binding and the transcrip-
tional activity of activated STAT3. This could be the reason for
the increase in the expression of STAT3-responsive MUC1 in IL-
11 treated JEG-3 cells but, not in the HTR-8/SVneo cells.
Trophoblastic cells express several proteases and their inhibitors
but, the final outcome in terms of invasive behavior is governed by
cytokine mediated shift in the fine balance between the activating
and inhibiting molecules. Several cytokines and growth factors
have been shown to increase the invasiveness of trophoblastic cells
through changes in the expression of MMPs and TIMPs [29–32].
IL-11 reduced the expression of MMP2, MMP3 and MMP9 in
HTR-8/SVneo cells but, not in JEG-3 cells. We observed an IL-
11 mediated decrease in the expression of MMP2 and MMP9 after
24 h treatment of HTR-8/SVneo cells but, in an earlier study
conducted after 48 h of IL-11 treatment, there was no significant
change in their enzymatic activity [10]. This difference could be
due to the differences in the time point for the analysis of the
expression and activity of MMPs after IL-11 treatment. No effects
of IL-11 were seen on TIMP expression in both the cell lines.
MMP23B is unique membrane anchored MMP whose expression
got significantly increased in IL-11 treated JEG-3 cells but, not
HTR-8/SVneo cells, which was reflected by microarray as well as
by qRT-PCR analysis [33,34]. Interestingly, silencing of MMP23B
expression led to a significant decrease in the invasion of JEG-3
cells at the basal as well as after IL-11 treatment. This observation
indicates MMP23B as a novel regulator of IL-11 mediated
invasion of JEG-3 cells. Beyond MMPs and TIMPs, adhesion
molecules like integrins and cadherins also play an important role
in invasion of trophoblastic cells [35,36]. Treatment of JEG-3 as
well as of HTR-8/SVneo cells with IL-11 did not show any
significant change in the expression of integrin a5, aV and a6.
However, microarray analysis of gene expression upon IL-11
treatment showed upregulation of the expression of cadherin 13
(CDH13) or H-cadherin in JEG-3 cells while, downregulation in
HTR-8/SVneo cells. It will be of interest to study the role of
CDH13 in trophoblast invasion.
From the above studies, following conclusions can be drawn. 1)
In JEG-3 cells, IL-11 mediated activation of STAT and ERK1/2
signaling pathway is responsible for the increase in the expression
of Jun, Fos, MUC1, PDPN and MMP23B, which ultimately leads to
an increase in the invasiveness of JEG-3 cells (Fig. 8). 2) IL-11
mediated decrease in HTR-8/SVneo cells invasiveness was
associated with a decrease in ERK1/2 activation, PIAS1/3
mediated activated STAT3(tyr705) sequestration and decrease in
PIAS1 expression leading to a decrease in the expression of Fos
and major families of MMPs (MMP2, MMP3, MMP9 and
MMP23B) (Fig. 8). 3) MMP23B has emerged as a novel regulator
of the IL-11 mediated invasion of JEG-3 and HTR-8/SVneo cells.
Thus, ERK1/2 and PIAS1/3 seems to be the critical factors that
may be responsible for the differential effects of IL-11 on HTR-8/
SVneo and JEG-3 cells. Taking cues from this study and that
observed in case of TGF b, it appears that despite sharing gene
expression signatures with EVT cells, the lack of crucial signaling
components like Smad3 and PIAS3 in JEG-3 cells would bring
about dramatic differences in the intricate regulatory mechanisms
in response to external stimulus. Keeping in view of the
observations described in this manuscript, it would be of interest
to extend this study to analyze the gene expression and regulatory
mechanisms associated with IL-11 mediated invasion of EVT cells.
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IT’S A WOMAN THING: PART II - THE PLACENTA 
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As exposed in part I, tobacco use during pregnancy is recognized by the WHO 
as one of the most important, preventable risk factors for developing a series of 
pregnancy pathologies. Many of these include those deemed to be mediated by the 
placenta: fetal growth retardation, preterm labor and stillbirth. Furthermore, 
preeclampsia, a hypertensive pregnancy disorder considered to be placenta-
associated, seems to be subverted in women who smoke during pregnancy.  
In general, smoking is considered a risk factor for cardiovascular diseases, 
and is associated with vascular dysfunction. Elevated vasoconstriction status, signs 
of altered uteroplacental blood flow and impaired endothelial nitric oxide synthase 
expression and activity have been demonstrated in pregnant women who smoke. 
Modifications in the maternal immune system have been proposed, including 
increased adhesion molecules expression and elevated leukocyte number, with 
increased T lymphocyte percentage, although the impact of these events is not 
completely understood.  
The above changes seem to take a toll on the placenta. Prenatal smoking 
promotes adverse effects on trophoblast cells, with evident morphological and 
biochemical changes in early and term placenta. Altered apoptosis rate in 
trophoblasts and decreased expression of biochemical markers directly related to 
placental functional status have been described. Several modifications are also 
observed in villous development. Considered together, this data supports the concept 
that cigarette smoking is strongly associated with histological and physiological 
modifications during pregnancy, with subsequent impairment of placental and fetal 
development. 
In part I, we identified and compared the placenta-associated disease profiles 
linked with individual types of nicotine exposure (cigarette, smokeless tobacco, 
nicotine replacement, secondhand smoke). Now, we review the literature on tobacco 
constituent effects on the placenta. We believe there are lessons to be learned from 
comparing epidemiological and laboratory data, since after we finally revisit the 
relevant pregnancy diseases, we can identify clarifying points and expose 
contradictions or research gaps.   
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Trophoblast cells are the most exposed compartment of the placenta to toxic 
insults induced through chemicals such as nicotine, cotinine, benzo(a)pyrene, 
cadmium and others cigarette constituents/ by-products which are usually present in 
the circulating blood of pregnant women who smoke. Smoking during pregnancy has 
pleiotropic effects on trophoblast cells, with evident morphological and biochemical 
changes in early and term placenta. Some of these effects on trophoblast cells are 
summarized in this section. 
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Trophoblast Apoptosis 
There is not a unified consensus about the effect of smoking on trophoblast 
apoptosis. Nicotine (see Table 3) has been proven to have cytoprotective effects, 
with apoptosis inhibition in fibroblasts, thymic cells and some cancerous cell lines. 
Women who smoke show significantly weaker labeling for apoptosis in 
syncytiotrophoblasts when compared to normal healthy women [1]. On the other 
hand, some reports convincingly show increased trophoblast apoptosis in women 
who smoke during pregnancy [2]. As described in the earlier section, both placentas 
from smokers as well as from snuff users display signs of increased trophoblast 
necrosis and apoptosis. This indicates that nicotine, the common product of both 
tobacco consumption forms, would be the main instigator of this effect.  The 
increased apoptosis in trophoblast might be correlated with smoking-induced 
hypoxia, reduced intervillous blood flow and altered Epidermal Growth Factor (EGF) 
expression in the placenta. As mentioned in the earlier section, smoking is also 
associated with hyperplastic changes in the villous trophoblasts, with subsequent 
changes in the gas exchange between mother and growing fetus - which might result 
in intrauterine growth retardation [1].  
Interestingly, carbon monoxide is able to inhibit syncytiotrophoblastic 
apoptosis and necrosis events that were mediated through hypoxia and 
reoxygenation in an in vitro model [3]. This observation indicates that carbon 
monoxide has potent antiapoptotic properties within the human placenta.  
Considering the above information, it seems paradox that smokers’ placentae 
show such morphological differences indicating increase in apoptosis and necrosis. 
Thus, it is interesting to compare placentae of cigarette smokers and snuff users. To 
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our knowledge, there is no work dedicated specifically to this theme, however, 
Ashfaq et al published two separate papers comparing the respective pathological 
placentae with normal placentae using identical measured endpoints and methods. A 
comparison of these sets of results makes apparent that the placentae of smokers, 
compared to that of snuff users, seem more heavily affected in terms of collagen 
content of chorionic villi and syncytial knots per unit area, but not in terms of 
morphologically apparent apoptosis rate [4, 5]. It should be mentioned here that the 
method of apoptosis measurement (morphological signs) was different from the study 
by Bainbridge [3], in which apoptotic markers as well as morphological observations 
on the electron microscopic level were investigated. In any case, it seems that there 
are dissimilarities between the placentae of tobacco users depending on 
consumption form, which indicates that nicotine and combustion products also 
mediate their effects differentially. Additional research is required to determine the 
underlying causes of these differences. 
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Trophoblast Proliferation and Differentiation 
Maternal smoking is associated with reduced proliferation and abnormal 
differentiation (see Table 2) [6]. The non-progression in S phase of the cell cycle has 
been suggested to play an important role in this mechanism. It seems that especially 
the balance between cytotrophoblast proliferation and differentiation is altered in 
smokers’ placentae, since explantation experiments of chorionic villi derived from 
smoking gravidas revealed that these cytotrophoblasts had a marked inability to 
differentiate into the invasive phenotype (reviewed by [7]; [6]). 
Apart from nicotine, cigarette smoke is also a source of heavy metal-like 
cadmium (approximately 1-2µg per cigarette), which is, as mentioned above, 
detrimental to placental development mostly due to cadmium’s characteristic as an 
endocrine disruptor, which alters placental steroidal and hormonal synthesis 
(reviewed also in [8]). Calmodulin is the intracellular calcium-binding protein which is 
affected by high doses of cadmium in trophoblast(ic) cells, subsequently decreasing 
trophoblast(ic)cell proliferation [9]. In vitro studies also indicate that B(a)P negatively 
influences the transcription of trophoblast stem cell proliferation and differentiation 
regulating proteins ins a manner which correlates high levels of B(a)P to declined 
trophblast stem cell proliferation and differentiation, and possibly to implantation 
failure [10].  
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Trophoblast Function 
The general functional status of the trophoblast can be assessed in many 
manners, and often depends on the subtype under scrutiny. All trophoblast are 
capable of producing hormones, but is a main accomplishment of the 
syncytiotrophoblast, while cytotrophoblast and intermediate trophoblast are known 
mainly for their invasive capabilities.  
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- Trophoblast Invasion 
Some of the in vivo and in vitro findings in the literature support the idea 
aroused from the epidemiological data that especially trophoblast invasion is 
negatively altered when pregnant women use tobacco. Many of the effects that 
indicate faulty placentation or trophoblast invasion while using tobacco products 
during pregnancy can also be explained through the alterations of proliferation and 
differentiation, particularly of trophoblast cells entering the invasive pathway 
(reviewed by [6]). However, there are some hints that trophoblast invasion is also 
directly impacted by tobacco usage, as described below. 
An increased percentage of cytotrophoblast columns of anchoring villi fail to 
reach the uterus and tend to degenerate in the intervillous space, instead of invading 
the decidua [11] albeit this altered anchorage has also been made attributable to a 
nicotine mediated down-regulation of the l-selectin adhesion system [12]. In vitro 
exposure to nicotine inhibits the expression of fibronectin, integrin fibronectin 
receptor α5β1 and the 92 kDa type IV collagenase in cytotrophoblasts [11, 13], all 
factors that are normally associated with migration and invasion of the trophoblast 
cell. The migration capability of the macaque trophoblast cell is inhibited when 
cultured in the presence of medium conditioned with cigarette smoke [14]. B(a)P 
significantly inhibits trophoblastic choriocarcinoma cell invasion of the basement 
membrane in vitro [15]. It remains to be investigated whether a purported reduction of 
trophoblast invasion within maternal smokers’ placentae actually results in deficient 
spiral artery remodeling, which is associated with preeclampsia and IUGR. 
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 - Hormone and Growth Factor Production
Functional integrity is often assessed by expression of several biochemical 
markers, such as human chorionic gonadotropin (hCG), human placental lactogen 
(hPL), placental growth factor (PlGF), oestriol and oestradiol expressed by 
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trophoblasts (reviewed by [16]; [17]; [18]). The expression of these markers is altered 
in pregnant women who smoke (see Table 2) [19, 20].  
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HCG, oestriol and oestradiol are classical hormones used in the observation of 
placental or even gestational integrity. These hormones are implicated in a plethora 
of responsibilities associated with the maintenance of pregnancy. Listing all of them 
would go far beyond the scope of this review. Some of the relevant vital functions 
associated with some or all of the above mentioned hormones are: trophoblast 
fusion, proliferation and differentiation, placental hormone production or lipoprotein 
uptake (for a more specific review: [21]). Especially HCG-level in maternal serum has 
often been correlated with several pregnancy pathologies, and is commonly used to 
monitor gestational well-being (reviewed in [22, 23]). High levels are registered in 
some chromosomal deviations (such as trisomy 21) and gestational trophoblastic 
disease [23, 24], while erratic levels are found in ectopic pregnancies ([22, 25]). Too 
low levels have also been described for early detection of preeclampsia, IUGR and 
gestational diabetes [26], although not all of these results could be corroborated in a 
wide-spread manner (for example for preeclampsia: [27]). Reduced maternal serum 
levels of all three hormones are registered in cigarettes smokers [46, 47][28]. 
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HPL and PlGF are factors more recently described in playing a role especially 
in pregnancy pathologies.  PlGF is secreted by the trophoblast, its secretion rises 
during the course of gestation, shares 53% sequence homology with VEGF 
(Vascular Endothelial Growth Factor) and probably mediates a part of its angiogeneic 
activity by forming heterodimers with VEGF (all reviewed in [29]). Indeed, PlGF has 
been put forward as a determinant of placental vascularity [18]. PlGF concentration is 
elevated in the serum of prenatal smokers as compared to non-smokers, and low 
levels of this protein even during early gestation in maternal serum is associated with 
preeclampsia [27, 30]. HPL is also a growth hormone derived from the placenta that 
is normally synthesized by fully differentiated syncytiotrophoblast and intermediate 
(invasive) trophoblast cells located at the implantation site (reviewed in [31]). 
Secretion of HPL, unlike ßHCG which peaks in the first trimester, is continually 
produced throughout gestation and may constitute an indicator for syncytial well-
being (reviewed in [32]).  It is associated with maternal insulin resistance, thus raised 
maternal blood glucose levels, and other metabolic processes geared to ensuring 
fetal nutrition (reviewed in [17]). Reduced HPL levels at around midgestation are 
associated with growth restricted pregnancies (Bersinger, Odegard, 2004, Acta 
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Obstet Gynecol Scand). Smoking cigarettes negatively influences maternal blood 
levels of this protein [46, 47]. 
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 - Protein Synthesis  
In addition to the histological view described in an earlier section, maternal 
smoking is also associated with increased alkaline ribonuclease (RNase) levels, 
possibly resulting in disturbed protein synthesis. This is accompanied by biochemical 
evidence of significantly increased cellularity (increased DNA/gm of placental mass 
and decreased protein/DNA ratios) (reviewed in [33]). Leucine Amino Peptidase 
(LAP), Alanine Amino Peptidase (APP) and membrane-associated ACE (Acetyl 
Choline Esterase)-like activities are significantly higher in smokers’ trophoblast cells, 
which might be responsible for altered peptide hormone metabolism in the placenta 
[34]. Additionally, metalloproteinases play an important role in trophoblast invasion 
and its production and activation is downregulated with high doses of nicotine (see 
Table 2) [35]. 
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 - Generation of Energy  
There are indications that prenatal smoking is associated with perturbed 
mitochondrial function with the placenta, which might limit the amount of available 
energy in cells (reviewed in [7]). A reduction by 30% of a mitochondrial membrane 
bound cytochrome was recently described in the placental mitochondria of smokers 
as compared to that of non-smokers [36]. Whether this placental dysfunctionality 
contribute to the pathogenesis of IUGR in prenatal smokers’ remains to be further 
investigated. The uptake of glucose, at least by cells of the human choriocarcinoma 
cell line, BeWo, was not altered through nicotine [37]. 
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 - Oxidative Stress Management: 
Free radicals are highly reactive molecules mainly generated by endogenous 
metabolic pathways, which include oxidative phosphorylation, DADPH (lactaldehyde 
reductase) oxidase and xanthine oxidase. Two types of free radicals have been 
extensively studied: reactive oxygen species (ROS) and reactive nitrogen species 
(RSN) [38]. These oxidative factors have been shown to impair most of the 
processes present during pre-implantation, such as oocyte fertilization and 
endometrial receptivity. Implantation and placental development are also negatively 
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affected [38]. The underlying mechanisms seem to be associated with changes in 
some ROS targets, such as DNA, protein and lipids, which are extremely relevant 
molecules in the fertilization process [39]. One study conducted a set of experiments 
dedicated to examining markers for oxidative damage on placental and cord blood 
DNA, lipids and proteins of prenatal smokers [40]. Here, maternal cotinine levels 
correlated with markers for DNA oxidation. Furthermore, maternal oxidative stress 
markers correlated to the level of DNA-adducts in the placenta, which in turn 
correlated to protein carbonylation in cord blood plasma. Interestingly, oxidative DNA 
damage and DNA-adduct level (in the placentae of smokers) negatively correlated to 
placental lipid peroxidation. Lipid peroxidation can change the property of a cell 
membrane, such as its fluidity or the activity of a membrane-bund property, and this 
can negatively alter the cell’s function. This observation would indicate that smoking 
cigarettes might convey DNA and thus protein damage through oxidative stress, but 
also protect placental cell membranes. 
 
Placental antioxidant systems: 
In order to prevent oxidative conditions that might promote embryo injury or 
death, cells activate protective antioxidant mechanisms that degrade oxidative 
factors [39] .  Four main antioxidant systems have been described in placenta: 
cooper/zinc superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase 
(GPx) and heme oxigenase (HO)[41]. Their function is to inactivate toxic substances 
that may lead to oxidative stress. SOD inactivates superoxide anion ( ), CAT acts 
on hydrogen peroxide ( ), GPx inactivates  and lipid peroxides, and heme 
oxygenase enzymes (HO-1 and HO-2) degrade heme to CO, biliverdin (bilirubin) and 
Fe2+ [42]. 
−
2O
22OH 22OH
Recent reports have shown some differences in smokers’ placenta concerning 
the expression and function of antioxidant enzymes. Studies in vivo have 
demonstrated increased expression of HO-1 and HO-2 in placental basal plate from 
smokers. No differences regarding this expression were observed in anchoring villi 
(AV). Additionally, no changes in CAT, GPx and SOD levels were identified [41]. On 
the other hand, in vitro experiments using cigarette smoke extract (CSE) on a 
trophoblast choriocarcinoma hybrid cell line (HTR-8SVneo) showed a dose-
dependent increase in HO-1 expression, but no changes in HO-2, SOD, GPx and 
CAT expression [41]. HO-1, besides being an anti-oxidant, is also anti-inflammatory 
 10
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
(reviewed by [43]). HO activity decreases during hypoxia, and HO protein is 
decreased in the placentae of preeclampsia patients (reviewed by [44]). HO-1 is able 
to negatively regulate the release of sFlt-1 and sEng in endothelial cells, and 
inhibition of HO-1 in placental villous explants potentiated the production of sFlt-1 
and sEng [45]. Interestingly, the expression of HO is multifold elevated in pregnant 
myometrium compared to non-pregnant, and activation of HO significantly reduced 
both oxytocin-mediated, as well as spontaneous, uterine contractility [46].   
      Exogenous antioxidant system: 
Cigarette smoke inhalation during pregnancy triggers activation of 
antioxidative systems through the generation of free radicals [47]. Oxidative stress 
might be reduced with supplementation of antioxidant compounds such as Vitamin C 
and E in diet. Increased vitamin deficiency in smokers has been shown [48]. In 
pregnant women who smoke, the concentration of vitamin E is decreased in plasma 
and erythrocytes when compared to non-smoking gravidas. Furthermore, Vitamin A, 
vitamin E, fS-carotene and total plasma antioxidant capacity were lowered in 
smokers’ newborns [49]. The role that vitamins might play in embryo implantation, 
intrauterine growth and abortion control is controversial (as reviewed by Gupta et al 
[50]). Moreover, studies have implicated that vitamin C/E supplementation decreases 
the incidence of preeclampsia by decreasing the biochemical indices of oxidative 
stress [51], however, in a large prospective cohort study, the overall incidence of pre-
eclampsia did not correlate with dietary vitamin C and E intake. In the same study, a 
decreasing trend in the incidence of severe pre-ecplampsia, eclampsia and HELLP 
with increasing dietary vitamin C intake was delineated [52]. Neither vitamin C nor E 
have an effect on sFlt-1 release [45]. 
 
 
27  - Effects of Specific Tobacco Constituents
28 
29 
30 
31 
32 
33 
34 
Nicotine seems to restore endothelial dysfunction (as seen on experiments 
with umbilical endothelial cells) caused by excess antiangiogenic factors, such as 
soluble fms-like tyrosine kinase 1 (sFlt1) and soluble endoglin (sEng), both factors 
whose higher circulation in maternal serum is associated with onset of pre-eclampsia 
[53]. However, this restoration does not seem to be due to nicotinic acetylcholine 
receptor stimulation induced alteration of sFlt expression in placental cells, since 
neither nicotine nor its agonist alter expression of these factors [54]. Nicotine also 
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failed to affect sFlt-1, sEng, PlGF and TGF-ß mRNA expression in trophoblast cells. 
Smoking during pregnancy, however, is associated with lower circulating 
concentrations of sFlt1 and sEng [55] and exposure of placental villous explants to 
cigarette smoke extract lowers sFlt1 secretion [56]. Nicotine lowers sFlt-1 and s-Eng 
secretion in trophoblast cells [57]. Furthermore, in trophoblast cells, nicotine reduces 
PlGF release, but VEGF release seems unaffected [58]. The substance is also 
capable of suppressing placental cytokine production (TNF, IL6, IL8, IL1ß), although 
it is not yet corroborated which placental cell is responsible for this [54]. Nicotine 
activates phospholipase A2, which is implicated in prostaglandin E2 formation (a 
labor-inducing prostaglandin). Nicotine can also, however, activate placental nicotinic 
receptors and the release of placental acetylcholine, a vasodilator of placental 
arteries [59]. Nicotine has been described in elevating either sEng or sFlt-1 secretion 
in human umbilical cells ([57]; [58]). PlGF secretion appears to be stimulated by 
nicotine in human umbilical endothelial cells [58]. The subcutaneous applications of 
nicotine to gravid rats lead not only to a significant reduction of birthweight, but also 
an induction of cytochromes (CYP1A1, CYP2E2) indicative of oxidative stress [60]. 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
B(a)P down-regulates the receptor expression of Epithelial Growth Factor 
(EGF), an important factor responsible for early implantation, and whose tyrosine 
kinase receptor activity has been demonstrated to be significantly decreased in 
smokers’ trophoblast cells (see Table 3). Furthermore, benzo(a)pyrene reduces the 
expression of the proto-oncogene c-myc and of hCG (a positive regulator of 
trophoblast invasion), while it increases TGF-β1 expression (a negative regulator of 
trophoblast invasion) in first trimester placental villous explants and in 
choriocarcinoma cell lines [16, 23, 61]. Ethoxyresorufin-O-deethylase (EROD) is an 
enzyme that can be used as an indicator of placental hypoxia. Its activity is induced 
by exposure to polycyclic aromatic hydrocarbons found in tobacco smoke (see Table 
3). There is a very high correlation between the plasmatic level of cotinine and 
placental EROD activity, indicating the direct impact of maternal cigarette smoking on 
placenta [62].  
30 
31 
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Cadmium (see Table 3) produces ultrastructural placental changes (lysosomal 
vesiculation, nuclear chromatin clumping, mitochondrial calcification) and decreases 
hCG secretion by trophoblast cells [63]. Animal experiments show that placental 
cadmium accumulation may interfere with the transfer of various essential minerals 
and other nutrients to the growing fetus [64]. Leptin mRNA in human trophoblast cells 
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declined dose-dependently to cadmium exposure [65].  Leptin is considered a pro-
inflammatory cytokine/ adipokine that is associated with preeclampsia, because of 
the higher levels of this substance found in pre-eclampsia patients (reviewed in [43]). 
Leptin also probably stimulates trophoblast invasion, so cadmium might indirectly 
lower trophoblast invasion. Cadmium also interferes with trophoblast biosynthesis of 
progesterone, a steroid that plays a role, amongst others, in promoting uterine 
myometrial quiescence [66]. Acute exposure of high concentrations of cadmium to 
human placental explants may even lead to inhibited synthesis of thromboxane A2 
and thus altered balance of thromboxane A2 to prostacyclin [64, 67]. In pre-
eclampsia, the prostaglandin PGI2 is decreased, while the TXA2/PGI2 ratio is 
elevated so that lower TXA2 would lead to a more favorable TXA2/PGI2 ratio [68]. 
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CO and CO-releasing molecules lower sFlt1 and sEng production in 
endothelial cells and placental villous explants derived from preeclamptics [45]. As 
mentioned earlier, CO also seems to down-regulate syncytiotrophoblast apoptosis 
and necrosis [3]. Pretreatment of HUVEC with CO releasing molecules results in a 
decrease of LPA-induced inflammation (as seen in through up-regulation of HO-1, 
inhibition of NF-kappaB and down-regulation of ICAM-1 and granulocyte adhesion 
[69]. 
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Cotinine activates placental phospholipase-A2-like enzymes, resulting in the 
formation of prostaglandins (reviewed in [59]). Cotinine cannot, in contrast to 
nicotine, activate nicotinic and muscarinic receptors, and seems to enhance the 
effects of PGE2 [59]. Cotinine, as nicotine, reduces sFlt-1, sEng and, only at high 
dosages, PlGF release by trophoblast cells, while it increases PlGF and sFlt-1 
release in HUVEC [58]. 
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